{"messages": [{"role": "system", "content": "You are BioASQ-GPT, an AI expert in question answering, research, and information retrieval in the biomedical domain."}, {"role": "user", "content": "Given this question: 'What were the results of the DESTINY-Breast04 Trial?' select the top 10 snippets that are most helpful for answering this question from this list of snippets, \n        rerank them by helpfulness: ```[{\"id\": 0, \"text\": \"Findings from the phase III DESTINY-Breast04 trial indicate that the antibody-drug conjugate trastuzumab deruxtecan (T-DXd) is effective for patients with inoperable/metastatic HER2-low breast cancer.\"}, {\"id\": 2, \"text\": \"CONCLUSIONS: In this trial involving patients with HER2-low metastatic breast cancer, trastuzumab deruxtecan resulted in significantly longer progression-free and overall survival than the physician's choice of chemotherapy. (Funded by Daiichi Sankyo and AstraZeneca; DESTINY-Breast04 ClinicalTrials.gov number, NCT03734029.).\"}, {\"id\": 1, \"text\": \"METHODS: We conducted a phase 3 trial involving patients with HER2-low metastatic breast cancer who had received one or two previous lines of chemotherapy. (Low expression of HER2 was defined as a score of 1+ on immunohistochemical [IHC] analysis or as an IHC score of 2+ and negative results on in situ hybridization.) Patients were randomly assigned in a 2:1 ratio to receive trastuzumab deruxtecan or the physician's choice of chemotherapy. \"}]``` return a json array of their ids called 'snippets'"}, {"role": "assistant", "content": "{\"snippets\": [1, 2, 0]}"}]}
{"messages": [{"role": "system", "content": "You are BioASQ-GPT, an AI expert in question answering, research, and information retrieval in the biomedical domain."}, {"role": "user", "content": "Given this question: 'Are LOQ and LOD the same?' select the top 10 snippets that are most helpful for answering this question from this list of snippets, \n        rerank them by helpfulness: ```[{\"id\": 9, \"text\": \"Results indicated that the dynamic ranges of three fur-bearing animals were all from 1% to 90%; the limit of detection (LOD) and limit of quantification (LOQ) for three fur-bearing animals were same, with LOD 0.1% (w/w) and LOQ 1% (w/w).\"}, {\"id\": 1, \"text\": \"The limit of detection (LoD) and limit of quantitation (LoQ) \"}, {\"id\": 6, \"text\": \"Real-time PCR (qPCR) is the principal technique for the quantification of pathogen biomass in host tissue, yet no generic methods exist for the determination of the limit of quantification (LOQ) and the limit of detection (LOD) in qPCR.\"}, {\"id\": 0, \"text\": \"Limit of detection (LQD)/limit of quantitation (LOQ): comparison of the empirical and the statistical methods exemplified with GC-MS assays of abused drugs.\"}, {\"id\": 2, \"text\": \"* Limit of Blank (LoB), Limit of Detection (LoD), and Limit of Quantitation (LoQ) are terms used to describe the smallest concentration of a measurand that can be reliably measured by an analytical procedure.\"}, {\"id\": 7, \"text\": \"tion is important for the analysis of aflatoxin in hazelnuts. The limit of detection (LOD) and limit of quantification (LOQ) are two important paramet\"}, {\"id\": 8, \"text\": \"The linear range of glyoxylic acid concentration is 0-0.028\\u00e2\\u20ac\\u2030M. The limits of detection (LOD) and quantitation (LOQ) are 0.0019\\u00e2\\u20ac\\u2030M and 0.00577\\u00e2\\u20ac\\u2030M, respectively.\"}, {\"id\": 12, \"text\": \"Limits of detection (LOD) and quantitation (LOQ) for UV detection are 1 and 2 mg/L, respectively.\"}, {\"id\": 5, \"text\": \"The quantitative parameters of sensor for silver ion are determined as the limit of detection (LOD) 5.95\\u00c2\\u00a0\\u00c3\\u2014\\u00c2\\u00a010-7 M, and limit of quantitation (LOQ) 1.98\\u00c2\\u00a0\\u00c3\\u2014\\u00c2\\u00a010-8 M in the linear range\"}, {\"id\": 10, \"text\": \"Limits of detection (LOD) and quantification (LOQ) at 10 and 20\\u00e2\\u20ac\\u2030ng/g were achieved,\"}, {\"id\": 3, \"text\": \"The limits of detection (LOD) and quantitation (LOQ) were 0.6 and 2.1 microg/L, respectively.\"}, {\"id\": 11, \"text\": \"Missing values caused by the limit of detection or quantification (LOD/LOQ) were widely observed in mass spectrometry\"}, {\"id\": 4, \"text\": \"The limit of detection (LOD) for any analytical procedure, the point at which analysis is just feasible, may be determined by a statistical approach based on measuring replicate blank (negative) samples or by an empirical approach, consisting of measuring progressively more dilute concentrations of analyte. The limit of quantitation (LOQ), or concentration at which quantitative results can be reported with a high degree of confidence, may likewise be determined by either approach. We used both methods to determine LOD and LOQ for forensic gas chromatographic-mass spectrometric (GC-MS) analyses of abused drugs. The statistically determined LOD and LOQ values for these assays underestimated the LOD because of th\"}]``` return a json array of their ids called 'snippets'"}, {"role": "assistant", "content": "{\"snippets\": [1, 11, 10, 5, 6, 2, 8, 9, 0, 3, 7, 12, 4]}"}]}
{"messages": [{"role": "system", "content": "You are BioASQ-GPT, an AI expert in question answering, research, and information retrieval in the biomedical domain."}, {"role": "user", "content": "Given this question: 'Histone acetyltransferases (HATs) transfer acetyl groups from acetyl CoA to lysine residues on histones. What is the purpose of this transfer?' select the top 10 snippets that are most helpful for answering this question from this list of snippets, \n        rerank them by helpfulness: ```[{\"id\": 9, \"text\": \"Histone acetyltransferases (HATs) mediate the transfer of an acetyl group from the cofactor, acetyl-CoA, to the side chain amino group of specific lysines in diverse protein substrates, most notably nuclear histones.\"}, {\"id\": 10, \"text\": \"Histone modifications and more specifically \\u00ce\\u00b5-lysine acylations are key epigenetic regulators that control chromatin structure and gene transcription, thereby impacting on various important cellular processes and phenotypes. Furthermore, lysine acetylation of many non-histone proteins is involved in key cellular processes including transcription, DNA damage repair, metabolism, cellular proliferation, mitosis, signal transduction, protein folding, and autophagy. Acetylation affects protein functions through multiple mechanisms including regulation of protein stability, enzymatic activity, subcellular localization, crosstalk with other post-translational modifications as well as regulation of protein-protein and protein-DNA interactions.\"}, {\"id\": 1, \"text\": \"Acetylation is a core cellular process involved in maintaining genomic integrity, gene regulation, and metabolism. Histone acetyltransferases (HATs) are an enzyme family that regulates these processes by catalyzing the transfer of an acetyl moiety onto target proteins.\"}, {\"id\": 13, \"text\": \"Histone acetyltransferases (HATs) are a group of enzymes that play a significant role in the regulation of gene expression. These enzymes covalently modify the N-terminal lysine residues of histones by the addition of acetyl groups from acetyl-CoA. Dysfunction of these enzymes is often associated with the manifestation of several diseases, predominantly cancer.\"}, {\"id\": 2, \"text\": \"Histone acetyltransferases (HATs) catalyze the transfer of an acetyl group from an acetyl-coenzyme A donor molecule to specific lysine residues within proteins. The acetylation state of proteins, particularly histones, is known to modulate their intermolecular binding properties and control various cellular processes, most notably transcriptional activation.\"}, {\"id\": 19, \"text\": \"Histone acetyltransferases (HATs) catalyze the transfer of an acetyl group from acetyl-CoA to lysine residues of histones and play a central role in transcriptional regulation in diverse biological processes.\"}, {\"id\": 16, \"text\": \"In cancer cells, enhancer hijacking mediated by chromosomal alterations and/or increased deposition of acetylated histone H3 lysine 27 (H3K27ac) can support oncogene expression. However, how the chromatin conformation of enhancer-promoter interactions is affected by these events is unclear. In the present study, by comparing chromatin structure and H3K27ac levels in normal and lymphoma B cells, we show that enhancer-promoter-interacting regions assume different conformations according to the local abundance of H3K27ac.\"}, {\"id\": 17, \"text\": \"Histone acetylation emerges as a central switch that allows interconversion between permissive and repressive chromatin domains in terms of transcriptional competence. The mechanisms underlying the histone acetylation-dependent control of gene expression include a direct effect on the stability of nucleosomal arrays and the creation of docking sites for the binding of regulatory proteins. Histone acetyltransferases and deacetylases are, respectively, the enzymes devoted to the addition and removal of acetyl groups from lysine residues on the histone N-terminal tails. \"}, {\"id\": 4, \"text\": \"Histone acetylation regulates gene transcription. Histone acetylation is a reversible process: histone acetyltransferases (HAT) transfer the acetyl moiety from acetyl coenzyme A to the lysine, and histone deacetylases (HDAC) remove the acetyl groups re-establishing the positive charge in the histones.\"}, {\"id\": 11, \"text\": \"Yeast ESA1 is a member of the MYST subfamily of histone acetyltransferases (HATs), which use acetyl-coenzyme A (CoA) to acetylate specific Lys residues within histones to regulate gene expression.\"}, {\"id\": 12, \"text\": \"Histone acetyltransferases (HATs) are enzymes able to acetylate lysine side chains of histones.\"}, {\"id\": 7, \"text\": \"Acetylation of histones by lysine acetyltransferases (KATs) is essential for chromatin organization and function\"}, {\"id\": 14, \"text\": \"Histone acetylation is a critical epigenetic modification that changes chromatin architecture and regulates gene expression by opening or closing the chromatin structure. It plays an essential role in cell cycle progression and differentiation.\"}, {\"id\": 15, \"text\": \"Transcriptional regulation in eukaryotes occurs within a chromatin setting and is strongly influenced by nucleosomal barriers imposed by histone proteins. Among the well-known covalent modifications of histones, the reversible acetylation of internal lysine residues in histone amino-terminal domains has long been positively linked to transcriptional activation.\"}, {\"id\": 6, \"text\": \"Histone acetylation is an influential post-translational modification in chromatin architecture. Acetylation affects chromatin structure by offering binding signals for reader proteins that harbor acetyl-lysine recognition domains.\"}, {\"id\": 5, \"text\": \"Histone acetyltransferases (HATs) are important enzymes that transfer acetyl groups onto histones and thereby regulate both gene expression and chromosomal structures.\"}, {\"id\": 18, \"text\": \"Histone lysine acetylation is well known for being important in the epigenetic regulation of gene expression in eukaryotic cells. Recent studies have uncovered a plethora of acetylated proteins involved in important metabolic pathways, such as photosynthesis and respiration in plants. Enzymes involved in histone acetylation and deacetylation are being identified as regulators of acetylation of metabolic enzymes.\"}, {\"id\": 0, \"text\": \"Histone acetyltransferases (HATs) catalyze the acetyl-group transfer from acetyl-CoA to the epsilon-amino group of specific lysine residues within core histone proteins.\"}, {\"id\": 3, \"text\": \"Histone acetylation is a diagnostic feature of transcriptionally active chromatin. The group of enzymes, histone acetyltransferases (HATs), involved in this crucial step of gene regulation, covalently modifies the N-terminal lysine residues of histones by the addition of an acetyl group from acetyl coenzyme A. Dysfunction of these enzymes is often associated with several diseases, ranging from neurodegenerative disorders to cancer.\"}, {\"id\": 20, \"text\": \"HATs and other chromatin-remodeling enzymes have been recently shown to regulate gene activation within specific loci.\"}, {\"id\": 8, \"text\": \" The transfer of acetyl groups from acetyl-coenzyme A on histone lysine residues is catalyzed by histone acetyltransferases.\"}]``` return a json array of their ids called 'snippets'"}, {"role": "assistant", "content": "{\"snippets\": [14, 6, 16, 0, 9, 19, 20, 5, 12, 8, 18, 10, 2, 11, 4, 1, 3, 7, 15, 17, 13]}"}]}
{"messages": [{"role": "system", "content": "You are BioASQ-GPT, an AI expert in question answering, research, and information retrieval in the biomedical domain."}, {"role": "user", "content": "Given this question: 'Which gene is most frequently mutated in hereditary angioedema ?' select the top 10 snippets that are most helpful for answering this question from this list of snippets, \n        rerank them by helpfulness: ```[{\"id\": 0, \"text\": \"Almost all cases of HAE are caused by mutations in the SERPING1 gene resulting in a deficiency in functional plasma C1 esterase inhibitor (C1EI), a serine protease inhibitor that normally inhibits proteases in the contact, complement, and fibrinolytic systems\"}]``` return a json array of their ids called 'snippets'"}, {"role": "assistant", "content": "{\"snippets\": [0]}"}]}
{"messages": [{"role": "system", "content": "You are BioASQ-GPT, an AI expert in question answering, research, and information retrieval in the biomedical domain."}, {"role": "user", "content": "Given this question: 'What is casimersen's mechanism of action?' select the top 10 snippets that are most helpful for answering this question from this list of snippets, \n        rerank them by helpfulness: ```[{\"id\": 2, \"text\": \"Casimersen (Amondys 45\\u00e2\\u201e\\u00a2) is an antisense oligonucleotide of the phosphorodiamidate morpholino oligomer subclass developed by Sarepta Therapeutics for the treatment of Duchenne muscular dystrophy (DMD) in patients who have a mutation in the DMD gene that is amenable to exon\\u00c2\\u00a045 skipping.\"}, {\"id\": 4, \"text\": \"for the treatment of DMD in patients who have a confirmed mutation of the DMD gene that is amenable to exon\\u00c2\\u00a045 skipping.\"}, {\"id\": 0, \"text\": \"INTRODUCTION/AIMS: Duchenne muscular dystrophy (DMD) is caused by mutations in the DMD gene resulting in the absence of dystrophin. Casimersen is a phosphorodiamidate morpholino oligomer designed to bypass frameshift DMD mutations and produce internally truncated, yet functional, dystrophin protein in patients amenable to exon 45 skipping. Our primary study objective was to evaluate safety and tolerability of casimersen; the secondary objective was to characterize the plasma pharmacokinetics.ME\"}, {\"id\": 1, \"text\": \"casimersen is designed to bind to exon\\u00c2\\u00a045 of the DMD gene pre-mRNA, resulting in skipping of this exon during mRNA processing, intended to allow for production of an internally truncated but functional dystrophin protein in patients with DMD. \"}, {\"id\": 5, \"text\": \"Casimersen (Amondys 45\\u00e2\\u201e\\u00a2) is an antisense oligonucleotide of the phosphorodiamidate morpholino oligomer subclass developed by Sarepta Therapeutics for the treatment of Duchenne muscular dystrophy (DMD) in patients who have a mutation in the DMD gene that is amenable to exon\\u00c2\\u00a045 skipping. Administered by intravenous infusion, casimersen is designed to bind to exon\\u00c2\\u00a045 of the DMD gene pre-mRNA, resulting in skipping of this exon during mRNA processing, intended to allow for production of an internally truncated but functional dystrophin protein in patients with DMD. Casimersen received its first approval on 25\\u00c2\\u00a0February 2021, in the USA, for the treatment of DMD in patients who have a confirmed mutation of the DMD gene that is amenable to exon\\u00c2\\u00a045 skipping.\"}, {\"id\": 3, \"text\": \"With the development of viable RNA technologies, such as chemistry and pharmaceutics, eight antisense oligonucleotides (ASOs) (fomivirsen, mipomersen, eteplirsen, nusinersen, inotersen, golodirsen, viltolarsen and casimersen), one aptamer (pegaptanib), and three small interfering RNAs (siRNAs) (patisiran, givosiran and lumasiran) have been approved by the United States Food and Drug Administration (FDA) for therapies, and two mRNA vaccines (BNT162b2 and mRNA-1273) under Emergency Use Authorization for the prevention of COVID-19.\"}]``` return a json array of their ids called 'snippets'"}, {"role": "assistant", "content": "{\"snippets\": [1, 4, 2, 3, 0, 5]}"}]}
{"messages": [{"role": "system", "content": "You are BioASQ-GPT, an AI expert in question answering, research, and information retrieval in the biomedical domain."}, {"role": "user", "content": "Given this question: 'What is the mechanism of action of tiragolumab?' select the top 10 snippets that are most helpful for answering this question from this list of snippets, \n        rerank them by helpfulness: ```[{\"id\": 0, \"text\": \"Our aim was to evaluate ex vivo the capacity of the combination of atezolizumab (anti-PD-L1) and tiragolumab (anti-TIGIT) to reactivate the immune response of tumor infiltrating lymphocytes (TILs) in MSS-CRC. \"}, {\"id\": 2, \"text\": \"Genentech's TIGIT-targeted antibody tiragolumab missed its endpoints in two late-stage lung cancer trials, raising doubts about one of the most widely studied next-generation checkpoint targets in immuno-oncology. \"}, {\"id\": 1, \"text\": \"BACKGROUND: Targeted inhibition of the PD-L1-PD-1 pathway might be further amplified through combination of PD-1 or PD-L1 inhibitors with novel anti-TIGIT inhibitory immune checkpoint agents, such as tiragolumab. \"}]``` return a json array of their ids called 'snippets'"}, {"role": "assistant", "content": "{\"snippets\": [2, 1, 0]}"}]}
{"messages": [{"role": "system", "content": "You are BioASQ-GPT, an AI expert in question answering, research, and information retrieval in the biomedical domain."}, {"role": "user", "content": "Given this question: 'What are the serum biomarkers that have been proposed in Neuromyelitis Optica Spectrum Disorders (NMOSD) to monitor disease activity?' select the top 10 snippets that are most helpful for answering this question from this list of snippets, \n        rerank them by helpfulness: ```[{\"id\": 8, \"text\": \"Recently, several serum biomarkers have been proposed in Neuromyelitis Optica Spectrum Disorders (NMOSD) to monitor disease activity.\"}, {\"id\": 12, \"text\": \". As our understanding regarding the immune pathophysiology of NMOSD expands, emerging biomarkers, including serum neurofilament light chain and glial fibrillary acidic protein (GFAP), may facilitate earlier relapse detection and inform long-term treatment decisions.\"}, {\"id\": 6, \"text\": \"Neuromyelitis optica (NMO) is an inflammatory disease that resembles MS in the relapsing clinical course of optic neuritis and myelitis. Two decades of studies have revealed that autoantibodies, reactive to the water channel protein aquaporin 4 (AQP4)\\u00c2\\u00a0are detected in the core group of patients\"}, {\"id\": 3, \"text\": \" The antibody against aquaporin-4 (AQP4)-immunoglobulin G (IgG) discovered in 2004 was found to be both the pathologic cause and a reliable biomarker for neuromyelitis optica spectrum disorders\"}, {\"id\": 5, \"text\": \"Serum Glial Fibrillary Acidic Protein: A Neuromyelitis Optica Spectrum Disorder Biomarker.\"}, {\"id\": 0, \"text\": \"GFAP might be the most appropriate for monitoring NMOSD longitudinally, which warrants future confirming studies.\"}, {\"id\": 7, \"text\": \"We prospectively recruited consecutive NMOSD patients with anti-aquaporin-4 antibody and obtained serum samples at enrollment, after 6-12\\u00e2\\u20ac\\u2030months of follow-up (main period), and at attacks. \"}, {\"id\": 11, \"text\": \"OBJECTIVE: To test the hypothesis that serum levels of glial fibrillary acidic protein (GFAP) and neurofilament light chain (NfL), which are an intermediate astrocyte and neuron filaments, respectively, are clinically useful biomarkers of disease activity and disability in neuromyelitis optica spectrum disorders (NMOSD).METHODS: Levels of GFAP and NfL in serum (sGFAP and sNfL, respectively) and in CSF samples were measured in healthy controls (HCs) (n = 49; 49 serum samples), patients with NMOSD (n = 33; 42 CSF and 102 serum samples), and patients with multiple sclerosis (MS) (n = 49; 53 CSF and 91 serum samples) by ultrasensitive single-mo\"}, {\"id\": 1, \"text\": \"During the acute phase of NMOSD and MOGAD, plasma C3 and C4 may become potential biomarkers for distinguishing the two diseases and reflecting the NMOSD BBB damage.\"}, {\"id\": 9, \"text\": \"We investigated the serum neurofilament light chain (sNfL) and glial fibrillary acidic protein (sGFAP) levels in a cohort of Chinese patients with neuromyelitis optica spectrum disorders (NMOSD) and multiple sclerosis (MS) in relation to clinical disease course and treatment.\"}, {\"id\": 10, \"text\": \"During the study, five (8%) patients developed new attacks; only serum GFAP levels increased consistently upon these events compared with baseline levels.\"}, {\"id\": 2, \"text\": \"The discovery of the pathogenic aquaporin-4 (AQP4)-IgG autoantibody and characterization of NMOSD as an autoimmune astrocytopathy have spearheaded the identification of key immunologic therapeutic targets in this disease, including but not limited to the complement system, the interleukin 6 (IL-6) receptor, and B cells. \"}, {\"id\": 4, \"text\": \"multiple sclerosis, AQP4-IgG-positive neuromyelitis optica spectrum disorder, and MOG-IgG-associated disorde\"}]``` return a json array of their ids called 'snippets'"}, {"role": "assistant", "content": "{\"snippets\": [4, 3, 8, 0, 7, 10, 6, 1, 2, 12, 9, 5, 11]}"}]}
{"messages": [{"role": "system", "content": "You are BioASQ-GPT, an AI expert in question answering, research, and information retrieval in the biomedical domain."}, {"role": "user", "content": "Given this question: 'What are the major thrombotic complications in patients with COVID-19?' select the top 10 snippets that are most helpful for answering this question from this list of snippets, \n        rerank them by helpfulness: ```[{\"id\": 18, \"text\": \"These include microvascular and macrovascular thrombotic complications such as arterial and venous thromboembolism, myocardial injury or inflammation resulting in infarction, heart failure, and arrhythmias.\"}, {\"id\": 12, \"text\": \"No patient developed disseminated intravascular coagulation.\"}, {\"id\": 0, \"text\": \"COVID-19 may predispose to both venous and arterial thromboembolism due to excessive inflammation, hypoxia, immobilisation and diffuse intravascular coagulation.\"}, {\"id\": 1, \"text\": \"The most common thrombotic complication is pulmonary embolism, which though may occur in the absence of a recognizable deep venous thrombosis and may be due to pulmonary arterial thrombosis rather than embolism, resulting in thrombotic occlusion of small- to mid-sized pulmonary arteries and subsequent infarction of lung parenchyma.\"}, {\"id\": 20, \"text\": \"Due to several inflammatory changes that occur in severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infections such as alterations in the levels of clotting factors, platelet activation leads to thrombus formation in coronary and cerebral vessels, leading to myocardial infarction and cerebrovascular accidents, respectively.\"}, {\"id\": 13, \"text\": \"Thrombotic complications from COVID-19 are believed to be due to a hyperinflammatory response caused by the virus. Several complications have been described in the literature. These include acute limb ischemia, abdominal and thoracic aortic thrombosis, mesenteric ischemia, myocardial infarction, venous thromboembolism, acute cerebrovascular accident, and disseminated intravascular coagulation.\"}, {\"id\": 10, \"text\": \"Major bleeding occurred in six of the 25 studied patients. Four patients were on therapeutic anticoagulation at the onset of the bleed, two required embolization for bleeding control and one died from hemorrhagic shock.\"}, {\"id\": 5, \"text\": \"Despite anticoagulation, a high number of patients with ARDS secondary to COVID-19 developed life-threatening thrombotic complications.\"}, {\"id\": 15, \"text\": \"Several observational studies have described hemostatic derangements and thrombotic complications in patients with COVID-19.\"}, {\"id\": 3, \"text\": \"Our analysis does not suggest that rates of intracerebral hemorrhage are higher in patients with COVID-19. The higher mortality in patients with intracerebral hemorrhage and COVID-19 compared with those without COVID-19 is likely mediated by higher frequency of comorbidities and adverse in-hospital events.\"}, {\"id\": 21, \"text\": \"Recent clinical data has highlighted that coronavirus disease 2019 (COVID-19) is associated with a significant risk of thrombotic complications ranging from microvascular thrombosis, venous thromboembolic disease, and stroke.\"}, {\"id\": 19, \"text\": \" In 28 studies including 2928 patients, thrombotic complications occurred in 34% of ICU-managed patients, with deep venous thrombosis reported in 16.1% and pulmonary embolism in 12.6% of patients, despite anticoagulant thromboprophylaxis, and were associated with high mortality.\"}, {\"id\": 16, \"text\": \"Despite thromboprophylaxis, there is a very high incidence of thrombotic complications in patients with COVID-19 on the ICU.\"}, {\"id\": 8, \"text\": \"The radiographically confirmed VTE rate was 4.8% (95% confidence interval [CI], 2.9-7.3), and the overall thrombotic complication rate was 9.5% (95% CI, 6.8-12.8). The overall and major bleeding rates were 4.8% (95% CI, 2.9-7.3) and 2.3% (95% CI, 1.0-4.2), respectively. In the critically ill, radiographically confirmed VTE and major bleeding rates were 7.6% (95% CI, 3.9-13.3) and 5.6% (95% CI, 2.4-10.7), respectively.\"}, {\"id\": 22, \"text\": \"Most of the reports on a high incidence of thrombotic complications are in relation to deep vein thrombosis and pulmonary embolism, while the evidence about arterial thrombosis in patients with COVID-19 is limited.\"}, {\"id\": 4, \"text\": \"Critically ill COVID patients are at increased risk of serious thrombotic events and hence increased mortality. On the other side, COVID-19 patients are also showing major life-threatening bleeds, especially when systemic anticoagulation is used.\"}, {\"id\": 23, \"text\": \"Most of these complications are associated with venous thromboembolism and pulmonary embolism; and arterial thrombosis is rare.\"}, {\"id\": 11, \"text\": \"Early reports describe high venous thromboembolism (VTE) and disseminated intravascular coagulation (DIC) rates, but data are limited.\"}, {\"id\": 2, \"text\": \"However, in patients with COVID-19 the subsequent endothelial inflammation, complement activation, thrombin generation, platelet, and leukocyte recruitment, and the initiation of innate and adaptive immune responses culminate in immunothrombosis, ultimately causing (micro)thrombotic complications, such as deep vein thrombosis, pulmonary embolism, and stroke.\"}, {\"id\": 6, \"text\": \"Emerging evidence points to an association between severe clinical presentation of COVID-19 and increased risk of thromboembolism. One-third of patients hospitalized due to severe COVID-19 develops macrovascular thrombotic complications, including venous thromboembolism, myocardial injury/infarction and stroke.\"}, {\"id\": 14, \"text\": \"A large proportion of patients with coronavirus disease 19 (COVID-19) suffer from excessive coagulation activation and coagulopathy which predisposes them to a wide spectrum of thrombotic events including in situ pulmonary thrombosis, deep-vein thrombosis, and associated pulmonary embolism, as well as arterial thrombotic events.\"}, {\"id\": 7, \"text\": \"Common thrombotic complications include pulmonary embolism, cerebral infarction, or venous thromboembolism; less commonly seen are acute myocardial injury, renal artery thrombosis, and mesenteric ischemia.\"}, {\"id\": 17, \"text\": \"Sixty-four clinically relevant thrombotic complications were diagnosed in 150 patients, mainly pulmonary embolisms (16.7%).\"}, {\"id\": 9, \"text\": \"A prothrombotic state is reported with severe COVID-19 infection, which can manifest in venous and arterial thrombotic events.\"}]``` return a json array of their ids called 'snippets'"}, {"role": "assistant", "content": "{\"snippets\": [20, 9, 19, 16, 6, 11, 8, 17, 12, 5, 4, 10, 3, 2, 21, 1, 14, 18, 15, 23, 22, 7, 0, 13]}"}]}
{"messages": [{"role": "system", "content": "You are BioASQ-GPT, an AI expert in question answering, research, and information retrieval in the biomedical domain."}, {"role": "user", "content": "Given this question: 'What is Cinryze?' select the top 10 snippets that are most helpful for answering this question from this list of snippets, \n        rerank them by helpfulness: ```[{\"id\": 1, \"text\": \"Nanofiltered human C1 inhibitor concentrate (Cinryze\\u00c2\\u00ae): in hereditary angioedema.\"}, {\"id\": 0, \"text\": \"Intravenous nanofiltered human C1 inhibitor (C1-INH NF) concentrate (Cinryze\\u00c2\\u00ae) is used as a direct replacement of deficient levels of plasma C1 inhibitor in patients with hereditary angioedema (HAE). In the EU, C1-INH NF concentrate 1000\\u00e2\\u20ac\\u2030U is indicated in the treatment, pre-procedural prevention, and routine prevention of angioedema attacks in adults and adolescents with HAE. Intravenous C1-INH NF concentrate 1000\\u00e2\\u20ac\\u2030U effectively relieved angioedema attacks in patients with HAE.\"}]``` return a json array of their ids called 'snippets'"}, {"role": "assistant", "content": "{\"snippets\": [1, 0]}"}]}
{"messages": [{"role": "system", "content": "You are BioASQ-GPT, an AI expert in question answering, research, and information retrieval in the biomedical domain."}, {"role": "user", "content": "Given this question: 'Do machine learning-based methods outperform statistical methods for survival analysis?' select the top 10 snippets that are most helpful for answering this question from this list of snippets, \n        rerank them by helpfulness: ```[{\"id\": 1, \"text\": \"DeepSurv models consistently outperformed CoxPH; both approaches performed best when provided with all the datasets. \"}, {\"id\": 4, \"text\": \"Then, we demonstrate that the resulting method, referred to as ELMCoxBAR, can outperform some other state-of-art survival prediction methods such as L1 - or L2 -regularized Cox regression, random survival forest with various splitting rules, and boosted Cox model, in terms of its predictive performance using both simulated and real world datasets.\"}, {\"id\": 3, \"text\": \"This analysis revealed that survival analysis models outperformed binary classification models for risk assessment, and the performance of the survival analysis methods-Cox model regularized with ridge penalty (Cox-Ridge) and partial least squares (PLS) regression for Cox model (Cox-PLS)-were generally more robust than the other methods.\"}, {\"id\": 5, \"text\": \"Furthermore, machine learning approaches have been adapted for survival analysis, to fit nonlinear and complex interaction effects between predictors, and achieve more accurate prediction of individual survival probability.\"}, {\"id\": 6, \"text\": \"Our results reveal that machine-learning-based models such as random survival forests, gradient boosted survival model, and survival support vector machine can outperform the traditional statistical methods, i.e., Cox proportional hazard model.\"}, {\"id\": 0, \"text\": \"BACKGROUND: Machine learning-based risk prediction models may outperform traditional statistical models in large datasets with many variables, by identifying both novel predictors and the complex interactions between them\"}, {\"id\": 2, \"text\": \" Furthermore, although machine learning and data mining methods are based on statistics, most such techniques do not address the biologist's requirement for sound mathematical confidence measures.\"}, {\"id\": 7, \"text\": \" We review traditional survival methods and regularization methods, with various penalty functions, for the analysis of high-dimensional genomics, and describe machine learning techniques that have been adapted to survival analysis.\"}, {\"id\": 8, \"text\": \"BACKGROUND: Over the recent years, machine learning methods have been increasingly explored in cancer prognosis because of the appearance of improved machine learning algorithms. These algorithms can use censored data for modeling, such as support vector machines for survival analysis and random survival forest (RSF). However, it is still debated whether traditional (Cox proportional haz\"}]``` return a json array of their ids called 'snippets'"}, {"role": "assistant", "content": "{\"snippets\": [6, 1, 3, 4, 5, 7, 2, 0, 8]}"}]}
{"messages": [{"role": "system", "content": "You are BioASQ-GPT, an AI expert in question answering, research, and information retrieval in the biomedical domain."}, {"role": "user", "content": "Given this question: 'ZF2001 is used for which disease?' select the top 10 snippets that are most helpful for answering this question from this list of snippets, \n        rerank them by helpfulness: ```[{\"id\": 5, \"text\": \"Effective protection of ZF2001 against the SARS-CoV-2 Delta variant in lethal K18-hACE2 mice.\"}, {\"id\": 2, \"text\": \"Safety and immunogenicity of heterologous boost immunization with an adenovirus type-5-vectored and protein-subunit-based COVID-19 vaccine (Convidecia/ZF2001): A randomized, observer-blinded, placebo-controlled trial.\"}, {\"id\": 4, \"text\": \"Previously, we developed the protein subunit vaccine ZF2001 based on the dimeric receptor-binding domain (RBD) of prototype SARS-CoV-2. \"}, {\"id\": 0, \"text\": \"To investigate the protective efficacy and mechanism of ZF2001 (a protein subunit vaccine with conditional approval in China) to SARS-CoV-2 Delta variant-induced severe pneumonia, the lethal challenge model of K18-hACE2 transgenic mice was used in this study. \"}, {\"id\": 6, \"text\": \"Conclusion: SARS-CoV-2 vaccines (CoronaVac, BBIBP-CorV, and ZF2001) are safe in thyroid cancer patients. \"}, {\"id\": 3, \"text\": \"CONCLUSIONS: Heterologous boosting with ZF2001 following primary vaccination with Convidecia is more immunogenic than a single dose of Convidecia and is not associated with safety concerns. \"}, {\"id\": 1, \"text\": \"We assessed the safety and immunogenicity of heterologous immunization with a recombinant adenovirus type-5-vectored Coronavirus Disease 2019 (COVID-19) vaccine (Convidecia, hereafter referred to as CV) and a protein-subunit-based COVID-19 vaccine (ZF2001, hereafter referred to as ZF).\"}]``` return a json array of their ids called 'snippets'"}, {"role": "assistant", "content": "{\"snippets\": [2, 1, 3, 6, 5, 0, 4]}"}]}
{"messages": [{"role": "system", "content": "You are BioASQ-GPT, an AI expert in question answering, research, and information retrieval in the biomedical domain."}, {"role": "user", "content": "Given this question: 'What mammal has the lowest known chromosome number?' select the top 10 snippets that are most helpful for answering this question from this list of snippets, \n        rerank them by helpfulness: ```[{\"id\": 8, \"text\": \" Here we used the unique cytological attributes of female Indian muntjac, the mammal with the lowest known chromosome number (2n\\u00c2\\u00a0= 6), to characterize and track individual chromosomes with distinct kinetochore size throughout mitosis.\"}, {\"id\": 2, \"text\": \"The Indian muntjac (Muntiacus muntjak) has a diploid chromosome number of 7 in the male and 6 in the female, the lowest number yet described in a mammal.\"}, {\"id\": 9, \"text\": \"The Indian muntjac, an asiatic deer, has the lowest diploid chromosome number among mammals (female 2N = 6; male 2N = 7).\"}, {\"id\": 4, \"text\": \"The Indian muntjac is believed to have the lowest chromosome number in mammals (2n = 6 in females and 2n = 7 in males).\"}, {\"id\": 3, \"text\": \"Here we used the unique cytological attributes of female Indian muntjac, the mammal with the lowest known chromosome number (2n\\u00c2\\u00a0= 6),\"}, {\"id\": 5, \"text\": \"Here we used the unique cytological attributes of female Indian muntjac, the mammal with the lowest known chromosome number (2n\\u00c2\\u00a0= 6), to characterize and track individual chromosomes with distinct kinetochore size throughout mitosis.\"}, {\"id\": 1, \"text\": \"Indian Muntjac, a Placental Mammal with Only Three Chromosomes.\"}, {\"id\": 6, \"text\": \"By combining molecular perturbations and phenotypic analyses in Indian muntjac fibroblasts containing the lowest known diploid chromosome number in mammals (2N\\u00c2\\u00a0= 6) and distinctively large kinetochores, with fixed/live-cell super-resolution coherent-hybrid stimulated emission depletion (CH-STED) nanoscopy and laser microsurgery, we demonstrate a key role for augmin in kinetochore microtubule self-organization and maturation, regardless of pioneer centrosomal microtubules.\"}, {\"id\": 0, \"text\": \"The karyotype of Indian muntjacs (Muntiacus muntjak vaginalis) has been greatly shaped by chromosomal fusion, which leads to its lowest diploid number among the extant known mammals.\"}, {\"id\": 7, \"text\": \" Indian muntjac, a placental mammal with the lowest known chromosome number (n\\u00c2\\u00a0=\\u00c2\\u00a03).\"}]``` return a json array of their ids called 'snippets'"}, {"role": "assistant", "content": "{\"snippets\": [3, 1, 7, 5, 2, 4, 9, 6, 0, 8]}"}]}
{"messages": [{"role": "system", "content": "You are BioASQ-GPT, an AI expert in question answering, research, and information retrieval in the biomedical domain."}, {"role": "user", "content": "Given this question: 'When modifying histones with either activating or repressing marks, such as with acetyl and methyl groups, histone acetyltransferases and histone methyltransferases normally modify which amino acids?' select the top 10 snippets that are most helpful for answering this question from this list of snippets, \n        rerank them by helpfulness: ```[{\"id\": 3, \"text\": \"Lysine residue 9 of histone H3 can either be acetylated or mono-, di-, or tri-methylated.\"}, {\"id\": 19, \"text\": \" Histone methylation modification affects chromatin through the addition of methyl groups to lysine or arginine residues of histones H3 and H4 by means of histone methyl transferases or histone demethylases.\"}, {\"id\": 1, \"text\": \"Histone modifications; acetylation, methylation (both Lysine and Arginine) etc., at different positions regulates the chromatin fluidity and function in a combinatorial manner, which could be referred as an epigenetic language.\"}, {\"id\": 15, \"text\": \"Over the past year or so, methylation of histones has come to be recognised as a major player in the regulation of gene activity. This notion follows the discovery of lysine and arginine methyltransferases and proteins that recognise the methyl-lysine 'mark' on histones. Methylated histones have been implicated in heterochromatic repression, promoter regulation and the propagation of a repressed state via DNA methylation.\"}, {\"id\": 0, \"text\": \"Histone post-translational modifications are essential for the regulation of gene expression in eukaryotes. Gcn5 (KAT2A) is a histone acetyltransferase that catalyzes the post-translational modification at multiple positions of histone H3 through the transfer of acetyl groups to the free amino group of lysine residues.\"}, {\"id\": 10, \"text\": \"Microsequence analyses of H3 from Tetrahymena, yeast, and HeLa cells indicate that lysine 4 is a highly conserved site of methylation, which to date, is the major site detected in Tetrahymena and yeast.\"}, {\"id\": 14, \"text\": \"Histone lysine and arginine residues are subject to a wide array of post-translational modifications including methylation, citrullination, acetylation, ubiquitination, and sumoylation. The combinatorial action of these modifications regulates critical DNA processes including replication, repair, and transcription. In addition, enzymes that modify histone lysine and arginine residues have been correlated with a variety of human diseases including arthritis, cancer, heart disease, diabetes, and neurodegenerative disorders.\"}, {\"id\": 20, \"text\": \"Histone methylation events, especially on arginine- and lysine-residues, are among the best-characterized PTMs, and many of these modifications have been linked to downstream effects.\"}, {\"id\": 12, \"text\": \"The most well studied posttranslational modification of histones is the acetylation of epsilon-amino groups on conserved lysine residues in the histones' amino-terminal tail domains.\"}, {\"id\": 5, \"text\": \"Chemical mechanisms of histone lysine and arginine modifications.\"}, {\"id\": 6, \"text\": \"Histone acetylation is commonly associated with activation of gene expression whereas histone methylation is linked to either activation or repression of gene expression.\"}, {\"id\": 9, \"text\": \"Histone lysine methylation has been implicated in both gene activation and repression, depending on the specific lysine (K) residue that becomes methylated and the state of methylation (mono-, di-, or trimethylation).\"}, {\"id\": 18, \"text\": \"Recent studies have focused on histone arginine and lysine methylation and the roles of these modifications in transcriptional regulation and the establishment of heterochromatin. Concomitantly, several families of histone methyltransferases (HMTs) have been identified that catalyze the methylation of specific arginines or lysines in histones H3 and H4.\"}, {\"id\": 4, \"text\": \"Studies into posttranslational modifications of histones, notably acetylation, have yielded important insights into the dynamic nature of chromatin structure and its fundamental role in gene expression.\"}, {\"id\": 16, \"text\": \"Among the well-known covalent modifications of histones, the reversible acetylation of internal lysine residues in histone amino-terminal domains has long been positively linked to transcriptional activation.\"}, {\"id\": 11, \"text\": \"Kinetic studies show that acetylation at any of the four acetylatable lysine residues of histone H4 results in more efficient methylation.\"}, {\"id\": 8, \"text\": \"Histone methylation represents one of the most critical epigenetic events in DNA function regulation in eukaryotic organisms.\"}, {\"id\": 17, \"text\": \"Histone lysine methylation is known to either activate or repress gene expression depending upon the position and status of the methylated lysine residue.\"}, {\"id\": 7, \"text\": \"Histones are the major protein constituent of chromatin in the eukaryotic nucleus. These proteins undergo a host of different post-translational modifications, including phosphorylation, acetylation, and methylation, which have profound effects on the remodeling of chromatin.\"}, {\"id\": 13, \"text\": \"Chromatin remodelling events play an important role in the secondary metabolism of filamentous fungi. Previously, we showed that a bacterium, Streptomyces rapamycinicus, is able to reprogram the histone-modifying Spt-Ada-Gcn5-acetyltransferase/ADA (SAGA/ADA) complex of the model fungus Aspergillus nidulans. Consequently, the histone H3 amino acids lysine 9 and lysine 14 at distinct secondary metabolism genes were specifically acetylated during the bacterial fungal interaction, which, furthermore, was associated with the activation of the otherwise silent orsellinic acid gene cluster.\"}, {\"id\": 2, \"text\": \"Methylation of histone H3 at lysine 4 is highly conserved and correlates with transcriptionally active nuclei in Tetrahymena.\"}]``` return a json array of their ids called 'snippets'"}, {"role": "assistant", "content": "{\"snippets\": [14, 8, 4, 10, 2, 13, 15, 7, 18, 1, 6, 3, 17, 9, 11, 19, 12, 16, 5, 20, 0]}"}]}
{"messages": [{"role": "system", "content": "You are BioASQ-GPT, an AI expert in question answering, research, and information retrieval in the biomedical domain."}, {"role": "user", "content": "Given this question: 'Which company produces Ruconest?' select the top 10 snippets that are most helpful for answering this question from this list of snippets, \n        rerank them by helpfulness: ```[{\"id\": 0, \"text\": \"Recombinant human C1 esterase inhibitor (rhC1INH) (Ruconest(\\u00c2\\u00ae), Pharming) is a new drug developed for the relief of symptoms occurring in patients with angioedema due to C1-inhibitor deficiency.\"}]``` return a json array of their ids called 'snippets'"}, {"role": "assistant", "content": "{\"snippets\": [0]}"}]}
{"messages": [{"role": "system", "content": "You are BioASQ-GPT, an AI expert in question answering, research, and information retrieval in the biomedical domain."}, {"role": "user", "content": "Given this question: 'What is usually the age of diagnosis in Duchenne muscular dystrophy?' select the top 10 snippets that are most helpful for answering this question from this list of snippets, \n        rerank them by helpfulness: ```[{\"id\": 1, \"text\": \"In 10 cases of the group with locomotion problems (45.4%) the diagnosis was made between 3 and 11 years of age.\"}, {\"id\": 2, \"text\": \"The mean [median] ages in years of diagnostic milestones were: first signs, 2.7 [2.0]; first creatine kinase (CK), 4.6 [4.6]; DNA/muscle biopsy testing, 4.9 [4.8]; and time from first signs to diagnostic confirmation, 2.2 [1.4].\"}, {\"id\": 7, \"text\": \"The disease is typically diagnosed between 3 and 7 years of age and follows a predictable clinical course marked by progressive skeletal muscle weakness with loss of ambulation by 12 years of age.\"}, {\"id\": 8, \"text\": \" The average age at diagnosis is 4.83 years but an early diagnosis is possible\"}, {\"id\": 0, \"text\": \"ive loss of muscle function. Despite technological advances in diagnostic genetic testing, the mean age at diagnosis (4.7 years) has re\"}, {\"id\": 5, \"text\": \"The mean age for DMD diagnosis was 4.9 years.\"}, {\"id\": 6, \"text\": \" The mean age for DMD diagnosis was 4.9 years. \"}, {\"id\": 3, \"text\": \"The mean age of diagnosis was 4.43\\u00e2\\u20ac\\u2030years. \"}, {\"id\": 4, \"text\": \"lso frequent. The average age at diagnosis is 4.83 years but an early diagnosis is possible.CLINICAL CASE: An 18-month male infant in ambulatory study for failure to thrive and malnutrition was admitted in our hospi\"}]``` return a json array of their ids called 'snippets'"}, {"role": "assistant", "content": "{\"snippets\": [2, 3, 6, 1, 5, 4, 7, 8, 0]}"}]}
{"messages": [{"role": "system", "content": "You are BioASQ-GPT, an AI expert in question answering, research, and information retrieval in the biomedical domain."}, {"role": "user", "content": "Given this question: 'Was erythropoietin effective for optic neuritis in the TONE trial?' select the top 10 snippets that are most helpful for answering this question from this list of snippets, \n        rerank them by helpfulness: ```[{\"id\": 0, \"text\": \"INTERPRETATION: Erythropoietin as an adjunct to corticosteroids conveyed neither functional nor structural neuroprotection in the visual pathways after optic neuritis. \"}]``` return a json array of their ids called 'snippets'"}, {"role": "assistant", "content": "{\"snippets\": [0]}"}]}
{"messages": [{"role": "system", "content": "You are BioASQ-GPT, an AI expert in question answering, research, and information retrieval in the biomedical domain."}, {"role": "user", "content": "Given this question: 'What is the R value with respect to hepatoxicity' select the top 10 snippets that are most helpful for answering this question from this list of snippets, \n        rerank them by helpfulness: ```[{\"id\": 3, \"text\": \"AST can reliably replace ALT when calculating pattern of liver injury in DILI, while GGT can only substitute ALP when the R value scores as hepatocellular. \"}, {\"id\": 2, \"text\": \"RECENT FINDINGS: Several case series of DILI because of various drugs have been published, and analysis of these case series points to the fact that individual drugs have characteristic DILI signatures. These clinical phenotypes can be characterized by latency, biochemical features (R-value), as well as clinical symptoms and signs. \"}, {\"id\": 0, \"text\": \"We aimed to explore the validity of using aspartate aminotransferase (AST) and gamma-glutamyl transpeptidase (GGT) as biomarkers of hepatocelullar and cholestatic damage, respectively, when calculating the R value.\"}, {\"id\": 1, \"text\": \"We compared 3 ways to use Hy's Law to predict which patients would develop ALF; all included TBL greater than 2-fold the upper limit of normal (\\u00c3\\u2014ULN) and either ALT\\u00c2\\u00a0level greater than 3\\u00c2\\u00a0\\u00c3\\u2014 ULN, a ratio (R) value (ALT\\u00c2\\u00a0\\u00c3\\u2014 ULN/alkaline phosphatase\\u00c2\\u00a0\\u00c3\\u2014 ULN) of 5 or greater, or a new ratio (nR) value (ALT or AST, whichever produced the highest\\u00c2\\u00a0\\u00c3\\u2014ULN/ alkaline phosphatase\\u00c2\\u00a0\\u00c3\\u2014 ULN value) of 5 or greater.\"}]``` return a json array of their ids called 'snippets'"}, {"role": "assistant", "content": "{\"snippets\": [2, 0, 3, 1]}"}]}
{"messages": [{"role": "system", "content": "You are BioASQ-GPT, an AI expert in question answering, research, and information retrieval in the biomedical domain."}, {"role": "user", "content": "Given this question: 'Is COVID-19 caused by the Omicron variant less severe than infection caused by other variants?' select the top 10 snippets that are most helpful for answering this question from this list of snippets, \n        rerank them by helpfulness: ```[{\"id\": 2, \"text\": \" The Omicron is highly transmissible and is spreading faster than any previous variant, but may cause less severe symptoms than previous variants.\"}, {\"id\": 5, \"text\": \"The Omicron variant (B.1.1.529) is estimated to be more transmissible than previous strains of SARS-CoV-2 especially among children, potentially resulting in croup which is a characteristic disease in children.\"}, {\"id\": 14, \"text\": \"Omicron variant infection is associated with significantly lower severity of disease compared with the Delta variant.\"}, {\"id\": 11, \"text\": \"After propensity-score matching for demographics, socio-economic determinants of health, comorbidities, medications and vaccination status, the 3-day risks in the Emergent Omicron cohort outcomes were consistently less than half those in the Delta cohort: ED visit: 4.55% vs. 15.22% (risk ratio or RR: 0.30, 95% CI: 0.28-0.33); hospitalization: 1.75% vs. 3.95% (RR: 0.44, 95% CI: 0.38-0.52]); ICU admission: 0.26% vs. 0.78% (RR: 0.33, 95% CI:0.23-0.48); mechanical ventilation: 0.07% vs. 0.43% (RR: 0.16, 95% CI: 0.08-0.32).\"}, {\"id\": 17, \"text\": \"Omicron appears to lead to a milder illness for patients compared with previous COVID-19 variants.\"}, {\"id\": 23, \"text\": \"However, we found that infections by Omicron were significantly less severe than those caused by Delta and other previous variants.\"}, {\"id\": 18, \"text\": \"In the general population, illness after infection with the SARS-CoV-2 Omicron variant is less severe compared with previous variants.\"}, {\"id\": 8, \"text\": \"The omicron variant (B.1.1.529) of SARS-CoV-2 has demonstrated partial vaccine escape and high transmissibility, with early studies indicating lower severity of infection than that of the delta variant (B.1.617.2). We aimed to better characterise omicron severity relative to delta by assessing the relative risk of hospital attendance, hospital admission, or death in a large national cohort.\"}, {\"id\": 10, \"text\": \"We found that infections caused by the Omicron variant caused significantly less morbidity, including admission to the hospital and requirement for oxygen supplementation, and significantly less mortality than those caused by the Delta variant.\"}, {\"id\": 19, \"text\": \"A significant difference between the age-specific susceptibility to the Omicron and that to the pre-Omicron variants was found in the younger age group. The rise in susceptibility to the Omicron/pre-Delta variant was highest in the 10-15 years age group (5.28 times [95% CI, 4.94-5.60]), and the rise in susceptibility to the Omicron/Delta variant was highest in the 15-19 years age group (3.21 times [95% CI, 3.12-3.31]), whereas in those aged 50 years or more, the susceptibility to the Omicron/pre-Omicron remained stable at approximately twofold.\"}, {\"id\": 24, \"text\": \"The adjusted hazard ratio (HR) of hospital attendance (not necessarily resulting in admission) with omicron compared with delta was 0\\u00c2\\u00b756 (95% CI 0\\u00c2\\u00b754-0\\u00c2\\u00b758); for hospital admission and death, HR estimates were 0\\u00c2\\u00b741 (0\\u00c2\\u00b739-0\\u00c2\\u00b743) and 0\\u00c2\\u00b731 (0\\u00c2\\u00b726-0\\u00c2\\u00b737), respectively.\"}, {\"id\": 0, \"text\": \"In this study, symptoms of COVID-19 tended to be milder than described for previous SARS-CoV2 variants.\"}, {\"id\": 20, \"text\": \"One of the newest variants is Omicron, which shows an increase in its transmissibility, but also reportedly reduces hospitalization rates and shows milder symptoms, such as in those who have been vaccinated.\"}, {\"id\": 13, \"text\": \"Infection with SARS-CoV-2 variant Omicron is considered to be less severe than infection with variant Delta, with rarer occurrence of severe disease requiring intensive care.\"}, {\"id\": 3, \"text\": \"Most of those infected with Omicron experience symptoms, and the Omicron variant appears to lead to less severe disease. However, this does not mean that all the infected experience an Omicron infection as mild.\"}, {\"id\": 4, \"text\": \"Here we compared 3-day risks of emergency department (ED) visit, hospitalization, intensive care unit (ICU) admission, and mechanical ventilation in patients who were first infected during a time period when the Omicron variant was emerging to those in patients who were first infected when the Delta variant was predominant.\"}, {\"id\": 21, \"text\": \"Severe acute respiratory syndrome coronavirus 2 infection from the Omicron variant in children/adolescents is less severe than infection from the Delta variant.\"}, {\"id\": 22, \"text\": \" Early work suggests that infections caused by the Omicron variant may be less severe than those caused by the Delta variant.\"}, {\"id\": 7, \"text\": \"Even after adjusting for contact pattern, vaccination status, and waning of vaccine effectiveness, the Omicron variant of SARS-CoV-2 tends to propagate more easily among children than the pre-Omicron strains.\"}, {\"id\": 6, \"text\": \"These early national data suggest that omicron is associated with a two-thirds reduction in the risk of COVID-19 hospitalisation compared with delta.\"}, {\"id\": 1, \"text\": \"First time SARS-CoV-2 infections occurring at a time when the Omicron variant was rapidly spreading were associated with significantly less severe outcomes than first-time infections when the Delta variant predominated.\"}, {\"id\": 9, \"text\": \"Globally, SARS CoV-2 omicron variant has led to a notable increase of COVID-19 diagnoses, although with less severe clinical manifestations and decreased hospitalizations.\"}, {\"id\": 15, \"text\": \" Early reports of Omicron variant confirmed patients indicated less severe disease course compared with the disease caused by previously encountered variants with absence of data regarding cardiac involvement by Omicron\"}, {\"id\": 16, \"text\": \"The Omicron is highly transmissible and is spreading faster than any previous variant, but may cause less severe symptoms than previous variants.\"}, {\"id\": 12, \"text\": \" The risk of severe outcomes following SARS-CoV-2 infection is substantially lower for omicron than for delta, with higher reductions for more severe endpoints and significant variation with age.\"}]``` return a json array of their ids called 'snippets'"}, {"role": "assistant", "content": "{\"snippets\": [17, 3, 0, 6, 9, 20, 4, 1, 11, 16, 8, 24, 12, 5, 19, 7, 13, 10, 22, 2, 15, 23, 21, 14, 18]}"}]}
{"messages": [{"role": "system", "content": "You are BioASQ-GPT, an AI expert in question answering, research, and information retrieval in the biomedical domain."}, {"role": "user", "content": "Given this question: 'What is hereditary angioedema?' select the top 10 snippets that are most helpful for answering this question from this list of snippets, \n        rerank them by helpfulness: ```[{\"id\": 0, \"text\": \"Hereditary angioedema (HAE) is a rare disease that causes episodic attacks of subcutaneous and submucosal edema, which can be painful, incapacitating, and potentially fatal. These attacks are mediated by excessive bradykinin production, as a result of uncontrolled activation of the plasma kallikrein/kinin system, which is caused by a C1 esterase inhibitor deficiency or dysfunction in HAE types 1 and 2, respectively.\"}]``` return a json array of their ids called 'snippets'"}, {"role": "assistant", "content": "{\"snippets\": [0]}"}]}
{"messages": [{"role": "system", "content": "You are BioASQ-GPT, an AI expert in question answering, research, and information retrieval in the biomedical domain."}, {"role": "user", "content": "Given this question: 'What is viltolarsen's mechanism of action?' select the top 10 snippets that are most helpful for answering this question from this list of snippets, \n        rerank them by helpfulness: ```[{\"id\": 3, \"text\": \"Viltolarsen, also known as NS-065/NCNP-01, is a PMO developed through comprehensive sequence optimization and is designed to skip exon 53 on the DMD primary transcript.\"}, {\"id\": 1, \"text\": \"OBJECTIVE: The novel morpholino antisense oligonucleotide viltolarsen targets exon 53 of the dystrophin gene, and could be an effective treatment for patients with Duchenne muscular dystr\"}, {\"id\": 4, \"text\": \"The morpholino AON viltolarsen (code name: NS-065/NCNP-01) has been shown to induce exon 53 skipping, restoring the reading frame for patients with exon 52 deletions.\"}, {\"id\": 5, \"text\": \"Viltolarsen is a drug of phosphorodiamidate morpholino oligomer (PMO) chemistry, designed to skip exon 53 of the DMD gene.\"}, {\"id\": 0, \"text\": \"Viltolarsen restores the reading frame of the DMD gene by skipping \\u00c2\\u00a0exon 53\\u00c2\\u00a0and produces a truncated but functional form of dystrophin.\"}, {\"id\": 6, \"text\": \"Viltolarsen is a phosphorodiamidate morpholino antisense oligonucleotide (PMO) designed to skip exon 53 of the DMD gene\"}, {\"id\": 2, \"text\": \"Viltolarsen binds to exon 53 of the dystrophin mRNA precursor and restores the amino acid open-reading frame by skipping exon 53, resulting in the production of a shortened dystrophin protein that contains essential functional portions.\"}]``` return a json array of their ids called 'snippets'"}, {"role": "assistant", "content": "{\"snippets\": [6, 0, 3, 2, 5, 1, 4]}"}]}
{"messages": [{"role": "system", "content": "You are BioASQ-GPT, an AI expert in question answering, research, and information retrieval in the biomedical domain."}, {"role": "user", "content": "Given this question: 'Should be used bexarotene for relapsing-remitting multiple sclerosis?' select the top 10 snippets that are most helpful for answering this question from this list of snippets, \n        rerank them by helpfulness: ```[{\"id\": 0, \"text\": \"INTERPRETATION: We do not recommend the use of bexarotene to treat patients with multiple sclerosis because of its poor tolerability and negative primary efficacy outcome. \"}]``` return a json array of their ids called 'snippets'"}, {"role": "assistant", "content": "{\"snippets\": [0]}"}]}
{"messages": [{"role": "system", "content": "You are BioASQ-GPT, an AI expert in question answering, research, and information retrieval in the biomedical domain."}, {"role": "user", "content": "Given this question: 'Hepcidin is a key regulator of what processes?' select the top 10 snippets that are most helpful for answering this question from this list of snippets, \n        rerank them by helpfulness: ```[{\"id\": 0, \"text\": \"Hepcidin is the key regulator of systemic iron homeostasis.\"}, {\"id\": 46, \"text\": \"Iron transport across the human placenta is regulated by hepcidin.\"}, {\"id\": 35, \"text\": \"BACKGROUND: Hepcidin is a key regulator of iron metabolism. It binds to ferroportin and causes the trapping of iron in cells, rendering it unavailable\"}, {\"id\": 43, \"text\": \"Hepcidin is thought to be a key regulator in iron metabolism and has been implicated in ACD.\"}, {\"id\": 32, \"text\": \"The peptide hormone hepcidin is a key homeostatic regulator of iron metabolism and involved in pathological regulation of iron in response to infection, inflammation, hypoxia, and anemia.\"}, {\"id\": 7, \"text\": \"Hepcidin, a small peptide synthesized in the liver, is a key regulator of iron absorption and homeostasis in mammals.\"}, {\"id\": 27, \"text\": \"Hepatic peptide hormone hepcidin is the key regulator of iron metabolism and the mediator of anemia of inflammation.\"}, {\"id\": 25, \"text\": \"Information on the metabolism of hepcidin and its possible significance as a biochemical parameter in iron deficiency anemia is reported in this review, which was based on a survey of the databases PubMed and LILACS for articles published between 2006 and 2010 on hepcidin as a biomarker for the regulation of iron metabolism\"}, {\"id\": 37, \"text\": \"The role of hepcidin in regulating iron homeostasis in selected diseases.\"}, {\"id\": 22, \"text\": \"Hepcidin, discovered in the year 2000, is an endogenous peptide responsible for iron homeostasis.\"}, {\"id\": 2, \"text\": \"Hepcidin is a key regulator of iron homeostasis and plays a role in the pathogenesis of anaemia of chronic disease.\"}, {\"id\": 31, \"text\": \"Hepcidin is the major regulator of systemic iron metabolism, while the role of this peptide in the brain has just recently been elucidated.\"}, {\"id\": 50, \"text\": \"Hepcidin is a liver-made peptide proposed to be a central regulator of intestinal iron absorption and iron recycling by macrophages.\"}, {\"id\": 11, \"text\": \"central role in hepcidin regulation. Hepcidin is a key regulator ofiron homeostasis and has now been suggested as a central mediator ofiron metabolism\"}, {\"id\": 6, \"text\": \"we investigate the role of hepcidin, a master regulator of iron homeostasis, on regulation of iron transport across trophoblast cells.\"}, {\"id\": 36, \"text\": \"Hepcidin, a key regulator of iron metabolism, plays a crucial role in the pathogenesis of anemia of chronic disease.\"}, {\"id\": 49, \"text\": \"Hepcidin is a key regulator controlling iron intestinal absorption and distribution through the body.\"}, {\"id\": 10, \"text\": \"Hepcidin: a direct link between iron metabolism and immunity.\"}, {\"id\": 53, \"text\": \"The regulation of iron export is controlled predominantly at the systemic level by the master regulator of iron homeostasis hepcidin. Hepcidin, in turn, responds to changes in body iron demand, making use of a range of regulatory mechanisms that center on the bone morphogenetic protein signaling pathway. \"}, {\"id\": 14, \"text\": \"Hepcidin, which is mainly produced by the liver, is the key regulator in iron homeostasis.\"}, {\"id\": 20, \"text\": \"PURPOSE OF REVIEW: Hepcidin is a recently discovered hepatic peptide that regulates intestinal iron absorption as well as maternal-fetal iron transport a\"}, {\"id\": 19, \"text\": \"Hepcidin is the key regulator of iron metabolism.\"}, {\"id\": 41, \"text\": \" Hepcidin is a key regulator of systemic iron balance.\"}, {\"id\": 52, \"text\": \"Hepcidin, a 25-amino-acid peptide secreted by the liver, distributed in the plasma and excreted in urine, is a key central regulator of body iron homeostasis.\"}, {\"id\": 5, \"text\": \"Hepcidin, a key regulator of iron homeostasis, is known to have three isoforms: hepcidin-20, -22, and -25.\"}, {\"id\": 4, \"text\": \"Hepcidin is the master regulator of iron metabolism. It plays a key role in the regulation of iron transport across the duodenal epithelium, which in \"}, {\"id\": 38, \"text\": \"Hepcidin is an iron-regulatory protein that is upregulated in response to increased iron or inflammatory stimuli.\"}, {\"id\": 42, \"text\": \"Hepcidin is related to the pathogenesis of chronic renal failure anemia, which is considered a chronic inflammatory state\"}, {\"id\": 33, \"text\": \"Hepcidin, a key regulator of iron metabolism, is synthesized by the liver. Hepcidin binds to the iron exporter ferroportin to regulate the release of \"}, {\"id\": 47, \"text\": \"Although hepcidin, a small circulating peptide produced by the liver, has been found to be the key regulator of iron trafficking, molecular pathways of iron sensing that control iron metabolism and hepcidin production are still incompletely understood.\"}, {\"id\": 48, \"text\": \"Hepcidin: A key regulator of iron.\"}, {\"id\": 16, \"text\": \"Hepcidin, a key regulator of iron homeostasis, is increased by iron overload and inflammation while suppressed by hypoxia.\"}, {\"id\": 13, \"text\": \"ved in postmenopausal osteoporosis. Hepcidin is a key regulator of iron homeostasis. However, the exact role of hepcidin in bone metabolism and the un\"}, {\"id\": 26, \"text\": \"Recent data suggests that hepcidin is a major mediator of anemia and plays a central role in iron homeostasis and metabolism\"}, {\"id\": 51, \"text\": \"The discovery of hepcidin as a key regulator of iron homeostasis has advanced our current knowledge of this field.\"}, {\"id\": 1, \"text\": \"y reducing iron export through ferroportin to blood plasma, hepcidin inhibits the mobilization of iron from stores and the absorption of dietary iron.\"}, {\"id\": 40, \"text\": \"Hepcidin is the master regulator of iron metabolism.\"}, {\"id\": 34, \"text\": \"BACKGROUND: Hepcidin is a central regulator of iron metabolism. Serum hepcidin levels are increased in patients with renal insufficiency, which may co\"}, {\"id\": 54, \"text\": \"The Dual Role of Hepcidin in Brain Iron Load and Inflammation.\"}, {\"id\": 44, \"text\": \"Iron is an essential metal for cell survival that is regulated by the peptide hormone hepcidin. However, its influence on certain diseases is directly related to iron metabolism or secondary to underlying diseases.\"}, {\"id\": 12, \"text\": \"Hepcidin is a key hormone that is involved in the control of iron homeostasis in the body.\"}, {\"id\": 23, \"text\": \"The peptide hormone hepcidin is one of the key regulators of iron absorption, plasma iron levels, and tissue iron distribution.\"}, {\"id\": 39, \"text\": \"Hepcidin, a key regulator of iron metabolism and mediator of anemia of inflammation.\"}, {\"id\": 17, \"text\": \"Hepcidin, a key regulator of iron metabolism, decreases intestinal absorption of iron and its release from macrophages.\"}, {\"id\": 45, \"text\": \"Since its discovery in 2001, there have been a number of important discoveries and findings that have increased our knowledge about the functioning of hepcidin. Hepcidin, the master iron regulator has been shown to be regulated by a number of physiological stimuli and their associated signaling pathways. This chapter will summarize our current understanding of how these physiological \"}, {\"id\": 30, \"text\": \"The hepatic hormone hepcidin is a key regulator of systemic iron metabolism.\"}, {\"id\": 28, \"text\": \"Hepcidin is a small disulfide-rich peptide hormone that plays a key role in the regulation of iron homeostasis by binding and mediating the degradation of the cell membrane iron efflux transporter, ferroportin.\"}, {\"id\": 15, \"text\": \"Hepcidin is the key regulator of iron absorption and recycling, and its expression is suppressed by red blood cell production.\"}, {\"id\": 21, \"text\": \"Hepcidin is a key regulator of iron homeostasis, while hemojuvelin is an important component of the hepcidin regulation pathway.\"}, {\"id\": 29, \"text\": \" Studies suggest a dual role of hepcidin in neuronal iron load and inflammation.\"}, {\"id\": 3, \"text\": \"In mammalian systems, iron availability is controlled by the interaction of the iron-regulatory hormone hepcidin with ferroportin, a molecule that functions both as the hepcidin receptor as well as the sole known cellular exporter of iron. \"}, {\"id\": 24, \"text\": \"Regulation of the Iron Homeostatic Hormone Hepcidin.\"}, {\"id\": 18, \"text\": \"n from hemoglobin. Connecting iron metabolism to innate immunity, hepcidin is a key mediator of hypoferremia of inflammation.RECENT FINDINGS: The essential role of hepcidin in iron metabolism is being elucidated through mouse and human genetics, biochemistry, and cell biology.SUMMARY: Studies of hepcidin are leading to fundamental understanding of iron homeostasis and pointing to potential treatments for hemochromatosis and anemia\"}, {\"id\": 8, \"text\": \"The serum level of iron in humans is tightly controlled by the action of the hormone hepcidin on the iron efflux transporter ferroportin. Hepcidin regulates iron absorption and recycling by inducing the internalization and degradation of ferroportin1\"}, {\"id\": 9, \"text\": \"Hepcidin is a main regulator of iron metabolism, of which abnormal expression affects intestinal absorption and reticuloendothelial sequestration of iron by interacting with ferroportin.\"}]``` return a json array of their ids called 'snippets'"}, {"role": "assistant", "content": "{\"snippets\": [16, 22, 26, 53, 3, 1, 25, 42, 46, 6, 30, 47, 50, 32, 23, 38, 7, 52, 39, 28, 12, 20, 18, 37, 41, 54, 40, 29, 49, 19, 0, 10, 48, 5, 36, 14, 15, 17, 2, 4, 13, 11, 34, 35, 21, 27, 43, 51, 33, 9, 31, 24, 8, 45, 44]}"}]}
{"messages": [{"role": "system", "content": "You are BioASQ-GPT, an AI expert in question answering, research, and information retrieval in the biomedical domain."}, {"role": "user", "content": "Given this question: 'Can analgesics or antipyretics be taken for side effects following COVID-19 vaccination?' select the top 10 snippets that are most helpful for answering this question from this list of snippets, \n        rerank them by helpfulness: ```[{\"id\": 12, \"text\": \"Some studies revealed changes in certain immune response parameters post-vaccination when analgesics/antipyretics were used either prophylactically or therapeutically.\"}, {\"id\": 4, \"text\": \" Some studies revealed changes in certain immune response parameters post-vaccination when analgesics/antipyretics were used either prophylactically or therapeutically.\"}, {\"id\": 1, \"text\": \" Although fever is part of the normal inflammatory process after immunisation, prophylactic antipyretic drugs are sometimes recommended to allay concerns of high fever and febrile convulsion. We assessed the effect of prophylactic administration of paracetamol at vaccination on infant febrile reaction rates and vaccine responses.\"}, {\"id\": 0, \"text\": \"Worldwide, paracetamol is administered as a remedy for complaints that occur after vaccination. Recently published results indicate that paracetamol inhibits the vaccination response in infants when given prior to vaccination.\"}, {\"id\": 8, \"text\": \"Analgesics or antipyretic medications are often used to alleviate vaccine side effects, but their effect on immunogenicity remains uncertain. Few studies have assessed the effect of analgesics/antipyretics on vaccine immunogenicity and reactogenicity. Some studies revealed changes in certain immune response parameters post-vaccination when analgesics/antipyretics were used either prophylactically or therapeutically. Still, there is no evidence that these changes impact vaccine efficacy. Specific data on the impact of analgesic/antipyretic medications on immunogenicity of COVID-19 vaccines are limited. However, available data from clinical trials of licensed vaccines, along with recommendations from public health bodies around the world, should provide reassurance to both healthcare professionals and vaccine recipients that short-term use of analgesics/antipyretics at non-prescription doses is unlikely to affect vaccine-induced immunity.\"}, {\"id\": 9, \"text\": \"Analgesics or antipyretic medications are often used to alleviate vaccine side effects, but their effect on immunogenicity remains uncertain.\"}, {\"id\": 3, \"text\": \" Although febrile reactions significantly decreased, prophylactic administration of antipyretic drugs at the time of vaccination should not be routinely recommended since antibody responses to several vaccine antigens were reduced.\"}, {\"id\": 11, \"text\": \"Specific data on the impact of analgesic/antipyretic medications on immunogenicity of COVID-19 vaccines are limited.\"}, {\"id\": 10, \"text\": \" Specific data on the impact of analgesic/antipyretic medications on immunogenicity of COVID-19 vaccines are limited.\"}, {\"id\": 5, \"text\": \"While antipyretic analgesics are widely used to ameliorate vaccine adverse reactions, their use has been associated with blunted vaccine immune responses.\"}, {\"id\": 7, \"text\": \"However, available data from clinical trials of licensed vaccines, along with recommendations from public health bodies around the world, should provide reassurance to both healthcare professionals and vaccine recipients that short-term use of analgesics/antipyretics at non-prescription doses is unlikely to affect vaccine-induced immunity.\"}, {\"id\": 13, \"text\": \"Antibody geometric mean concentrations (GMCs) were significantly lower in the prophylactic paracetamol group than in the no prophylactic paracetamol group after primary vaccination for all ten pneumococcal vaccine serotypes, protein D, antipolyribosyl-ribitol phosphate, antidiphtheria, antitetanus, and antipertactin.\"}, {\"id\": 2, \"text\": \"One month after the second booster vaccination, the anti-HBs level in the prophylactic paracetamol group was significantly lower (p = 0.048) than the level in the control group (4257 mIU/mL vs. 5768 mIU/mL). The anti-HBs level in the therapeutic paracetamol group (4958 mIU/mL) was not different (p = 0.34) from the level in the control group. Only prophylactic paracetamol treatment, and not therapeutic treatment, during vaccination has a negative influence on the antibody concentration after hepatitis B vaccination in adults. These findings prompt to consider therapeutic instead of prophylactic treatment to ensure maximal vaccination efficacy and retain the possibility to treat pain and fever after vaccination.\"}, {\"id\": 6, \"text\": \" Analgesics or antipyretic medications are often used to alleviate vaccine side effects, but their effect on immunogenicity remains uncertain.\"}]``` return a json array of their ids called 'snippets'"}, {"role": "assistant", "content": "{\"snippets\": [8, 1, 3, 13, 0, 2, 9, 12, 5, 7, 11, 6, 4, 10]}"}]}
{"messages": [{"role": "system", "content": "You are BioASQ-GPT, an AI expert in question answering, research, and information retrieval in the biomedical domain."}, {"role": "user", "content": "Given this question: 'Which drug was the first recombinant human C1 inhibitor protein (C1INH) for the treatment of acute attacks of hereditary angioedema (HAE)?' select the top 10 snippets that are most helpful for answering this question from this list of snippets, \n        rerank them by helpfulness: ```[{\"id\": 0, \"text\": \"Conestat alfa (Ruconest, rhC1INH) is the first recombinant human C1 inhibitor protein (C1INH) for the treatment of acute attacks of hereditary angioedema (HAE).\"}]``` return a json array of their ids called 'snippets'"}, {"role": "assistant", "content": "{\"snippets\": [0]}"}]}
{"messages": [{"role": "system", "content": "You are BioASQ-GPT, an AI expert in question answering, research, and information retrieval in the biomedical domain."}, {"role": "user", "content": "Given this question: 'What type of DMD can viltolarsen be used for?' select the top 10 snippets that are most helpful for answering this question from this list of snippets, \n        rerank them by helpfulness: ```[{\"id\": 12, \"text\": \"Viltolarsen is a phosphorodiamidate morpholino antisense oligonucleotide (PMO) designed to skip exon 53 of the DMD gene\\u00c2\\u00a0for the treatment of Duchenne muscular dystrophy (DMD), one of the most common lethal genetic disorders characterized by progressive degeneration of skeletal muscles and cardiomyopathy.\"}, {\"id\": 5, \"text\": \"Viltolarsen is a phosphorodiamidate morpholino antisense oligonucleotide (PMO) designed to skip exon 53 of the DMD gene\\u00c2\\u00a0for the treatment of Duchenne muscular dystrophy (DMD)\"}, {\"id\": 1, \"text\": \"OBJECTIVE: The novel morpholino antisense oligonucleotide viltolarsen targets exon 53 of the dystrophin gene, and could be an effective treatment for patients with Duchenne muscular dystr\"}, {\"id\": 10, \"text\": \"Viltolarsen, also known as NS-065/NCNP-01, is a PMO developed through comprehensive sequence optimization and is designed to skip exon 53 on the DMD primary transcript.\"}, {\"id\": 7, \"text\": \"In March 2020, intravenous viltolarsen received its first global approval in Japan for the treatment of DMD in patients with confirmed deletion of the dystrophin gene that is amenable to exon 53 skipping.\"}, {\"id\": 0, \"text\": \"Viltolarsen restores the reading frame of the DMD gene by skipping \\u00c2\\u00a0exon 53\\u00c2\\u00a0and produces a truncated but functional form of dystrophin.\"}, {\"id\": 8, \"text\": \"Viltolarsen is a phosphorodiamidate morpholino antisense oligonucleotide (PMO) designed to skip exon 53 of the DMD gene\\u00c2\\u00a0for the treatment of Duchenne muscular dystrophy (DMD),\"}, {\"id\": 11, \"text\": \"Viltolarsen (Viltepso\\u00c2\\u00ae in Japan) is a phosphorodiamidate morpholino antisense oligonucleotide being developed by Nippon Shinyaku, in collaboration with the National Center of Neurology and Psychiatry (NCNP), for the treatment of Duchenne muscular dystrophy (DMD). Viltolarsen binds to exon 53 of the dystrophin mRNA precursor and restores the amino acid open-reading frame by skipping exon 53, resulting in the production of a shortened dystrophin protein that contains essential functional portions. In March 2020, intravenous viltolarsen received its first global approval in Japan for the treatment of DMD in patients with confirmed deletion of the dystrophin gene that is amenable to exon 53 skipping.\"}, {\"id\": 4, \"text\": \" Two exon 53 skipping PMOs, golodirsen and viltolarsen, have received conditional approval for treating patients due to their ability to restore dystrophin protein expression.\"}, {\"id\": 2, \"text\": \" Viltolarsen, an AON for DMD exon 53 skipping, was approved in Japan earlier this year.\"}, {\"id\": 13, \"text\": \"Viltolarsen binds to exon 53 of the dystrophin mRNA precursor and restores the amino acid open-reading frame by skipping exon 53, resulting in the production of a shortened dystrophin protein that contains essential functional portions.\"}, {\"id\": 6, \"text\": \"BACKGROUND: Duchenne muscular dystrophy (DMD) is a rare, genetic disease caused by mutations in the DMD gene resulting in an absence of functional dystrophin protein. Viltolarsen, an exon 53 skipping therapy, has been shown to increase endogenous dystrophin levels. Herein, long-term (>2 years) functional outcomes in viltolarsen treated patients were compared to a matched historical control group.OBJECTIVE: To evaluate long-term efficacy and safety of the anti-sense oligonucleotide viltolarsen in the treatment of patients wit\"}, {\"id\": 9, \"text\": \"en for DMD exon 51 skipping and golodirsen and viltolarsen for DMD exon 53 skipping, have been approved in the last 4 years. We are witnessing the sta\"}, {\"id\": 3, \"text\": \"Viltolarsen is a drug of phosphorodiamidate morpholino oligomer (PMO) chemistry, designed to skip exon 53 of the DMD gene.\"}, {\"id\": 14, \"text\": \"Importance: An unmet need remains for safe and efficacious treatments for Duchenne muscular dystrophy (DMD). To date, there are limited agents available that address the underlying cause of the disease.Objective: To evaluate the safety, tolerability, and efficacy of viltolarsen, a novel antisense oligonucleotide, in participants with DMD amenable to exon 53 skipping.Design, Setting, and Participants: This phase 2 study was a 4-week randomized clinical trial for safety followed by a 20-week open-label treatment period of patients aged 4 to 9\"}]``` return a json array of their ids called 'snippets'"}, {"role": "assistant", "content": "{\"snippets\": [5, 0, 7, 12, 10, 1, 13, 3, 2, 4, 9, 14, 6, 11, 8]}"}]}
{"messages": [{"role": "system", "content": "You are BioASQ-GPT, an AI expert in question answering, research, and information retrieval in the biomedical domain."}, {"role": "user", "content": "Given this question: 'What is the triad of the Cat eye syndrome?' select the top 10 snippets that are most helpful for answering this question from this list of snippets, \n        rerank them by helpfulness: ```[{\"id\": 1, \"text\": \"BACKGROUND: Cat eye syndrome (CES) is a rare chromosomal disease, with estimated incidence of about 1 in 100,000 live newborns. The classic triad of iris coloboma, anorectal malformations, and auricular abnormalities is present in 40% of patients, and other congenital defects may also be observed. \"}, {\"id\": 0, \"text\": \"Cat-eye syndrome is a rare genetic disease that involves the proximal long (q) arm of chromosome 22. The classic clinical triad includes coloboma of the iris, ears, and anal malformations. \"}]``` return a json array of their ids called 'snippets'"}, {"role": "assistant", "content": "{\"snippets\": [0, 1]}"}]}
{"messages": [{"role": "system", "content": "You are BioASQ-GPT, an AI expert in question answering, research, and information retrieval in the biomedical domain."}, {"role": "user", "content": "Given this question: 'Is OXLUMO (lumasiran) used for the treatment of primary hyperoxaluria?' select the top 10 snippets that are most helpful for answering this question from this list of snippets, \n        rerank them by helpfulness: ```[{\"id\": 8, \"text\": \"On 19 November 2020, lumasiran received its first global approval in the EU for the treatment of PH1 in all age groups.\"}, {\"id\": 2, \"text\": \"SIONS: Lumasiran had an acceptable safety profile and reduced urinary oxalate excretion in all patients with primary hyperoxaluria type 1 to near-normal levels.CLINI\"}, {\"id\": 6, \"text\": \"Lumasiran in the Management of Patients with Primary Hyperoxaluria Type 1: From Bench to Bedside.\"}, {\"id\": 4, \"text\": \" Lumasiran was recently approved in the treatment of primary hyperoxaluria type 1 and nedosiran is in the approval process.\"}, {\"id\": 7, \"text\": \"On 23 November 2020, lumasiran was approved in the USA for the treatment of adult and paediatric patients with PH1.\"}, {\"id\": 0, \"text\": \"OXLUMO (lumasiran) for the treatment of primary hyperoxaluria,\"}, {\"id\": 11, \"text\": \"The effect of lumasiran therapy for primary hyperoxaluria type 1 in small infants.\"}, {\"id\": 12, \"text\": \"RATIONALE & OBJECTIVE: Lumasiran reduces urinary and plasma oxalate (POx) in patients with primary hyperoxaluria type 1 (PH1) and relatively preserved kidney function. ILLUMINATE-C evaluates the efficacy, safety, pharmacokinetics, and pharmacodynamics of lumasiran in patients with PH1 and a\"}, {\"id\": 1, \"text\": \"Conjugation of oligonucleotide therapeutics, including small interfering RNAs (siRNAs) or antisense oligonucleotides, to N-acetylgalactosamine (GalNAc) ligands has become the primary strategy for hepatocyte-targeted delivery, and with the recent approvals of GIVLAARI (givosiran) for the treatment of acute hepatic porphyria, OXLUMO (lumasiran) for the treatment of primary hyperoxaluria, and Leqvio (inclisiran) for the treatment of hypercholesterolemia, the technology has been well validated clinically.\"}, {\"id\": 15, \"text\": \"Lumasiran (Oxlumo\\u00e2\\u201e\\u00a2) is a subcutaneously administered small interfering RNA (siRNA) targeting the mRNA for hydroxyacid oxidase 1 gene (HAO1; encodes glycolate oxidase) and was developed by Alnylam Pharmaceuticals for the treatment of primary hyperoxaluria type 1 (PH1).\"}, {\"id\": 3, \"text\": \"Lumasiran is an RNA interference (RNAi) therapeutic agent that reduces hepatic oxalate production, which has been recently approved for the treatment of PH1.\"}, {\"id\": 13, \"text\": \"In this context we discuss nedosiran (Dicerna Pharmaceuticals, Inc.) and lumasiran (Alnylam Pharmaceuticals), which are both novel RNAi therapies for primary hyperoxaluria that selectively reduce hepatic expression of lactate dehydrogenase and glycolate oxidase respectively, reducing hepatic oxalate production and urinary oxalate levels.\"}, {\"id\": 10, \"text\": \"Phase 3 trial of lumasiran for primary hyperoxaluria type 1: A new RNAi therapeutic in infants and young children.\"}, {\"id\": 14, \"text\": \"Several new drugs have been approved to treat rare genetic disorders: setmelanotide for certain conditions causing obesity; lumasiran for primary hyperoxaluria type 1, a kidney disorder; and lonafarnib for two diseases that cause premature aging.\"}, {\"id\": 5, \"text\": \"Efforts made to develop pharmacological treatments succeeded with the biotechnological agent lumasiran, a siRNA product against glycolate oxidase, which has become the first effective therapy to treat PH1.\"}, {\"id\": 9, \"text\": \"Lumasiran, an RNAi Therapeutic for Primary Hyperoxaluria Type 1.\"}]``` return a json array of their ids called 'snippets'"}, {"role": "assistant", "content": "{\"snippets\": [15, 0, 1, 13, 7, 9, 8, 5, 10, 14, 6, 11, 4, 2, 3, 12]}"}]}
{"messages": [{"role": "system", "content": "You are BioASQ-GPT, an AI expert in question answering, research, and information retrieval in the biomedical domain."}, {"role": "user", "content": "Given this question: 'Should patients using inhaled glucocorticoids for asthma or COPD be advised to stop these medications to prevent COVID-19?' select the top 10 snippets that are most helpful for answering this question from this list of snippets, \n        rerank them by helpfulness: ```[{\"id\": 3, \"text\": \"The meta-analysis revealed no significant difference in the risk for the development of a fatal course of COVID-19 with preadmission use of inhaled corticosteroids in patients with COVID-19 relative to non-use of inhaled corticosteroids (pooled odds ratio=1.28; 95% confidence interval 0.73-2.26). Similarly, the meta-analysis observed no significant difference in the risk for the development of a severe course of COVID-19 with preadmission use of inhaled corticosteroids in patients with COVID-19 relative to non-use of inhaled corticosteroids (pooled odds ratio=1.45; 95% confidence interval 0.96-2.20).\"}, {\"id\": 10, \"text\": \"The available recommendations state that patients with asthma should use inhaled glucocorticosteroids (GCS) on a regular basis.\"}, {\"id\": 8, \"text\": \"Our findings assured the safety of continued use of inhaled corticosteroids during the COVID-19 pandemic.\"}, {\"id\": 7, \"text\": \"Additionally, the use of systemic or inhaled glucocorticoids does not appear to increase the risk of severe COVID-19, but there is no evidence guiding the use of biologic therapy.\"}, {\"id\": 0, \"text\": \"However, patients with asthma or COPD should continue all prescribed inhaled medications.\"}, {\"id\": 2, \"text\": \"Evidence from clinical studies indicates that the inhaled corticosteroids (ICS) routinely taken for asthma and COPD could have had a protective role in preventing severe COVID-19 and, therefore, may be a promising treatment for COVID-19.\"}, {\"id\": 12, \"text\": \"Due to its known and important benefits ICS should be prescribed as usual for both asthma and COPD.\"}, {\"id\": 4, \"text\": \"These findings should encourage clinicians to continue ICS therapy for COPD patients during the COVID-19 pandemic.\"}, {\"id\": 5, \"text\": \"International recommendations suggest maintaining asthma under control to limit exacerbations occurrence, by using all available treatment. The minimum steroid dosage effective to control symptoms should be maintained to avoid exacerbations;\"}, {\"id\": 1, \"text\": \"Patients with asthma in regular therapy with ICS at home had significantly shorter hospital stay compared to those with no treatments (25.2 vs. 11.3 days, p = 0.024).\"}, {\"id\": 9, \"text\": \" However, patients with asthma or COPD should continue all prescribed inhaled medications.\"}, {\"id\": 15, \"text\": \"Our study supports the recommendation that patients with chronic pulmonary diseases, including asthma and COPD who require treatment with either inhaled or systemic corticosteroids, should continue their use during the COVID-19 pandemic.\"}, {\"id\": 14, \"text\": \"The benefit-risk ratio is however clearly in favor of continuing inhaled corticosteroids in patients with asthma or COPD.\"}, {\"id\": 13, \"text\": \" Evidence from clinical studies indicates that the inhaled corticosteroids (ICS) routinely taken for asthma and COPD could have had a protective role in preventing severe COVID-19 and, therefore, may be a promising treatment for COVID-19.\"}, {\"id\": 11, \"text\": \"Our study showed that asthma is not associated with worse outcomes of COVID-19, despite the higher need for respiratory support compared with the general population, while the use of ICS allowed for a shorter hospital stay.\"}, {\"id\": 6, \"text\": \" The available evidence suggests that severe asthma patients do not have an increased risk of poor COVID-19 outcomes and that it is safe to treat asthmatic patients with inhaled corticosteroids (ICS) and biologics during the pandemic, even though some studies indicate that high doses of ICS may predispose to COVID-19.\"}]``` return a json array of their ids called 'snippets'"}, {"role": "assistant", "content": "{\"snippets\": [5, 3, 8, 11, 1, 2, 14, 12, 10, 4, 13, 6, 9, 0, 7, 15]}"}]}
{"messages": [{"role": "system", "content": "You are BioASQ-GPT, an AI expert in question answering, research, and information retrieval in the biomedical domain."}, {"role": "user", "content": "Given this question: 'Is Zanubrutinib a first-generation BTK inhibitor approved by US Food and Drug Administration (FDA)?' select the top 10 snippets that are most helpful for answering this question from this list of snippets, \n        rerank them by helpfulness: ```[{\"id\": 0, \"text\": \"In the United States, zanubrutinib, a next-generation BTK inhibitor, has been approved for treating adults with mantle cell lymphoma who have received at least one prior therapy, for adults with Waldenstr\\u00c3\\u00b6m macroglobulinemia, and for adults with relapsed or refractory marginal zone lymphoma who have received at least one anti-CD20-based therapy.\"}]``` return a json array of their ids called 'snippets'"}, {"role": "assistant", "content": "{\"snippets\": [0]}"}]}
{"messages": [{"role": "system", "content": "You are BioASQ-GPT, an AI expert in question answering, research, and information retrieval in the biomedical domain."}, {"role": "user", "content": "Given this question: 'What types of DMD can eteplirsen be used for?' select the top 10 snippets that are most helpful for answering this question from this list of snippets, \n        rerank them by helpfulness: ```[{\"id\": 1, \"text\": \"A relationship between exon skipping and dystrophin production in exon 51-amenable patients treated with eteplirsen (EXONDYS 51\\u00c2\\u00ae) \"}, {\"id\": 0, \"text\": \"treatment effects of eteplirsen over 4 years in patients with Duchenne muscular dystrophy and confirmed exon-51 amenable genetic mutations.\"}]``` return a json array of their ids called 'snippets'"}, {"role": "assistant", "content": "{\"snippets\": [0, 1]}"}]}
{"messages": [{"role": "system", "content": "You are BioASQ-GPT, an AI expert in question answering, research, and information retrieval in the biomedical domain."}, {"role": "user", "content": "Given this question: 'Is Cinpanemab effective for Parkinson\u00e2\u20ac\u2122s Disease?' select the top 10 snippets that are most helpful for answering this question from this list of snippets, \n        rerank them by helpfulness: ```[{\"id\": 0, \"text\": \"CONCLUSIONS: In participants with early Parkinson's disease, the effects of cinpanemab on clinical measures of disease progression and changes in DaT-SPECT imaging did not differ from those of placebo over a 52-week period. \"}]``` return a json array of their ids called 'snippets'"}, {"role": "assistant", "content": "{\"snippets\": [0]}"}]}
{"messages": [{"role": "system", "content": "You are BioASQ-GPT, an AI expert in question answering, research, and information retrieval in the biomedical domain."}, {"role": "user", "content": "Given this question: 'In what organ would you find the Ashwell receptor?' select the top 10 snippets that are most helpful for answering this question from this list of snippets, \n        rerank them by helpfulness: ```[{\"id\": 4, \"text\": \"Platelet-derived antibacterial peptides are important in bloodstream defense against SA, but \\u00ce\\u00b1-toxin decreased platelet viability, induced platelet sialidase to cause desialylation of platelet glycoproteins, and accelerated platelet clearance by the hepatic Ashwell-Morell receptor (AMR).\"}, {\"id\": 6, \"text\": \"The Ashwell receptor, the major lectin of hepatocytes, rapidly clears from blood circulation glycoproteins bearing glycan ligands that include galactose and N-acetylgalactosamine\"}, {\"id\": 2, \"text\": \"This study was designed to investigate several aspects of both models, using lactosylated albumin as a binding protein that can interact with the Ashwell receptor abundantly present on the hepatocyte.\"}, {\"id\": 1, \"text\": \"The asialoglycoprotein receptor (ASGPR) is a hepatic receptor that mediates removal of potentially hazardous glycoconjugates from blood in health and disease. T\"}, {\"id\": 9, \"text\": \"The mammalian asialoglycoprotein receptor (ASGPR) is located on the sinusoidal membrane of hepatocytes where it binds and endocytoses galactose-terminated glycoproteins (asialoglycoproteins). ASGPR is composed of two highly homologous subunits, termed hepatic lectin 1 and 2. Despite numerous studies the contribution of both subunits to biosynthesis and functional activity of ASGPR in vivo\"}, {\"id\": 8, \"text\": \"The Ashwell receptor, the major lectin of hepatocytes, rapidly clears from blood circulation glycoproteins bearing glycan ligands that include galactose and N-acetylgalactosamine.\"}, {\"id\": 10, \"text\": \"The Ashwell-Morell receptor (AMR) of hepatocytes, originally termed the hepatic asialoglycoprotein receptor, was the first cellular receptor to be identified and isolated and the first lectin to be detected in mammals.\"}, {\"id\": 7, \"text\": \"This leads to platelet clearance in the liver via hepatocyte Ashwell-Morell receptors, which is fundamentally different from the classical Fc-Fc\\u00ce\\u00b3R-dependent macrophage phagocytosis.\"}, {\"id\": 5, \"text\": \"From these data, we inferred an additional hepatic uptake mechanism, competing with the Ashwell-receptor-mediated internalization of galactose-terminated glycoproteins. \"}, {\"id\": 3, \"text\": \" This study was designed to investigate several aspects of both models, using lactosylated albumin as a binding protein that can interact with the Ashwell receptor abundantly present on the hepatocyte.\"}, {\"id\": 0, \"text\": \"The endocytic Ashwell-Morell receptor (AMR) of hepatocytes detects pathogen remodeling of host glycoproteins by neuraminidase in the bloodstream and mitigates the lethal coagulopathy of sepsis.\"}]``` return a json array of their ids called 'snippets'"}, {"role": "assistant", "content": "{\"snippets\": [5, 3, 1, 6, 10, 8, 0, 4, 2, 7, 9]}"}]}
{"messages": [{"role": "system", "content": "You are BioASQ-GPT, an AI expert in question answering, research, and information retrieval in the biomedical domain."}, {"role": "user", "content": "Given this question: 'What histone marks are indicative of enhancers in the chromatin landscape of a given cell?' select the top 10 snippets that are most helpful for answering this question from this list of snippets, \n        rerank them by helpfulness: ```[{\"id\": 1, \"text\": \"DNA methylation at promoters is largely correlated with inhibition of gene expression. However, the role of DNA methylation at enhancers is not fully understood, although a crosstalk with chromatin marks is expected. Actually, there exist contradictory reports about positive and negative correlations between DNA methylation and H3K4me1, a chromatin hallmark of enhancers.\"}, {\"id\": 6, \"text\": \"In general, transcription start sites of actively transcribed genes are marked by trimethylated H3K4 (H3K4me3) and acetylated H3K27 (H3K27ac), and active enhancers can be identified by enrichments of both monomethylated H3K4 (H3K4me1) and H3K27ac.\"}, {\"id\": 5, \"text\": \"Studies performed on mammalian embryonic stem cells and Drosophila embryos suggest that active enhancers form part of a defined chromatin landscape marked by histone H3 lysine 4 mono-methylation (H3K4me1) and histone H3 lysine 27 acetylation (H3K27ac).\"}, {\"id\": 11, \"text\": \"The coexistence of high mono-methylation and low tri-methylation levels of lysine 4 of histone H3 is considered a signature of enhancers, but a comprehensive view of histone modifications associated to enhancers is still lacking.\"}, {\"id\": 4, \"text\": \"We hypothesized \\\"seesaw\\\" dynamics between H3K4me1 and H3K4me3 in the low and intermediate DNA methylation range, in which DNA methylation discriminates between enhancers and promoters, marked by H3K4me1 and H3K4me3, respectively. Low methylated regions are H3K4me3 enriched, while those with intermediate DNA methylation levels are progressively H3K4me1 enriched. Additionally, the enrichment of H3K27ac, distinguishing active from primed enhancers, follows a plateau in the lower range of the intermediate DNA methylation level, corresponding to active enhancers, and decreases linearly in the higher range of the intermediate DNA methylation. Thus, the decrease of the DNA methylation switches smoothly the state of the enhancers from a primed to an active state.\"}, {\"id\": 8, \"text\": \"In mammalian cells, active or primed enhancers are commonly marked by monomethylation of histone H3 at lysine 4 (H3K4me1) in a cell-type-specific manner.\"}, {\"id\": 2, \"text\": \"These complex regulatory mechanisms are often defined by combinatorial histone PTMs; for instance, active enhancers are commonly occupied by both marks H3K4me1 and H3K27ac.\"}, {\"id\": 7, \"text\": \"Furthermore, 218 p53-bound enhancers (Enhp53) were identified by analyzing p53 ChIP-seq in HepG2 cells after DNA damage. The results showed that the enhancer expression and histone markers of enhancers (H3K4me1, H3K4me2, H3K4me3, H3K9ac, and H3K27ac) revealed significantly higher level on Enhp53 than Enhno-p53 which suggested that p53 participated in regulating enhancer activity and chromatin structure.\"}, {\"id\": 9, \"text\": \"Although certain chromatin features, such as the histone acetyltransferase P300 and the histone modification H3K4me1, indicate the presence of enhancers, only a fraction of enhancers are functionally active.\"}, {\"id\": 3, \"text\": \"For example, although histone H3 lysine 4 mono-methylation (H3K4me1) indicates the presence of transcriptional gene enhancers, it does not provide clearcut information about their actual position and stage-specific activity.\"}, {\"id\": 12, \"text\": \"H3K4 tri-methylation provides an epigenetic signature of active enhancers.\"}, {\"id\": 13, \"text\": \"Here we use ChIP sequencing (ChIP-seq) to identify domains enriched for the histone marks histone H3 lysine 4 trimethylation, histone H3 lysine 4 monomethylation, and histone H3 lysine 27 acetylation (H3K4me3, H3K4me1, and H3K27ac) and define, for the first time, the super enhancers and typical enhancers active in primary human corneal epithelial cells.\"}, {\"id\": 10, \"text\": \"We find that histone H3K27ac distinguishes active enhancers from inactive/poised enhancer elements containing H3K4me1 alone.\"}, {\"id\": 0, \"text\": \"Using ChIP-Seq data, we examined these regions for presence of H3K4me1, H3K27ac, and H3K9ac histone marks (typically associated with latent/active enhancers).\"}]``` return a json array of their ids called 'snippets'"}, {"role": "assistant", "content": "{\"snippets\": [7, 6, 1, 4, 3, 5, 8, 12, 9, 11, 13, 10, 2, 0]}"}]}
{"messages": [{"role": "system", "content": "You are BioASQ-GPT, an AI expert in question answering, research, and information retrieval in the biomedical domain."}, {"role": "user", "content": "Given this question: 'Can CRISPR/Cas12a be used for the detection of EGFR mutations in circulating DNA?' select the top 10 snippets that are most helpful for answering this question from this list of snippets, \n        rerank them by helpfulness: ```[{\"id\": 0, \"text\": \"The CRISPR-Cas12a system can detect both L858R and T790M with a limit of detection of 0.005% in less than three hours.\"}, {\"id\": 2, \"text\": \"A CRISPR Test for Rapidly and Sensitively Detecting Circulating EGFR Mutations.\"}, {\"id\": 3, \"text\": \" This proof of principle study demonstrates that the CRISPR-Cas12a system could rapidly and sensitively detect circulating EGFR mutations, and thus, has potential prognostic or therapeutic implications.\"}, {\"id\": 1, \"text\": \"The CRISPR-Cas12a system could detect L858R in plasma of two lung cancer patients whose tissue biopsies are positive for L858R, and one plasma sample of three lung cancer patients whose tissue biopsies are positive for T790M. \"}]``` return a json array of their ids called 'snippets'"}, {"role": "assistant", "content": "{\"snippets\": [2, 0, 1, 3]}"}]}
{"messages": [{"role": "system", "content": "You are BioASQ-GPT, an AI expert in question answering, research, and information retrieval in the biomedical domain."}, {"role": "user", "content": "Given this question: 'What type of DMD can casimersen be used for?' select the top 10 snippets that are most helpful for answering this question from this list of snippets, \n        rerank them by helpfulness: ```[{\"id\": 0, \"text\": \"Casimersen received its first approval on 25\\u00c2\\u00a0February 2021, in the USA, for the treatment of DMD in patients who have a confirmed mutation of the DMD gene that is amenable to exon\\u00c2\\u00a045 skipping.\"}]``` return a json array of their ids called 'snippets'"}, {"role": "assistant", "content": "{\"snippets\": [0]}"}]}
{"messages": [{"role": "system", "content": "You are BioASQ-GPT, an AI expert in question answering, research, and information retrieval in the biomedical domain."}, {"role": "user", "content": "Given this question: 'What is targeted by CIS43LS?' select the top 10 snippets that are most helpful for answering this question from this list of snippets, \n        rerank them by helpfulness: ```[{\"id\": 4, \"text\": \"CONCLUSIONS: CIS43LS was protective against P. falciparum infection over a 6-month malaria season in Mali without evident safety concerns. \"}, {\"id\": 2, \"text\": \"BACKGROUND: CIS43LS is a monoclonal antibody that was shown to protect against controlled Plasmodium falciparum infection in a phase 1 clinical trial. \"}, {\"id\": 3, \"text\": \"Based on these data, CIS43LS has advanced to phase I clinical trials, and AAV delivery provides a potential next-generation approach for malaria prevention.\"}, {\"id\": 1, \"text\": \"METHODS: We conducted a two-part, phase 1 clinical trial to assess the safety and pharmacokinetics of CIS43LS, an antimalarial monoclonal antibody with an extended half-life, and its efficacy against infection with Plasmodium falciparum. \"}, {\"id\": 5, \"text\": \"CONCLUSIONS: Among adults who had never had malaria infection or vaccination, administration of the long-acting monoclonal antibody CIS43LS prevented malaria after controlled infection.\"}, {\"id\": 0, \"text\": \"METHODS: We conducted a phase 2 trial to assess the safety and efficacy of a single intravenous infusion of CIS43LS against P. falciparum infection in healthy adults in Mali over a 6-month malaria season.\"}]``` return a json array of their ids called 'snippets'"}, {"role": "assistant", "content": "{\"snippets\": [2, 0, 4, 3, 1, 5]}"}]}
{"messages": [{"role": "system", "content": "You are BioASQ-GPT, an AI expert in question answering, research, and information retrieval in the biomedical domain."}, {"role": "user", "content": "Given this question: 'What does Cal-light do?' select the top 10 snippets that are most helpful for answering this question from this list of snippets, \n        rerank them by helpfulness: ```[{\"id\": 1, \"text\": \"We present a dual-protein switch system, Cal-Light, that translates neuronal-activity-mediated calcium signaling into gene expression in a light-dependent manner.\"}, {\"id\": 3, \"text\": \"In cultured neurons and brain slices, we show that Cal-Light drives expression of the reporter EGFP with high spatiotemporal resolution only in the presence of both blue light and calcium.\"}, {\"id\": 6, \"text\": \"Cal-Light, that translates neuronal-activity-mediated calcium signaling into gene expression in a light-dependent manner.\"}, {\"id\": 4, \"text\": \" Cal-Light drives expression of the reporter EGFP with high spatiotemporal resolution only in the presence of both blue light and calcium.\"}, {\"id\": 2, \"text\": \" Cal-Light, a photoactivatable calcium sensor, while slower to respond than CaMPARI, has the capacity to trigger the expression of genes, including effectors, activators, indicators, or other constructs.\"}, {\"id\": 0, \"text\": \"Cal-Light, a photoactivatable calcium sensor, while slower to respond than CaMPARI, has the capacity to trigger the expression of genes, including effectors, activators, indicators, or other constructs.\"}, {\"id\": 5, \"text\": \", Cal-Light enables dissection of neural circuits underlying complex mammalian behaviors with high spatiotemporal precision.\"}]``` return a json array of their ids called 'snippets'"}, {"role": "assistant", "content": "{\"snippets\": [2, 6, 4, 5, 0, 1, 3]}"}]}
{"messages": [{"role": "system", "content": "You are BioASQ-GPT, an AI expert in question answering, research, and information retrieval in the biomedical domain."}, {"role": "user", "content": "Given this question: 'To which region of a gene does an RNA polymerase bind to initiate transcription?' select the top 10 snippets that are most helpful for answering this question from this list of snippets, \n        rerank them by helpfulness: ```[{\"id\": 1, \"text\": \"Early work identified two promoter regions, the -10 and -35 elements, that interact sequence specifically with bacterial RNA polymerase (RNAP). However, we now know that several additional promoter elements contact RNAP and influence transcription initiation. \"}, {\"id\": 9, \"text\": \"RNA polymerases (RNAPs) differ from other polymerases in that they can bind promoter sequences and initiate transcription de novo and this promoter recognition requires the presence of specific DNA binding domains in the polymerase.\"}, {\"id\": 12, \"text\": \" RNA polymerases (RNAPs) differ from other polymerases in that they can bind promoter sequences and initiate transcription de novo and this promoter recognition requires the presence of specific DNA binding domains in the polymerase.\"}, {\"id\": 3, \"text\": \"Eukaryotic RNA polymerase I promoter binding is directed by protein contacts with transcription initiation factor and is DNA sequence-independent.\"}, {\"id\": 11, \"text\": \"BACKGROUND: RNA Polymerase II (RNAP II) is recruited to core promoters by the pre-initiation complex (PIC) of general transcript\"}, {\"id\": 10, \"text\": \"The binding region of the RNA polymerase extends from 30 base pairs (bp) upstream (-30) to 20 bp downstream (+20) from the in vivo transcription start site.\"}, {\"id\": 4, \"text\": \"A Drosophila RNA polymerase II transcription factor contains a promoter-region-specific DNA-binding activity.\"}, {\"id\": 7, \"text\": \"Regulatory information for transcription initiation is present in a stretch of genomic DNA, called the promoter region that is located upstream of the transcription start site (TSS) of the gene. The promoter region interacts with different transcription factors and RNA polymerase to initiate transcription and contains short stretches of transcription factor binding sites (TFBSs), as well as structurally unique elements. Recent experimental and computational analyses of promoter sequences show that they often have non-B-DNA structural motifs, as well as some conserved structural properties, such as stability, bendability, nucleosome positioning preference and curvature, across a class of organisms.\"}, {\"id\": 5, \"text\": \"It is concluded that RNA polymerase binding site and initiation site are identical parts of a promoter region, and that no \\\"drift\\\" between these sites is required as a step in RNA chain initiation.\"}, {\"id\": 13, \"text\": \"RNA polymerases initiate transcription at DNA sequences called promoters.\"}, {\"id\": 8, \"text\": \"RNA polymerase is known to bind and utilize the overlapping promoters P1 and P2 in Escherichia coli galactose operon. We have identified an additional specific site upstream of P2, where RNA polymerase binds in a heparin-resistant manner.\"}, {\"id\": 2, \"text\": \"Polymerases are integral factors of gene expression and are essential for the maintenance and transmission of genetic information. RNA polymerases (RNAPs) differ from other polymerases in that they can bind promoter sequences and initiate transcription de novo and this promoter recognition requires the presence of specific DNA binding domains in the polymerase.\"}, {\"id\": 6, \"text\": \"We infer that polymerase is directed to the promoter by a DNA sequence-independent mechanism, solely by protein-protein contacts with TIF.\"}, {\"id\": 0, \"text\": \"conventional transcription factors trigger transcription by the RNA polymerase II (pol II) paused within the proximal promoter region.\"}]``` return a json array of their ids called 'snippets'"}, {"role": "assistant", "content": "{\"snippets\": [13, 2, 0, 8, 10, 5, 3, 4, 6, 11, 12, 9, 7, 1]}"}]}
{"messages": [{"role": "system", "content": "You are BioASQ-GPT, an AI expert in question answering, research, and information retrieval in the biomedical domain."}, {"role": "user", "content": "Given this question: 'Is PRP-40 involved in microexon splicing?' select the top 10 snippets that are most helpful for answering this question from this list of snippets, \n        rerank them by helpfulness: ```[{\"id\": 0, \"text\": \"PRP-40 is particularly required for inclusion of neuronal microexons, and our data indicate that PRP-40 is a central regulator of microexon splicing. Microexons can be relieved from PRP-40 dependence by artificially increasing exon size or reducing flanking intron size, indicating that PRP-40 is specifically required for microexons surrounded by conventionally sized introns. Knockdown of the orthologous PRPF40A in mouse neuroblastoma cells causes widespread dysregulation of microexons but not conventionally sized exons. PRP-40 regulation of neuronal microexons is therefore a widely conserved phenomenon.\"}]``` return a json array of their ids called 'snippets'"}, {"role": "assistant", "content": "{\"snippets\": [0]}"}]}
{"messages": [{"role": "system", "content": "You are BioASQ-GPT, an AI expert in question answering, research, and information retrieval in the biomedical domain."}, {"role": "user", "content": "Given this question: 'At what range of ages usually occurs the loss of independent ambulation in Duchenne muscular dystrophy?' select the top 10 snippets that are most helpful for answering this question from this list of snippets, \n        rerank them by helpfulness: ```[{\"id\": 4, \"text\": \"ked by progressive skeletal muscle weakness with loss of ambulation by 12 years of age. Death occurs in early adulthood secondary to respiratory or ca\"}, {\"id\": 5, \"text\": \" The more severe Duchenne muscular dystrophy typically presents around ages 2 to 5 with gait disturbance, and historically has led to the loss of ambulation by age 12.\"}, {\"id\": 14, \"text\": \"Loss of independent gait occurred at similar ages in both groups (10.3 vs. 10.5 years).\"}, {\"id\": 7, \"text\": \"it disturbance, and historically has led to the loss of ambulation by age 12. It is important for the practicing pediatrician, however, to be aware of\"}, {\"id\": 11, \"text\": \"Duchenne muscular dystrophy is the most common and most severe form of childhood muscular dystrophies, resulting in early loss of ambulation between the ages of 7 and 13 years and death in the teens and twenties.\"}, {\"id\": 1, \"text\": \"trophies, resulting in early loss of ambulation between the ages of 7 and 13 years and death in the teens and twenties. Despite the phenomenal advance\"}, {\"id\": 3, \"text\": \" by progressive skeletal muscle weakness with loss of ambulation by 12 years of age. Death occurs in early adulthood secondary to respiratory or cardi\"}, {\"id\": 6, \"text\": \" childhood with loss of ambulation usually occurring around the age of 9-11\\u00c2\\u00a0years.OBJECTIVE, MATERIAL AND METHODS: Based on current guidelines and cli\"}, {\"id\": 2, \"text\": \"Patients with Duchenne muscular dystrophy (DMD) lose ambulation by age 12.\"}, {\"id\": 0, \"text\": \"To assess the effect of subcutaneous (s.c.) lower limb tenotomies on the ambulatory ability of patients with Duchenne muscular dystrophy (DMD), 54 patients were followed. Twenty-nine patients underwent hip, knee, and ankle tenotomies at a mean age of 10 2/12 years and were followed postoperatively for an average of 3 9/12 years. These children continued ambulation in long-leg braces to a mean age of 12 8/12 years and stood to an average of 13 5/12 years.\"}, {\"id\": 8, \"text\": \"BACKGROUND: Duchenne muscular dystrophy (DMD) is the most frequent genetic neuromuscular disease in childhood with loss of ambulation usually occurring around the age of 9-11\\u00c2\\u00a0years.OBJECTIVE, MATERIAL AND METHODS: Based on current guidelines and clinical trials, neuropediatric and neurological experts developed recommendations for the treatment of nonambulatory DMD p\"}, {\"id\": 10, \"text\": \" Duchenne muscular dystrophy (DMD) is an X-linked recessive genetic disorder, that is characterized by progressive muscle degeneration and loss of ambulation between 7-13 years of age.\"}, {\"id\": 12, \"text\": \"Subsequently, the disease immobilizes the patient (ages 9 to 14 years) and severe respiratory failure occurs due to chest and vertebral column deformity.\"}, {\"id\": 13, \"text\": \"Duchenne muscular dystrophy is a progressive disease with loss of ambulation at around 9-10 years of age, followed, if untreated, by development of scoliosis, respiratory insufficiency, and death in the second decade of life.\"}, {\"id\": 9, \"text\": \"Loss of walking ability occurred in the control group at an average of 9.29 years (5.85-13.63, SD 1.98) and in the operated group at an average of 10.55 years (8.17-14.39, SD 1.76).\"}]``` return a json array of their ids called 'snippets'"}, {"role": "assistant", "content": "{\"snippets\": [10, 13, 8, 2, 11, 9, 5, 7, 1, 4, 14, 12, 6, 3, 0]}"}]}
{"messages": [{"role": "system", "content": "You are BioASQ-GPT, an AI expert in question answering, research, and information retrieval in the biomedical domain."}, {"role": "user", "content": "Given this question: 'Is ocrelizumab effective for primary progressive multiple sclerosis?' select the top 10 snippets that are most helpful for answering this question from this list of snippets, \n        rerank them by helpfulness: ```[{\"id\": 2, \"text\": \"Ocrelizumab (Ocrevus\\u00c2\\u00ae) is an intravenously administered, humanized anti-CD20 monoclonal antibody approved for the treatment of adults with relapsing forms of multiple sclerosis (RMS) or primary progressive multiple sclerosis (PPMS).\"}, {\"id\": 0, \"text\": \"Ocrelizumab for multiple sclerosis.\"}, {\"id\": 1, \"text\": \"BACKGROUND: Ocrelizumab is a humanised anti-CD20 monoclonal antibody developed for the treatment of multiple sclerosis (MS). It was approved by the Food and Drug Administration (FDA) in March 2017 for using in adults with relapsing-remitting multiple sclerosis (RRMS) and primary progressive multiple sclerosis (PPMS).\"}, {\"id\": 3, \"text\": \"When using the anti-CD20 monoclonal antibodies ocrelizumab and ofatumumab in the treatment of MS, it is not necessary to test for NAbs as these occur very infrequently. \"}]``` return a json array of their ids called 'snippets'"}, {"role": "assistant", "content": "{\"snippets\": [2, 3, 0, 1]}"}]}
{"messages": [{"role": "system", "content": "You are BioASQ-GPT, an AI expert in question answering, research, and information retrieval in the biomedical domain."}, {"role": "user", "content": "Given this question: 'How is Indocyanine green (ICG) used?' select the top 10 snippets that are most helpful for answering this question from this list of snippets, \n        rerank them by helpfulness: ```[{\"id\": 44, \"text\": \"Indocyanine green was used to better visualize the anterior capsule before capsulotomy.\"}, {\"id\": 10, \"text\": \"We describe a case using indocyanine green (ICG) fluorescence imaging for diagnosis of postoperative gastrointestinal fistula.\"}, {\"id\": 17, \"text\": \"Indocyanine green (ICG) fluorescence-guided surgery is a modality of intra-operative navigation that might support the surgeon with enhanced visualization of anatomical structures in real time.\"}, {\"id\": 26, \"text\": \"Indocyanine green (ICG) is a dye used for fluorescent-guided surgery.\"}, {\"id\": 2, \"text\": \"BACKGROUND: Indocyanine green (ICG) is a sterile, water-soluble, tricarbocyanine dye that can be used in fundus angiography as an adjunct to sodium \"}, {\"id\": 5, \"text\": \"Indocyanine green imaging \"}, {\"id\": 35, \"text\": \"PURPOSE: To compare the results of macular hole surgery with the use of indocyanine green (ICG) to assist internal limiting membrane (ILM) peeling and macular hole surgery without indocyanine green use.METHODS: A retrospective, comparative, consecutive study of 68 patients w\"}, {\"id\": 15, \"text\": \"Indocyanine green (ICG) fluorescence imaging is widely used in abdominal surgery. The implementation of minimally invasive rectal surgery using new methods like robotics or a transanal approach required improvement of optical systems.\"}, {\"id\": 8, \"text\": \"Intraoperative Indocyanine Green (ICG) Angiography for the Identification of the Parathyroid Glands: Current Evidence and Future Perspectives.\"}, {\"id\": 45, \"text\": \"The present review aims to analyze the current data available on the different applications of indocyanine green (ICG) in gynecology. A semantic review of English-language publications was performed by searching for MeSH terms and keywords in the PubMed and Google Scholar databases. The studies were finally selected by one author according to the aim of this \"}, {\"id\": 11, \"text\": \" ICG fluorescence optimizes intraoperative vision of anatomical structures by improving blood and lymphatic flow. The purpose of this review was to summarize all potential applications of this upcoming technology in rectal cancer surgery. Each type of use has been separately addressed and the evid\"}, {\"id\": 32, \"text\": \"We believe that ICG could be used with novel biotechnological techniques, such as fluorescent endoscopy and photoacoustic equipment, in a range of biomedical fields.\"}, {\"id\": 0, \"text\": \"Indocyanine green (ICG) is widely used in medical imaging and testing.\"}, {\"id\": 9, \"text\": \" Indocyanine green (ICG) is a fluorescent dye that can be used to image both retinal and choroidal vessels\"}, {\"id\": 37, \"text\": \" Indocyanine green (ICG) is one of the methods used to assess vascularization, but this assessment is usually subjective\"}, {\"id\": 4, \"text\": \"BACKGROUND/AIM: Recently, indocyanine green (ICG) fluorescence imaging has been used for the identification of the parathyroid glands (PG) during thyroid and para\"}, {\"id\": 42, \"text\": \" We examined Indocyanine green (ICG) which is widely used in medical testing and is highly unstable.\"}, {\"id\": 14, \"text\": \"dosage, the timing of the ICG administration and finally its interpretation and clinical usefulness is still lacking evidence. The aim of this review is to investigate the use of ICG angiography during thyroidectomy an\"}, {\"id\": 22, \"text\": \"Application of indocyanine green (ICG)-guided surgery in clinical practice: lesson to learn from other organs-an overview on clinical applications and future perspectives.\"}, {\"id\": 34, \"text\": \"Fluorescent image-guided surgery with indocyanine green (ICG) to visualise the ureter is a relatively new technique. \"}, {\"id\": 13, \"text\": \"Role of indocyanine green fluorescence videoangiography in evaluation of subretinal disease.\"}, {\"id\": 27, \"text\": \"Clinical use of near-infrared fluorescence imaging with indocyanine green in thoracic surgery: a literature review.\"}, {\"id\": 33, \"text\": \" fundus photography. In addition, two cases are presented to illustrate the clinical application of ICG for diagnosis and treatment of choroidal neovascular membranes.RESULTS: ICG videoangiography can be used to reveal subfoveal choroidal neovascular membranes not previously identified with fluorescein; angiograms can also be used to dramatically highlight retinal and choroidal changes.CONCLUSIONS: The use of ICG for fundus videoangiography provides a more accurate and complete evaluation in certain\"}, {\"id\": 16, \"text\": \"The standardised technique of robotic (daVinci\\u00c2\\u00aeXiTM) anatomical Segment IVb and V liver resection guided by indocyanine green fluorescence is described here. \"}, {\"id\": 28, \"text\": \"Indocyanine green fluorescence (ICG) angiography of the choroid gives better visualization of the choroidal vessels than does fluorescein angiography.\"}, {\"id\": 43, \"text\": \"Intraoperative use of indocyanine green fluorescence imaging in rectal cancer surgery: The state of the art.\"}, {\"id\": 39, \"text\": \"Indocyanine green (ICG), a US Food and Drug Administration-approved fluorescent compound, has been on the medical stage for more than 60 years. Current uses include hepatic function evaluation before surgical procedure and fundus evaluation.\"}, {\"id\": 24, \"text\": \"PURPOSE: To report an altered uptake and possible complication associated with the use of indocyanine green (ICG) dye, internal limiting membrane (ILM) peeling, and infrared diode laser\"}, {\"id\": 36, \"text\": \"Conclusion: Indocyanine green fluorescence angiography is a safe imaging technology and its use is increasing rapidly in pediatric surgical specialties.\"}, {\"id\": 29, \"text\": \"hirteen patients with nonmetastatic gastric adenocarcinoma received endoscopic, peritumoural, submucosal indocyanine green fluorescence (ICG) injections before surgery, and ICG was assessed intraoperatively using a laparoscopic detection system. \"}, {\"id\": 38, \"text\": \"Indocyanine green (ICG) is a dye used for fluorescent-guided surgery. This review article addresses the recent surge in reported uses of ICG in variou\"}, {\"id\": 41, \"text\": \"INTRODUCTION: Since early 90th, infra-red angiography using indocyanine green, is an additional examination done after fluorescein angiography (FA) very often used in ARMD allowing deep retinal layers and choroid analysis\"}, {\"id\": 3, \"text\": \"Indocyanine green (ICG) is a fluorescent probe used in clinical imaging.\"}, {\"id\": 1, \"text\": \"Indocyanine green (ICG) is a fluorescent dye that has been used for the imaging of retinal and choroidal vasculatures for more than 30 years.\"}, {\"id\": 40, \"text\": \"We examined Indocyanine green (ICG) which is widely used in medical testing and is highly unstable.\"}, {\"id\": 23, \"text\": \"We report the first case of indocyanine green (ICG) being used in an eye with an anterior capsule that was not completely intact.\"}, {\"id\": 7, \"text\": \"Indocyanine Green (ICG) is frequently used during urologic robotic procedures and is generally considered to be safe.\"}, {\"id\": 19, \"text\": \"Indocyanine green (ICG; Cardio Green, Hynson, Westcott & Dunning, Baltimore, MD) is a cholephilic dye that is commonly used as a liver function test.\"}, {\"id\": 18, \"text\": \"indocyanine green angiography (ICG)\"}, {\"id\": 21, \"text\": \"Use of Indocyanine Green Angiography to Identify the Superficial Temporal Artery and Vein in Forehead Flaps for Facial Reconstruction.\"}, {\"id\": 31, \"text\": \"Indocyanine green (ICG) is a fluorescent dye largely used as functional indicator, fluorescent imaging contrast agent and recently as enhancer during diode laser photocoagulation.\"}, {\"id\": 12, \"text\": \"OBJECT: Recently, intraoperative fluorescence angiography in which indocyanine green (ICG) is used as a tracer has been introduced as a novel technique to confirm successful aneurysm clipping\"}, {\"id\": 20, \"text\": \" Studies have attempted to manipulate ICG as a reporter fluorophore with initial success. I\"}, {\"id\": 25, \"text\": \"Indocyanine green (ICG) is a fluorescent probe used in clinical imaging. However, its utility remains limited by optical instability, rapid circulatio\"}, {\"id\": 6, \"text\": \"Using indocyanine green (ICG), a standard reagent used in liver function tests, bile leaks from exfoliated liver sections can be detected with higher sensitivity than naked-eye observation.\"}, {\"id\": 30, \"text\": \"Indocyanine green (ICG) is extremely effective when used as a vital stain during macular hole surgery.\"}]``` return a json array of their ids called 'snippets'"}, {"role": "assistant", "content": "{\"snippets\": [39, 20, 32, 18, 29, 16, 34, 21, 5, 35, 31, 30, 1, 26, 2, 19, 33, 13, 23, 44, 28, 27, 3, 0, 42, 10, 7, 9, 40, 6, 38, 12, 25, 24, 37, 36, 41, 43, 15, 11, 8, 4, 14, 22, 17, 45]}"}]}
{"messages": [{"role": "system", "content": "You are BioASQ-GPT, an AI expert in question answering, research, and information retrieval in the biomedical domain."}, {"role": "user", "content": "Given this question: 'What is the process that generates multiple transcripts from the same gene?' select the top 10 snippets that are most helpful for answering this question from this list of snippets, \n        rerank them by helpfulness: ```[{\"id\": 4, \"text\": \"Alternative splicing is a widespread phenomenon, which generates multiple isoforms of the gene product.\"}, {\"id\": 22, \"text\": \"Alternative splicing (AS) is a process that produces various mRNA splicing isoforms via different splicing patterns of mRNA precursors (pre-mRNAs). AS is the primary mechanism for increasing the types and quantities of proteins to improve biodiversity and influence multiple biological processes, including chromatin modification, signal transduction, and protein expression.\"}, {\"id\": 9, \"text\": \"We propose that plants employ AS not only to potentially increasing proteomic complexity, but also to buffer against the stress-responsive transcriptome to reduce the metabolic cost of translating all AS transcripts.\"}, {\"id\": 12, \"text\": \" Alternative splicing (AS) is a pre-mRNA maturation process leading to the expression of multiple mRNA variants from the same primary transcript.\"}, {\"id\": 23, \"text\": \"Alternative splicing, which generates multiple transcripts from the same gene and potentially different protein isoforms, is a key posttranscriptional regulatory mechanism for expanding proteomic diversity and functional complexity in higher eukaryotes.\"}, {\"id\": 18, \"text\": \"Alternative Splicing (AS) is a mechanism that generates different mature transcripts from precursor mRNAs (pre-mRNAs) of the same gene.\"}, {\"id\": 6, \"text\": \"Over the past decade, alternative splicing has been progressively recognized as a major mechanism regulating gene expression patterns in different tissues and disease states through the generation of multiple mRNAs from the same gene transcript.\"}, {\"id\": 17, \"text\": \"Alternative splicing is a widespread mechanism in mammals that generates several mRNAs from one gene, thereby creating genetic diversity of the genome.\"}, {\"id\": 16, \"text\": \"Alternative splicing (AS), in higher eukaryotes, is one of the mechanisms of post-transcriptional regulation that generate multiple transcripts from the same gene.\"}, {\"id\": 15, \"text\": \" This task is complicated due to the complexity of alternative splicing - a mechanism by which the same gene may generate multiple distinct RNA transcripts.\"}, {\"id\": 3, \"text\": \"Alternative splicing is a physiological process by which cells generate several transcripts from one single gene and may in turn give rise to different proteins from the same gene.\"}, {\"id\": 5, \"text\": \"Alternative splicing (AS) increases the proteomic and functional capacity of genomes through the generation of alternative mRNA transcripts from the same gene.\"}, {\"id\": 1, \"text\": \"Alternative splicing generates multiple transcript and protein isoforms from the same gene and thus is important in gene expression regulation.\"}, {\"id\": 0, \"text\": \"Alternative splicing (AS) generates multiple transcripts from the same gene, however, AS contribution to proteome complexity remains elusive in plants.\"}, {\"id\": 8, \"text\": \"Alternative pre-mRNA splicing plays a very important role in expanding protein diversity as it generates numerous transcripts from a single protein-coding gene.\"}, {\"id\": 21, \"text\": \"Alternative splicing of messenger RNA (mRNA) precursors generates multiple transcripts from a single primary transcript.\"}, {\"id\": 2, \"text\": \"Alternative splicing, which generates multiple transcripts from the same gene, is an important modulator of gene expression that can increase proteome diversity and regulate mRNA levels.\"}, {\"id\": 20, \"text\": \"Alternative splicing of pre-mRNA is one of the main mechanisms regulating gene expression that generates multiple transcripts from one gene.\"}, {\"id\": 11, \"text\": \"Alternative splicing generates multiple transcript and protein isoforms from a single gene and controls transcript intracellular localization and stability by coupling to mRNA export and nonsense-mediated mRNA decay (NMD).\"}, {\"id\": 13, \"text\": \"Alternative splicing is an important biological process in the generation of multiple functional transcripts from the same genomic sequences.\"}, {\"id\": 10, \"text\": \"However, as well as conventional splicing, several genes have the inherent capacity to undergo alternative splicing, thus allowing synthesis of multiple gene transcripts, perhaps with different functional properties.\"}, {\"id\": 7, \"text\": \"Among eukaryotic organisms, alternative splicing is an important process that can generate multiple transcripts from one same precursor messenger RNA, which greatly increase transcriptome and proteome diversity.\"}, {\"id\": 14, \"text\": \"Alternative splicing generates multiple transcripts from a single gene, enriching the diversity of proteins and phenotypic traits.\"}, {\"id\": 19, \"text\": \"Indeed, through AS individual gene loci can generate multiple RNAs from the same pre-mRNA.\"}]``` return a json array of their ids called 'snippets'"}, {"role": "assistant", "content": "{\"snippets\": [0, 9, 2, 23, 16, 6, 3, 10, 5, 19, 13, 11, 18, 17, 8, 15, 20, 1, 4, 21, 7, 12, 22, 14]}"}]}
{"messages": [{"role": "system", "content": "You are BioASQ-GPT, an AI expert in question answering, research, and information retrieval in the biomedical domain."}, {"role": "user", "content": "Given this question: 'Does silencing of SRRM4 inhibit tumor growth across cancers?' select the top 10 snippets that are most helpful for answering this question from this list of snippets, \n        rerank them by helpfulness: ```[{\"id\": 0, \"text\": \"We show that this silencing is favorable for tumor growth, as decreased SRRM4 expression in tumors is correlated with an increase in mitotic gene expression, and up-regulation of SRRM4 in cancer cell lines dose-dependently inhibits proliferation in vitro and in a mouse xenograft model. Further, this proliferation inhibition is accompanied by induction of neural-like expression and splicing patterns in cancer cells, suggesting that SRRM4 expression shifts the cell state away from proliferation and toward differentiation. We therefore conclude that SRRM4 acts as a proliferation brake, and tumors gain a selective advantage by cutting off this brake.\"}, {\"id\": 1, \"text\": \"Silencing of SRRM4 suppresses microexon inclusion and promotes tumor growth across cancers.\"}]``` return a json array of their ids called 'snippets'"}, {"role": "assistant", "content": "{\"snippets\": [1, 0]}"}]}
{"messages": [{"role": "system", "content": "You are BioASQ-GPT, an AI expert in question answering, research, and information retrieval in the biomedical domain."}, {"role": "user", "content": "Given this question: 'What is the life expectancy for Duchenne muscular dystrophy patients?' select the top 10 snippets that are most helpful for answering this question from this list of snippets, \n        rerank them by helpfulness: ```[{\"id\": 1, \"text\": \"Over the course of the last century, the average life expectancy of these patients has doubled and now stands at \\u00e2\\u02c6\\u00bc25\\u00e2\\u20ac\\u2026years.\"}, {\"id\": 3, \"text\": \"Duchenne muscular dystrophy (DMD) is a severe neuromuscular disorder with increasing life expectancy from late teens to over 30\\u00c2\\u00a0years of age.\"}, {\"id\": 0, \"text\": \"s (95% confidence interval [CI] 21.2, 22.4). Analyses stratified by 3 time periods in which patients were born showed markedly increased life expectancy in more recent patient populations; patients born after 1990 have a median life expectancy of 28.1 years (95% CI 25.1, 30.3).DISCUSSION: This article presents a full overview of mortality across the lifetime of a patient\"}, {\"id\": 4, \"text\": \"Analyses stratified by 3 time periods in which patients were born showed markedly increased life expectancy in more recent patient populations; patients born after 1990 have a median life expectancy of 28.1 years (95% CI 25.1, 30.3)\"}, {\"id\": 2, \"text\": \"The special medical care in the National Sanatorium prolonged the life span of the patients with progressive muscular dystrophy from 15.8 years to 20.4 years over the last 20 years.\"}]``` return a json array of their ids called 'snippets'"}, {"role": "assistant", "content": "{\"snippets\": [4, 0, 1, 3, 2]}"}]}
{"messages": [{"role": "system", "content": "You are BioASQ-GPT, an AI expert in question answering, research, and information retrieval in the biomedical domain."}, {"role": "user", "content": "Given this question: 'Is daridorexant effective for insomnia?' select the top 10 snippets that are most helpful for answering this question from this list of snippets, \n        rerank them by helpfulness: ```[{\"id\": 1, \"text\": \"Daridorexant was superior to placebo in reducing wake time after sleep onset (MD\\u00e2\\u20ac\\u2030=\\u00e2\\u20ac\\u2030-13.26; 95% CI, -15.48 to -11.03; P\\u00e2\\u20ac\\u2030<\\u00e2\\u20ac\\u20300.00001), latency to persistent sleep (MD\\u00e2\\u20ac\\u2030=\\u00e2\\u20ac\\u2030-7.23; 95% CI, -9.60 to -4.85; P\\u00e2\\u20ac\\u2030<\\u00e2\\u20ac\\u20300.00001), with increasing the total sleep time (MD\\u00e2\\u20ac\\u2030=\\u00e2\\u20ac\\u203014.80; 95% CI, 11.18-18.42; P\\u00e2\\u20ac\\u2030<\\u00e2\\u20ac\\u20300.00001) and subjective total sleep time (MD\\u00e2\\u20ac\\u2030=\\u00e2\\u20ac\\u203014.80; 95% CI, 11.18-18.42], P\\u00e2\\u20ac\\u2030<\\u00e2\\u20ac\\u20300.00001). The 25 mg and 50 mg were the most officious doses. Treatment with daridorexant has resulted in a slightly higher incidence of adverse events [risk ratio (RR)\\u00e2\\u20ac\\u2030=\\u00e2\\u20ac\\u20301.19; 95% CI, 1.05-1.35;, P\\u00e2\\u20ac\\u2030=\\u00e2\\u20ac\\u20300.005], specifically somnolence (RR\\u00e2\\u20ac\\u2030=\\u00e2\\u20ac\\u20301.19; 95% CI, 1.13-3.23; P\\u00e2\\u20ac\\u2030=\\u00e2\\u20ac\\u20300.005) and fatigue (RR\\u00e2\\u20ac\\u2030=\\u00e2\\u20ac\\u20302.01; 95% CI, 1.21-3.36; P\\u00e2\\u20ac\\u2030=\\u00e2\\u20ac\\u20300.007). Daridorexant is superior to placebo in improving sleep quality. \"}, {\"id\": 0, \"text\": \"Daridorexant (Quviviq\\u00e2\\u201e\\u00a2; Idorsia Pharmaceuticals Ltd.) is an orally administered dual orexin type 1 and type 2 (OX1 and OX2) receptor antagonist (DORA) being developed for the treatment of insomnia.\"}]``` return a json array of their ids called 'snippets'"}, {"role": "assistant", "content": "{\"snippets\": [0, 1]}"}]}
{"messages": [{"role": "system", "content": "You are BioASQ-GPT, an AI expert in question answering, research, and information retrieval in the biomedical domain."}, {"role": "user", "content": "Given this question: 'What cells produce erythroferrone?' select the top 10 snippets that are most helpful for answering this question from this list of snippets, \n        rerank them by helpfulness: ```[{\"id\": 10, \"text\": \"ERFE is produced by erythroblasts in response to erythropoietin.\"}, {\"id\": 6, \"text\": \"Here the hormone erythroferrone, produced by erythroblasts, acts on hepatocytes to suppress hepcidin production, and thereby increase dietary iron absorption and mobilization from stores.\"}, {\"id\": 7, \"text\": \"Erythroferrone (ERFE) is produced by erythroblasts in response to erythropoietin (EPO) and acts in the liver to prevent hepcidin stimulation by BMP6.\"}, {\"id\": 12, \"text\": \" ERFE is produced by erythroblasts in response to erythropoietin.\"}, {\"id\": 16, \"text\": \"Erythroferrone, a factor produced and secreted by erythroid precursors in response to erythropoietin, has been identified and characterized as a suppressor of hepcidin synthesis to allow iron mobilization and facilitate erythropoiesis.\"}, {\"id\": 13, \"text\": \"Erythroferrone is a recently identified erythroid regulator produced by erythroblasts in the mammalian bone marrow and extramedullary sites, known to be induced in conditions of anemia or blood loss.\"}, {\"id\": 3, \"text\": \"Erythropoietin (EPO) enhances erythroferrone (ERFE) synthesis by erythroblasts, and ERFE suppresses hepatic hepcidin production through an unknown mechanism.\"}, {\"id\": 5, \"text\": \"Decreased hepcidin mobilizes iron, which facilitates erythropoiesis, but excess iron is pathogenic in \\u00ce\\u00b2-thalassemia. Erythropoietin (EPO) enhances erythroferrone (ERFE) synthesis by erythroblasts, and ERFE suppresses hepatic hepcidin production through an unknown mechanism. The BMP/SMAD pathway in the liver is critical for hepcidin control, and we show that EPO suppressed hepcidin and other BMP target genes in vivo in a partially ERF\"}, {\"id\": 4, \"text\": \"Erythroid overproduction of erythroferrone causes iron overload and developmental abnormalities in mice.\"}, {\"id\": 1, \"text\": \"The hormone erythroferrone (ERFE) is produced by erythroid cells in response to hemorrhage, hypoxia, or other erythropoietic stimuli, and it suppresses the hepatic production of the iron-regulatory hormone hepcidin, thereby mobilizing iron for erythropoiesis.\"}, {\"id\": 15, \"text\": \"Background: Erythroblast erythroferrone (ERFE) secretion inhibits hepcidin expression by sequestering several bone morphogenetic protein (BMP) family members to increase iron availability for erythropoiesis.Methods: To address whether ERFE functions also in bone and whether the mechanism of ERFE action in bone involves BMPs, we utilize the Erfe-/- mouse model as well as \\u00ce\\u00b2-thalassemic (Hbbth3/+) mice with systemic loss\"}, {\"id\": 0, \"text\": \"pcidin suppression during stress erythropoiesis. ERFE is produced by erythroblasts in response to erythropoietin. ERFE-deficient mice fail to suppress\"}, {\"id\": 8, \"text\": \"Erythroferrone (ERFE) is an iron-regulatory hormone which is highly expressed in erythroblasts by erythropoietin (EPO) stimulation and osteoblasts independently of EPO by sequestering bone morphogenetic proteins and inhibiting hepatic hepcidin expression.\"}, {\"id\": 9, \"text\": \". Erythroferrone, a factor produced and secreted by erythroid precursors in response to erythropoietin, has been identified and characterized as a suppressor of hepcidin synthesis to allow iron mobilization and facilitate erythropoiesis.\"}, {\"id\": 14, \"text\": \"The hormone erythroferrone (ERFE) is produced by erythroid cells in response to hemorrhage, hypoxia, or other erythropoietic stimuli, and it suppresses the hepatic production of the iron-regulatory hormone hepcidin\"}, {\"id\": 2, \"text\": \"Erythroferrone (ERFE) is a glycoprotein hormone secreted by erythroblasts in response to stimulation by erythropoietin (EPO).\"}, {\"id\": 11, \"text\": \"The paradigm is non-transfusion-dependent thalassemia where the release of erythroferrone from the expanded pool of immature erythroid cells results in hepcidin suppression and secondary iron overload that in turn worsens ineffective erythropoiesis and anemia.\"}]``` return a json array of their ids called 'snippets'"}, {"role": "assistant", "content": "{\"snippets\": [9, 14, 4, 6, 13, 1, 7, 2, 8, 10, 12, 3, 0, 16, 11, 5, 15]}"}]}
{"messages": [{"role": "system", "content": "You are BioASQ-GPT, an AI expert in question answering, research, and information retrieval in the biomedical domain."}, {"role": "user", "content": "Given this question: 'What is the role of the Mediator in gene expression?' select the top 10 snippets that are most helpful for answering this question from this list of snippets, \n        rerank them by helpfulness: ```[{\"id\": 3, \"text\": \"Eukaryotic transcription requires the assembly of a multisubunit preinitiation complex (PIC) composed of RNA polymerase II (Pol II) and the general transcription factors. The coactivator Mediator is recruited by transcription factors, facilitates the assembly of the PIC, and stimulates phosphorylation of the Pol II C-terminal domain (CTD) by the TFIIH subunit CDK7.\"}, {\"id\": 0, \"text\": \"The multi-subunit Mediator complex plays a critical role in gene expression by bridging enhancer-bound transcription factors and the RNA polymerase II machinery.\"}, {\"id\": 4, \"text\": \"At a basic level, Mediator functions by relaying signals from TFs directly to the pol II enzyme, thereby facilitating TF-dependent regulation of gene expression. Thus, Mediator is essential for converting biological inputs (communicated by TFs) to physiological responses (via changes in gene expression).\"}, {\"id\": 1, \"text\": \"The Mediator complex is a multi-subunit assembly that appears to be required for regulating expression of most RNA polymerase II (pol II) transcripts, which include protein-coding and most non-coding RNA genes. \"}, {\"id\": 7, \"text\": \"Transcription activation is a key phenomenon in the regulation of gene expression. In all eukaryotes, mediator of RNA polymerase II transcription (Mediator), a large complex with modular organization, is generally required for transcription by RNA polymerase II, and it regulates various steps of this process. The main function of Mediator is to transduce signals from the transcription activators bound to enhancer regions to the transcription machinery, which is assembled at promoters as the preinitiation complex (PIC) to control transcription initiation.\"}, {\"id\": 6, \"text\": \"The Mediator complex is an essential co-regulator of RNA polymerase II that is conserved throughout eukaryotes.\"}, {\"id\": 2, \"text\": \"The Mediator complex serves a crucial function in gene regulation, forming a link between gene-specific transcription factors and RNA polymerase II.\"}, {\"id\": 5, \"text\": \"Mediator is a conserved, multi-subunit macromolecular machine divided structurally into head, middle, and tail modules, along with a transiently associating kinase module. Mediator functions as an integrator of transcriptional regulatory activity by interacting with DNA-bound transcription factors and with RNA polymerase II (Pol II) to both activate and repress gene expression. Mediator has been shown to affect multiple steps in transcription, including chromatin looping between enhancers and promoters, pre-initiation complex formation, transcriptional elongation, and mRNA splicing. \"}]``` return a json array of their ids called 'snippets'"}, {"role": "assistant", "content": "{\"snippets\": [1, 5, 4, 2, 0, 6, 7, 3]}"}]}
{"messages": [{"role": "system", "content": "You are BioASQ-GPT, an AI expert in question answering, research, and information retrieval in the biomedical domain."}, {"role": "user", "content": "Given this question: 'What does FBDD stand for?' select the top 10 snippets that are most helpful for answering this question from this list of snippets, \n        rerank them by helpfulness: ```[{\"id\": 0, \"text\": \"Fragment-based drug discovery (FBDD) has grown and matured to a point where it is valuable to keep track of its extent and details of application. \"}]``` return a json array of their ids called 'snippets'"}, {"role": "assistant", "content": "{\"snippets\": [0]}"}]}
{"messages": [{"role": "system", "content": "You are BioASQ-GPT, an AI expert in question answering, research, and information retrieval in the biomedical domain."}, {"role": "user", "content": "Given this question: 'Is deucravacitinib effective for psoriasis?' select the top 10 snippets that are most helpful for answering this question from this list of snippets, \n        rerank them by helpfulness: ```[{\"id\": 1, \"text\": \"POETYK PSO-1 and PSO-2 involved 1688 patients with moderate-to-severe psoriasis. After 16\\u00c2\\u00a0weeks, in both studies, over 50% of patients treated with deucravacitinib reached PASI75, which was significantly superior to placebo and apremilast. In POETYK PSO-1, these results improved until week 24 and were maintained through week 52, with over 65% of patients achieving PASI75 at this point. A reduction in signs and symptoms was also reported by patients, with greater impact on itch. Deucravacitinib was well tolerated and safe. \"}, {\"id\": 3, \"text\": \"INTRODUCTION: Deucravacitinib is an oral, selective tyrosine kinase 2 inhibitor that demonstrated therapeutic benefit in a Phase 2 clinical trial of adults with moderate to severe plaque psoriasis. \"}, {\"id\": 2, \"text\": \"CONCLUSION: Deucravacitinib was superior to placebo and apremilast across multiple efficacy endpoints and was well tolerated in moderate to severe psoriasis.\"}, {\"id\": 0, \"text\": \"CONCLUSION: Deucravacitinib treatment produced early response and similar trends in improvements across multiple efficacy assessments and QoL in moderate to severe plaque psoriasis. \"}]``` return a json array of their ids called 'snippets'"}, {"role": "assistant", "content": "{\"snippets\": [1, 3, 0, 2]}"}]}
{"messages": [{"role": "system", "content": "You are BioASQ-GPT, an AI expert in question answering, research, and information retrieval in the biomedical domain."}, {"role": "user", "content": "Given this question: 'What processes do orexin/hypocretin neurons regulate?' select the top 10 snippets that are most helpful for answering this question from this list of snippets, \n        rerank them by helpfulness: ```[{\"id\": 5, \"text\": \"Orexins, or hypocretins, are excitatory neuropeptides involved in the regulation of feeding behavior and the sleep and wakefulness states.\"}, {\"id\": 14, \"text\": \"n the present review, we firstly describe the mechanisms underlining the orexin system and their interactions with the central nervous system (CNS). Then, the system's involvement in goal-directed behaviors, sleep/wakefulness state regulation, feeding behavior and energy homeostasis, reward system, \"}, {\"id\": 12, \"text\": \"A low level of hypocretin-1/orexin-A in the cerebrospinal fluid is sufficient to diagnose narcolepsy type 1, being a highly specific and sensitive biomarker, and the irreversible loss of hypocretin neurons is responsible for the main symptoms of the disease: \"}, {\"id\": 3, \"text\": \"Orexin (hypocretin) appears to play a role in the regulation of energy balances.\"}, {\"id\": 0, \"text\": \"The orexin-producing neurons in the lateral hypothalamus play an essential role in promoting arousal and maintaining wakefulness. These neurons receive a broad variety of signals related to environmental, physiological and emotional stimuli; they project to almost every brain region involved in the regulation of wakefulness; and they fire most strongly during active wakefulness, high motor activation, and sustained attention.\"}, {\"id\": 7, \"text\": \"Orexins (synonymous with hypocretins) are recently discovered neuropeptides made exclusively in hypothalamus. Behavioral, anatomical, and neurophysiological studies show that a subset of these cells, specifically those in lateral hypothalamus (LH), are involved in reward processing and addictive behaviors. Fos expression in LH orexin neurons varied in proportion to conditioned place preference (CPP) for morphine, cocaine, or food.\"}, {\"id\": 4, \"text\": \"Orexin/Hypocretin and MCH Neurons: Cognitive and Motor Roles Beyond Arousal.\"}, {\"id\": 13, \"text\": \"UNLABELLED: Orexins (hypocretins) are neuropeptides that regulate multiple homeostatic processes, including reward and arousal, in part by exciting serotonergic dorsal raphe neurons, the major source of forebrai\"}, {\"id\": 2, \"text\": \"sensitization, behavioral changes, and low body mass index (BMI). One possible cellular target that may mediate some of these findings is the hypocretin/orexin neurons. This neuronal system plays a role in regulating wakefulness/sleep cycles, pain perception, and appetite.\"}, {\"id\": 11, \"text\": \"Orexin neurons (hypocretin neurons) have a critical role in the regulation of sleep/wakefulness, especially in the maintenance of arousal.\"}, {\"id\": 10, \"text\": \"Coordination of metabolism, arousal, and reward by orexin/hypocretin neurons.\"}, {\"id\": 6, \"text\": \"Orexin/hypocretin neurons located in the lateral hypothalamus play a critical role in the maintenance of arousal and contribute to the regulation of multiple homeostatic and behavioral processes.\"}, {\"id\": 1, \"text\": \"Central orexin/hypocretin neurons promote wakefulness, feeding and reward-seeking, and control blood glucose levels by regulating sympathetic outflow to the periphery.\"}, {\"id\": 15, \"text\": \"Orexin neurons are \\\"multi-tasking\\\" neurons regulating a set of vital body functions, including sleep/wake states, feeding behavior, energy homeostasis, reward systems, cognition and mood.\"}, {\"id\": 8, \"text\": \" Food intake, in contrast, receives circadian modulation through hormones such as leptin, ghrelin, insulin and orexin. \"}, {\"id\": 9, \"text\": \"The effects of orexinergic peptides are diverse and are mediated by orexin-1 and orexin-2 receptors. Antagonists that target both receptors have been shown to promote sleep initiation and maintenance.\"}, {\"id\": 17, \"text\": \"Hypocretin/orexin neurons regulate many behavioral functions, including addiction.\"}, {\"id\": 16, \"text\": \"This review discusses the mechanism by which orexins maintain sleep/wakefulness states and how this mechanism relates to other systems that regulate emotion, reward, and energy homeostasis.\"}, {\"id\": 18, \"text\": \"Orexin A (OXA) and orexin B (OXB) are recently discovered neuropeptides that appear to play a role in various distinct functions such as arousal and the sleep-wake cycle as well as on appetite and regulation of feeding and energy homeostasis. Orexins were first described as neuropeptides expressed by a sp\"}]``` return a json array of their ids called 'snippets'"}, {"role": "assistant", "content": "{\"snippets\": [2, 8, 12, 5, 14, 9, 13, 16, 1, 10, 4, 17, 3, 11, 15, 0, 7, 18, 6]}"}]}
{"messages": [{"role": "system", "content": "You are BioASQ-GPT, an AI expert in question answering, research, and information retrieval in the biomedical domain."}, {"role": "user", "content": "Given this question: 'Can the epigenetic status of introns affect gene expression?' select the top 10 snippets that are most helpful for answering this question from this list of snippets, \n        rerank them by helpfulness: ```[{\"id\": 2, \"text\": \"Here, we show that the expression of the H3K9 demethylase IBM1 (increase in BONSAI methylation 1) requires DNA methylation. Surprisingly, the regulatory methylated region is contained in an unusually large intron that is conserved in IBM1 orthologues.\"}, {\"id\": 8, \"text\": \"Consistent with previous work we found that intragenic methylation is positively correlated with gene expression and that exons are more highly methylated than their neighboring intronic environment.\"}, {\"id\": 9, \"text\": \"Here we report that ASI1 and EDM2 form a protein complex in vivo via a bridge protein, ASI1-Immunoprecipitated Protein 1 (AIPP1), which is another RNA recognition motif-containing protein. The complex also may contain the Pol II CTD phosphatase CPL2, the plant homeodomain-containing protein AIPP2, and another BAH domain protein, AIPP3. As is the case with dysfunction of ASI1 and EDM2, dysfunction of AIPP1 impedes the use of distal polyadenylation sites at tested intronic HC-containing genes, such as the histone demethylase gene IBM1, resulting in a lack of functional full-length transcripts.\"}, {\"id\": 5, \"text\": \"Interestingly, hypomethylation of introns is correlated with higher levels of intron expression in mRNA and the methylation level of an intron is inversely correlated with its retention in mRNA from the gene in which it is located.\"}, {\"id\": 7, \"text\": \"Regulation of gene expression by DNA methylation in gene promoter regions is well studied; however, the effects of methylation in the gene body (exons and introns) on gene expression are comparatively understudied.\"}, {\"id\": 3, \"text\": \"DNA methylation in an intron of the IBM1 histone demethylase gene stabilizes chromatin modification patterns.\"}, {\"id\": 6, \"text\": \"In several eukaryotic organisms, heterochromatin (HC) in the introns of genes can regulate RNA processing, including polyadenylation, but the mechanism underlying this regulation is poorly understood.\"}, {\"id\": 4, \"text\": \"Heterochromatin is widespread in eukaryotic genomes and has diverse impacts depending on its genomic context.\"}, {\"id\": 1, \"text\": \"Combining methylation data with mRNA sequencing revealed that DNA methylation in promoters, introns and exons may have different roles in regulating gene expression.\"}, {\"id\": 0, \"text\": \"Polyadenylation (poly(A) sequencing reveals that AAE complex has a substantial influence on poly(A) site usage of heterochromatin-containing genes, including not only intronic heterochromatin-containing genes but also the genes showing overlap with heterochromatin.\"}]``` return a json array of their ids called 'snippets'"}, {"role": "assistant", "content": "{\"snippets\": [2, 3, 0, 4, 1, 6, 9, 5, 7, 8]}"}]}
{"messages": [{"role": "system", "content": "You are BioASQ-GPT, an AI expert in question answering, research, and information retrieval in the biomedical domain."}, {"role": "user", "content": "Given this question: 'What was Keytruda originally approved for by the FDA?' select the top 10 snippets that are most helpful for answering this question from this list of snippets, \n        rerank them by helpfulness: ```[{\"id\": 0, \"text\": \"FDA Approval Summary: Pembrolizumab for Treatment of Metastatic Non-Small Cell Lung Cancer: First-Line Therapy and Beyond.\"}, {\"id\": 1, \"text\": \"On October 24, 2016, the U.S. Food and Drug Administration (FDA) approved pembrolizumab (Keytruda; Merck & Co., Inc., https://www.merck.com) for treatment of patients with metastatic non-small cell lung cancer (mNSCLC) whose tumors express programmed death-ligand 1 (PD-L1) as determined by an FDA-approved test, as follows: (a) first-line treatment of patients with mNSCLC whose tumors have high PD-L1 expression (tumor proportion score [TPS] \\u00e2\\u2030\\u00a550%), with no epidermal growth factor receptor (EGFR) or anaplastic lymphoma kinase (ALK) genomic tumor aberrations, and (b) treatment of patients with mNSCLC whose tumors express PD-L1 (TPS \\u00e2\\u2030\\u00a51%), with disease progression on or after platinum-containing chemotherapy. P\"}]``` return a json array of their ids called 'snippets'"}, {"role": "assistant", "content": "{\"snippets\": [0, 1]}"}]}
{"messages": [{"role": "system", "content": "You are BioASQ-GPT, an AI expert in question answering, research, and information retrieval in the biomedical domain."}, {"role": "user", "content": "Given this question: 'What are clinical features of the Achard-Thiers syndrome?' select the top 10 snippets that are most helpful for answering this question from this list of snippets, \n        rerank them by helpfulness: ```[{\"id\": 1, \"text\": \"Diabetes in bearded women (Achard-Thiers-Syndrome) : A clinical and metabolic study of 20 cases.\"}, {\"id\": 0, \"text\": \"Twenty patients, selected on the basis of simultaneous existence of overt diabetes and marked hirsutism, were submitted to clinical and biological investigations. Obesity, hypertension and angiopathy were present in most of these patients.\"}]``` return a json array of their ids called 'snippets'"}, {"role": "assistant", "content": "{\"snippets\": [1, 0]}"}]}
{"messages": [{"role": "system", "content": "You are BioASQ-GPT, an AI expert in question answering, research, and information retrieval in the biomedical domain."}, {"role": "user", "content": "Given this question: 'Are Luminopsins a fusion proteins of luminol and Rhodopsin ?' select the top 10 snippets that are most helpful for answering this question from this list of snippets, \n        rerank them by helpfulness: ```[{\"id\": 2, \"text\": \"Here we have expanded and refined the versatility of luminopsin tools by fusing an alternative luciferase variant with high light emission, Gaussia luciferase mutant GLucM23, to depolarizing and hyperpolarizing channelrhodopsins\"}, {\"id\": 3, \"text\": \"Luminopsins are fusion proteins of luciferase and opsin that allow interrogation of neuronal circuits at different temporal and spatial resolutions by choosing either extrinsic physical or intrinsic biological light for its activation.\"}, {\"id\": 0, \"text\": \"Bioluminescence-optogenetics is mediated by luminopsin fusion proteins-light-sensing opsins fused to light-emitting luciferases.\"}, {\"id\": 4, \"text\": \" luminopsins by fusing light-sensing opsins with light-emitting luciferases. \"}, {\"id\": 1, \"text\": \"ouse iPS-NPCs were transduced with a novel optochemogenetics fusion protein, luminopsin 3 (LMO3), which consisted of a bioluminescent luciferase, Gaussia luciferase, and an opsin, Volvox Channelrhodopsin 1. \"}]``` return a json array of their ids called 'snippets'"}, {"role": "assistant", "content": "{\"snippets\": [0, 2, 4, 1, 3]}"}]}
{"messages": [{"role": "system", "content": "You are BioASQ-GPT, an AI expert in question answering, research, and information retrieval in the biomedical domain."}, {"role": "user", "content": "Given this question: 'What are coactivators?' select the top 10 snippets that are most helpful for answering this question from this list of snippets, \n        rerank them by helpfulness: ```[{\"id\": 1, \"text\": \"Coactivators are a novel class of transcriptional activator required at many eukaryotic promoters.\"}, {\"id\": 0, \"text\": \"Coactivator functions can be broadly divide into two classes: (a) adaptors that direct activator recruitment of the transcriptional apparatus, (b) chromatin-remodeling or -modifying enzymes.\"}, {\"id\": 6, \"text\": \"A critical insight to transcriptional control mechanisms was provided by the discovery of coactivators, a diverse array of cellular factors that connect sequence-specific DNA binding activators to the general transcriptional machinery, or that help activators and the transcriptional apparatus to navigate through the constraints of chromatin.\"}, {\"id\": 5, \"text\": \"Coactivators are diverse and multifunctional proteins that act downstream of DNA-binding activators to stimulate transcription.\"}, {\"id\": 4, \"text\": \"Transcriptional coactivators have evolved as an important new class of functional proteins that participate with virtually all transcription factors and nuclear receptors (NRs) to intricately regulate gene expression in response to a wide variety of environmental cues.\"}, {\"id\": 3, \"text\": \"Coactivators represent a large class of proteins that partner with nuclear receptors and other transcription factors to regulate gene expression.\"}, {\"id\": 2, \"text\": \"Coactivators function as adaptors in a signaling pathway that transmits transcriptional responses from the DNA bound receptor to the basal transcriptional machinery.\"}]``` return a json array of their ids called 'snippets'"}, {"role": "assistant", "content": "{\"snippets\": [5, 6, 0, 2, 1, 3, 4]}"}]}
{"messages": [{"role": "system", "content": "You are BioASQ-GPT, an AI expert in question answering, research, and information retrieval in the biomedical domain."}, {"role": "user", "content": "Given this question: 'What are PROTACs?' select the top 10 snippets that are most helpful for answering this question from this list of snippets, \n        rerank them by helpfulness: ```[{\"id\": 0, \"text\": \"Proteolysis-targeting chimeras (PROTACs) are bifunctional molecules that hijack the cell's ubiquitin-proteasome system (UPS).\"}]``` return a json array of their ids called 'snippets'"}, {"role": "assistant", "content": "{\"snippets\": [0]}"}]}
{"messages": [{"role": "system", "content": "You are BioASQ-GPT, an AI expert in question answering, research, and information retrieval in the biomedical domain."}, {"role": "user", "content": "Given this question: 'Which variables are included in the ALBI grade?' select the top 10 snippets that are most helpful for answering this question from this list of snippets, \n        rerank them by helpfulness: ```[{\"id\": 4, \"text\": \"We used each database to evaluate the relationship between the albumin-bilirubin grade (ALBI) and the microbiome in patients with hepatitis C.\"}, {\"id\": 2, \"text\": \"RESULTS: Fourteen, 13, and 24 patients were classified based on modified albumin-bilirubin (mALBI) grade 1, 2a, and 2b, respectively. \"}, {\"id\": 1, \"text\": \"At the diagnosis of PoPH, liver function was evaluated by albumin-bilirubin (ALBI) score. \"}, {\"id\": 0, \"text\": \"Independent factors associated with survival were previous HCC treatment (HR 2.01, 95% CI 1.23-3.27, p\\u00e2\\u20ac\\u2030=\\u00e2\\u20ac\\u20300.005), bi-lobar disease (HR 2.25, 95% CI 1.30-3.89, p\\u00e2\\u20ac\\u2030=\\u00e2\\u20ac\\u20300.003), ascites (HR 1.77, 95% CI 0.99-3.13, p\\u00e2\\u20ac\\u2030=\\u00e2\\u20ac\\u20300.05), neutrophil-to-lymphocyte ratio (HR 1.11, 95% CI 1.02-1.20, p\\u00e2\\u20ac\\u2030=\\u00e2\\u20ac\\u20300.01), Albumin-Bilirubin (ALBI) grade-3 (HR 2.69, 95% CI 1.22-5.92, p\\u00e2\\u20ac\\u2030=\\u00e2\\u20ac\\u20300.01), tumor thrombus (HR 2.95, 95% CI 1.65-5.24, p\\u00e2\\u20ac\\u2030<\\u00e2\\u20ac\\u20300.001), and disease control rate (HR 0.62, 95% CI 0.39-0.96, p\\u00e2\\u20ac\\u2030=\\u00e2\\u20ac\\u20300.03). \"}, {\"id\": 3, \"text\": \"Association between the albumin-bilirubin (ALBI) score and severity of portopulmonary hypertension (PoPH): A data-mining analysis.\"}]``` return a json array of their ids called 'snippets'"}, {"role": "assistant", "content": "{\"snippets\": [0, 4, 3, 1, 2]}"}]}
{"messages": [{"role": "system", "content": "You are BioASQ-GPT, an AI expert in question answering, research, and information retrieval in the biomedical domain."}, {"role": "user", "content": "Given this question: 'What drugs are used to treat FIP, Feline Infectious Peritonitis in cats?' select the top 10 snippets that are most helpful for answering this question from this list of snippets, \n        rerank them by helpfulness: ```[{\"id\": 4, \"text\": \"S-441524 was shown to be a safe and effective treatment for FIP. The optimum dosage was found to be 4.0 mg/kg SC q24h for at least 12 weeks.\"}, {\"id\": 18, \"text\": \"Feline infectious peritonitis (FIP) is a common and highly lethal coronavirus disease of domestic cats. Recent studies of diseases caused by several RNA viruses in people and other species indicate that antiviral therapy may be effective against FIP in cats. The small molecule nucleoside analog GS-441524 is a molecular precursor to a pharmacologically active nucleoside triphosphate molecule.\"}, {\"id\": 43, \"text\": \"Differential effects of viroporin inhibitors against feline infectious peritonitis virus serotypes I and II.\"}, {\"id\": 5, \"text\": \"Effect of Polyprenyl Immunostimulant on the survival times of three cats with the dry form of feline infectious peritoniti\"}, {\"id\": 23, \"text\": \"ed, and most of the affected cats die or are euthanized. Anecdotally, doxycycline has been used to treat FIP-affected cats, but there are currently no\"}, {\"id\": 33, \"text\": \"Curing Cats with Feline Infectious Peritonitis with an Oral Multi-Component Drug Containing GS-441524.\"}, {\"id\": 42, \"text\": \"fatal disease. Three cats with dry form FIP were treated with Polyprenyl Immunostimulant. Two of the three cats are still on treatment and are alive a\"}, {\"id\": 36, \"text\": \"ritonitis (FIP) were treated with a combination of recombinant feline interferon and glucocorticoid. A complete remission (over 2 years) and a partial\"}, {\"id\": 37, \"text\": \"Therapeutic effect of anti-feline TNF-alpha monoclonal antibody for feline infectious peritonitis.\"}, {\"id\": 3, \"text\": \"OBJECTIVES: The aim of this study was to determine the safety and efficacy of the nucleoside analog GS-441524 for cats suffering from various forms of naturally acquired feline infectious peritonitis (FIP).METHODS: Cats ranged from 3.4-73 months of age (mean 13.6 months); 26 had effusive or dry-to-effusive FIP and five had non-effusiv\"}, {\"id\": 2, \"text\": \"YPOTHESIS: Feline interferon-omega (FeIFN-omega) prolongs survival time and increases quality of life in cats with FIP.ANIMALS:\"}, {\"id\": 28, \"text\": \"Pharmacokinetic Profile of Oral Administration of Mefloquine to Clinically Normal Cats: A Preliminary In-Vivo Study of a Potential Treatment for Feline Infectious Peritonitis (FIP).\"}, {\"id\": 9, \"text\": \"BACKGROUND: Currently there is no drug proven to effectively treat cats with feline infectious peritonitis (FIP).HYPOTHESIS: Propentofylline (PPF) can decrease vasculitis, and therefore prolong survival time in cats with FIP, and increase their quality of life.ANIMALS: Twenty-three privately owned cats with FIP.METHO\"}, {\"id\": 39, \"text\": \"The aim of this study was to evaluate efficacy and toxicity of the multi-component drug Xraphconn\\u00c2\\u00ae in vitro and as oral treatment in cats with spontaneous FIP by examining survival rate, development of clinical and laboratory parameters, viral loads, anti-FCoV antibodies, and adverse effects.\"}, {\"id\": 14, \"text\": \"The aim of this study was to determine the safety and efficacy of the nucleoside analog GS-441524 for cats suffering from various forms of naturally acquired feline infectious peritonitis\"}, {\"id\": 32, \"text\": \"Oral Mutian\\u00c2\\u00aeX stopped faecal feline coronavirus shedding by naturally infected cats.\"}, {\"id\": 40, \"text\": \"Feline infectious peritonitis (FIP) caused by feline coronavirus (FCoV) is a common dis-ease in cats, fatal if untreated, and no effective treatment is currently legally available. The aim of this study was to evaluate efficacy and toxicity of the multi-component drug Xraphconn\\u00c2\\u00ae in vitro and as oral treatment in cats with spontaneous FIP by examining survival rate, development of clinical and laboratory parameters, viral loads, anti-FCoV antibodies, and adverse effects. Mass spectrometry and nuclear magnetic resonance identified GS-441524 as an active component of Xraphconn\\u00c2\\u00ae.\"}, {\"id\": 41, \"text\": \"Our study suggested that HCQ and rfIFN-\\u00cf\\u2030 are applicable for treatment of FIP.\"}, {\"id\": 11, \"text\": \"Feline infectious peritonitis (FIP) is considered a fatal disease. Three cats with dry form FIP were treated with Polyprenyl Immunostimulant. Two of the three cats are still on treatment and are alive and well 2 years after diagnosis. The third cat survived 14 months but was treated for only 4.5 months. Further studies are necessary to assess the potential of the Polyprenyl Immunostimulant.\"}, {\"id\": 25, \"text\": \"Propentofylline (PPF) can decrease vasculitis, and therefore prolong survival time in cats with FIP, and increase their quality of life.\"}, {\"id\": 46, \"text\": \"The pharmacokinetic profile of mefloquine was investigated as a preliminary study towards a potential treatment for feline coronavirus infections (such as feline infectious peritonitis) or feline calicivirus infections\"}, {\"id\": 1, \"text\": \"Here, we evaluated the therapeutic efficacy of our 3CLpro inhibitor in laboratory cats with FIP. Experimental FIP is 100% fatal once certain clinical and laboratory signs become apparent. We found that antiviral treatment led to full recovery of cats when treatment was started at a stage of disease that would be otherwise fatal if left untreated\"}, {\"id\": 24, \"text\": \"Efficacy and safety of the nucleoside analog GS-441524 for treatment of cats with naturally occurring feline infectious peritonitis\"}, {\"id\": 12, \"text\": \"The nucleoside analog GS-441524 strongly inhibits feline infectious peritonitis (FIP) virus in tissue culture and experimental cat infection studies.\"}, {\"id\": 45, \"text\": \"uccessful treatment of a South African cat with effusive feline infectious peritonitis with remdesivir.\"}, {\"id\": 26, \"text\": \"Mutian\\u00c2\\u00ae Xraphconn (Mutian X) is a product marketed to treat cats with FIP but is also being used to stop virus shedding, although no clear guidelines exist for its use for this purpose. \"}, {\"id\": 0, \"text\": \"In conclusion, itraconazole partly exerted a beneficial effect in a cat with FIP. However, further investigation of a possible role of itraconazole in FIP treatment is warranted.\"}, {\"id\": 27, \"text\": \"We previously reported the successful in vitro inhibition of FIPV replication by synthetic siRNA mediated RNA interference (RNAi) in an immortalised cell line (McDonagh et al., 2011).\"}, {\"id\": 20, \"text\": \"Therefore, PPF does not appear to be an effective treatment option in cats with a late stage of the disease FIP.\"}, {\"id\": 47, \"text\": \"Mefloquine may provide a safe effective treatment for feline coronavirus and feline calicivirus infections in cats.\"}, {\"id\": 31, \"text\": \"e examined the effect of HMA and other viroporin inhibitors (DIDS [4,4'-disothiocyano-2,2'-stilbenedisulphonic acid] and amantadine) on infection by FIPV serotypes I and II. HMA treatment drastically decreased the titers of FIPV serotype I strains Black and KU-2 in a dose-dependent manner, but it only slightly decreased the titer of FIPV serotype II strain 79-1146\"}, {\"id\": 19, \"text\": \"Antiviral treatment using the adenosine nucleoside analogue GS-441524 in cats with clinically diagnosed neurological feline infectious peritonitis.\"}, {\"id\": 21, \"text\": \" and no relapse was observed.Conclusions and relevance: GS-441524 combined with GC376 can be safely and effectively used to treat FIP and reduces the \"}, {\"id\": 10, \"text\": \"A total of 12 clinically ill cats previously diagnosed as feline infectious peritonitis (FIP) were treated with a combination of recombinant feline interferon and glucocorticoid.\"}, {\"id\": 34, \"text\": \"This study provides a proof of principle for the use of molnupiravir in cats and supports the need for future studies to further evaluate molnupiravir as a potentially safe and effective therapy for FIP.\"}, {\"id\": 7, \"text\": \"This paper reports on the successful resolution of immunohistochemistry-confirmed effusive FIP in an adolescent cat in South Africa following monotherapy with remdesivir at 4.9-5.6 mg/kg daily for 80 days.\"}, {\"id\": 15, \"text\": \"All cats received adjunctive treatment with glucocorticoids and antibiotics and passive immunization with Feliserin\"}, {\"id\": 44, \"text\": \" However, it is not clear whether HMA and other viroporin inhibitors affect replication of FIPV. \"}, {\"id\": 30, \"text\": \"Reversal of the Progression of Fatal Coronavirus Infection in Cats by a Broad-Spectrum Coronavirus Protease Inhibitor.\"}, {\"id\": 17, \"text\": \"These results strongly suggested that the anti-fTNF-alpha antibody is effective for the treatment of FIP.\"}, {\"id\": 13, \"text\": \"Treatment with GS-441524 shows clinical efficacy and may result in clearance and long-term resolution of neurological FIP\"}, {\"id\": 22, \"text\": \"s FIP is an immune-mediated disease, treatment is mainly aimed at controlling the immune response triggered by the infection with the feline coronavirus (FCoV). Immune suppressive drugs such as prednisone or cyclophosphamide may slow disease progression but do not produce a cure. \"}, {\"id\": 16, \"text\": \"In contrast, DIDS treatment decreased the titer of FIPV serotype II strain 79-1146 in dose-dependent manner, but it only slightly decreased the titers of FIPV serotype I strains Black and KU-2. \"}, {\"id\": 29, \"text\": \"these data inform the potential therapeutic application of antiviral RNAi against FIPV.\"}, {\"id\": 35, \"text\": \"Feline infectious peritonitis (FIP) is a highly fatal disease caused by a virulent feline coronavirus in domestic and wild cats. We have previously reported the synthesis of potent coronavirus 3C-like protease (3CLpro) inhibitors and the efficacy of a protease inhibitor, GC376, in client-owned cats with FIP. \"}, {\"id\": 8, \"text\": \"Clinical efficacy of combination therapy of itraconazole and prednisolone for treating effusive feline infectious peritonitis.\"}, {\"id\": 6, \"text\": \"Objectives: The main objectives of this study were to investigate the efficacy of the nucleotide analog GS-441524 in combination with the 3C-like protease inhibitor GC376 for the treatment of naturally aquired feline infectious peritonitis (FIP) and to test whether their combination shortens the dosing period and improves the cure rate\"}, {\"id\": 38, \"text\": \"Combination siRNA therapy against feline coronavirus can delay the emergence of antiviral resistance in vitro.\"}]``` return a json array of their ids called 'snippets'"}, {"role": "assistant", "content": "{\"snippets\": [22, 10, 2, 15, 25, 20, 11, 5, 35, 38, 29, 27, 43, 44, 31, 16, 30, 1, 37, 17, 19, 13, 26, 32, 28, 46, 47, 0, 8, 24, 14, 4, 7, 45, 9, 39, 12, 42, 23, 21, 36, 34, 6, 41, 3, 33, 40, 18]}"}]}
{"messages": [{"role": "system", "content": "You are BioASQ-GPT, an AI expert in question answering, research, and information retrieval in the biomedical domain."}, {"role": "user", "content": "Given this question: 'Is there a way to distinguish COVID-19 clinically from other respiratory illnesses, such as influenza?' select the top 10 snippets that are most helpful for answering this question from this list of snippets, \n        rerank them by helpfulness: ```[{\"id\": 12, \"text\": \"An understanding of differences in clinical phenotypes and outcomes COVID-19 compared with other respiratory viral infections is important to optimise the management of patients and plan healthcare.\"}, {\"id\": 11, \"text\": \"SARS-CoV-2 is associated with more severe outcomes compared with other respiratory viruses, and although associated with specific patient and clinical characteristics at admission, a substantial overlap precludes discrimination based on these characteristics.\"}, {\"id\": 0, \"text\": \" Clinical presentation of COVID-19, however, can be difficult to distinguish from other respiratory viral infections.\"}, {\"id\": 9, \"text\": \" Unfortunately, COVID-19 patients have symptoms similar to other common illnesses. Here, we hypothesize the order of symptom occurrence could help patients and medical professionals more quickly distinguish COVID-19 from other respiratory diseases, yet such essential information is largely unavailable.\"}, {\"id\": 10, \"text\": \"Although COVID-19 has been extensively characterized clinically, the factors distinguishing SARS-CoV-2 from other respiratory viruses are unknown.\"}, {\"id\": 7, \"text\": \"COVID-19 and flu are two respiratory illnesses which share similar clinical symptoms.\"}, {\"id\": 6, \"text\": \"Clinical presentation of COVID-19, however, can be difficult to distinguish from other respiratory viral infections.\"}, {\"id\": 3, \"text\": \" Since the symptoms are similar to other respiratory infections, differential diagnosis in travellers arriving from countries with wide-spread COVID-19 must include other more common infections such as influenza and other respiratory tract diseases.\"}, {\"id\": 2, \"text\": \"No symptoms are characteristic of a single infectious agent, with flu-like disorders being the most common.\"}, {\"id\": 5, \"text\": \"We show that although COVID-19 and influenza are different in many ways, there are numerous similarities; thus, in addition to using nucleic acid-based polymerase chain reaction (PCR) and antibody-based approaches, clinicians and epidemiologists should distinguish between the two using their respective characteristics in early stages.\"}, {\"id\": 8, \"text\": \"Unfortunately, COVID-19 patients have symptoms similar to other common illnesses.\"}, {\"id\": 4, \"text\": \"During influenza season, differentiating other causes of respiratory illness from COVID-19 is difficult, because common clinical manifestations of COVID-19 mimic those of influenza.\"}, {\"id\": 1, \"text\": \"It is difficult to distinguish coronavirus disease-2019 (COVID-19) from other viral respiratory tract infections owing to the similarities in clinical and radiological findings.\"}]``` return a json array of their ids called 'snippets'"}, {"role": "assistant", "content": "{\"snippets\": [9, 2, 5, 12, 11, 8, 6, 1, 10, 3, 0, 7, 4]}"}]}
{"messages": [{"role": "system", "content": "You are BioASQ-GPT, an AI expert in question answering, research, and information retrieval in the biomedical domain."}, {"role": "user", "content": "Given this question: 'Which form of cancer have paclitaxel, docetaxel, doxorubicin, and epirubicin been approved for?' select the top 10 snippets that are most helpful for answering this question from this list of snippets, \n        rerank them by helpfulness: ```[{\"id\": 0, \"text\": \"Paclitaxel, docetaxel, doxorubicin, and epirubicin have been longstanding,\\u00c2\\u00a0Food and Drug Administration (FDA)-approved therapies against TNBC.\"}]``` return a json array of their ids called 'snippets'"}, {"role": "assistant", "content": "{\"snippets\": [0]}"}]}
{"messages": [{"role": "system", "content": "You are BioASQ-GPT, an AI expert in question answering, research, and information retrieval in the biomedical domain."}, {"role": "user", "content": "Given this question: 'Talquetamab was developed for treatment of which disease?' select the top 10 snippets that are most helpful for answering this question from this list of snippets, \n        rerank them by helpfulness: ```[{\"id\": 0, \"text\": \"Effects of teclistamab and talquetamab on soluble BCMA levels in patients with relapsed/refractory multiple myeloma.\"}, {\"id\": 1, \"text\": \"The bispecific antibodies teclistamab (BCMA\\u00c3\\u2014CD3) and talquetamab (G protein-coupled receptor family C group 5 member D [GPRC5D]\\u00c3\\u2014CD3) are in clinical development as therapies for MM. \"}]``` return a json array of their ids called 'snippets'"}, {"role": "assistant", "content": "{\"snippets\": [0, 1]}"}]}
{"messages": [{"role": "system", "content": "You are BioASQ-GPT, an AI expert in question answering, research, and information retrieval in the biomedical domain."}, {"role": "user", "content": "Given this question: 'Please summarize Feline Spongiform Encephalopathy(FSE' select the top 10 snippets that are most helpful for answering this question from this list of snippets, \n        rerank them by helpfulness: ```[{\"id\": 4, \"text\": \"Feline spongiform encephalopathy (FSE) is a transmissible spongiform encephalopathy that affects domestic cats (Felis catus) and captive wild members of the family Felidae. \"}, {\"id\": 5, \"text\": \"Feline spongiform encephalopathy (FSE), affecting domestic and captive feline species, is a prion disease considered to be related to bovine spongiform encephalopathy.\"}, {\"id\": 1, \"text\": \"Feline spongiform encephalopathy (FSE) is a transmissible spongiform encephalopathy that affects domestic cats (Felis catus) and captive wild members of the family Felidae.\"}, {\"id\": 6, \"text\": \"Feline spongiform encephalopathy (FSE) is a transmissible spongiform encephalopathy associated with the consumption of feedstuffs contaminated with tissue from bovine spongiform encephalopathy-affected cattle and characterized by the accumulation in the central nervous system of an abnormal isoform of the prion protein (PrP(sc)).\"}, {\"id\": 7, \"text\": \"Clinically, it presents as a progressive fatal neurologic syndrome that is not easily distinguished from other feline neurologic conditions. Most cases of FSE have been reported in England, where it was first detected in 1990, but a few cases have been reported from other European countries. \"}, {\"id\": 0, \"text\": \"Feline spongiform encephalopathy (FSE) is a transmissible spongiform encephalopathy associated with the consumption of feedstuffs contaminated with tissue from bovine spongiform encephalopathy-affected cattle and characterized by the accumulation in the central nervous system of an abnormal isoform of the prion protein (PrP(sc))\"}, {\"id\": 2, \"text\": \"Feline spongiform encephalopathy (FSE), a transmissible spongiform encephalopathy or prion disease of cats, first reported in Great Britain in 1990, is believed to result from the consumption of food contaminated by the agent of bovine spongiform encephalopathy (BSE).\"}, {\"id\": 3, \"text\": \"Feline spongiform encephalopathy (FSE) is considered to be related to bovine spongiform encephalopathy (BSE) and has been reported in domestic cats as well as in captive wild cats including cheetahs, first in the United Kingdom (UK) and then in other European countries.\"}]``` return a json array of their ids called 'snippets'"}, {"role": "assistant", "content": "{\"snippets\": [2, 7, 0, 4, 6, 5, 3, 1]}"}]}
{"messages": [{"role": "system", "content": "You are BioASQ-GPT, an AI expert in question answering, research, and information retrieval in the biomedical domain."}, {"role": "user", "content": "Given this question: 'Can untranslated regions (UTRs) regulate gene expression?' select the top 10 snippets that are most helpful for answering this question from this list of snippets, \n        rerank them by helpfulness: ```[{\"id\": 16, \"text\": \"Eukaryotic gene expression is precisely regulated at all points between transcription and translation. In this review, we focus on translational control mediated by the 3'-untranslated regions (UTRs) of mRNAs. mRNA 3'-UTRs contain cis-acting elements that function in the regulation of protein translation or mRNA decay.\"}, {\"id\": 5, \"text\": \"Now, we are beginning to better appreciate the role of 3'-UTR (untranslated region) cis-elements which harbor not only microRNA but also RNA-binding protein (RBP) binding sites that have significant effect on the stability and translational rate of mRNAs.\"}, {\"id\": 18, \"text\": \"3' untranslated regions (UTRs) are known to play an important role in posttranscriptional regulation of gene expression.\"}, {\"id\": 17, \"text\": \"Our results suggest that 3'UTR sequences can function not only in cis to regulate protein expression, but also intrinsically and independently in trans, likely as noncoding RNAs, a conclusion supported by a number of previous genetic studies.\"}, {\"id\": 13, \"text\": \"Post-transcriptional regulation, via 5'-UTRs (5'-untranslated regions), plays an important role in the control of eukaryotic gene expression.\"}, {\"id\": 15, \"text\": \"The 5' and 3' untranslated regions (UTRs) regulate crucial aspects of post-transcriptional gene regulation that are necessary for the maintenance of cellular homeostasis. When these processes go awry through mutation or misexpression of certain regulatory elements, the subsequent deregulation of oncogenic gene expression can drive or enhance cancer pathogenesis.\"}, {\"id\": 12, \"text\": \"The 3' untranslated region (3' UTR) can control gene expression by affecting the localization, stability and translation of mRNAs.\"}, {\"id\": 11, \"text\": \"Many studies using reporter assays have demonstrated that 3' untranslated regions (3'-UTRs) regulate gene expression by controlling mRNA stability and translation.\"}, {\"id\": 3, \"text\": \"Untranslated regions (UTRs) in eukaryotes play a significant role in the regulation of translation and mRNA half-life, as well as interacting with specific RNA-binding proteins.\"}, {\"id\": 2, \"text\": \"The 3' untranslated regions (3'UTRs) of eukaryotic genes regulate mRNA stability, localization and translation.\"}, {\"id\": 7, \"text\": \" The untranslated regions (UTRs) of mRNA are hotspots for regulatory control.\"}, {\"id\": 10, \"text\": \"The 5' and 3' untranslated regions of eukaryotic mRNAs (UTRs) play crucial roles in the post-transcriptional regulation of gene expression through the modulation of nucleo-cytoplasmic mRNA transport, translation efficiency, subcellular localization, and message stability.\"}, {\"id\": 8, \"text\": \"Previously dismissed as \\\"junk DNA\\\", it is the non-coding regions of the genome that are responsible for regulation, facilitating complex temporal and spatial gene expression through the combinatorial effect of numerous mechanisms and interactions working together to fine-tune gene expression. The major regions involved in regulation of a particular gene are the 5' and 3' untranslated regions and introns.\"}, {\"id\": 6, \"text\": \"In higher eukaryotes, untranslated regions (UTRs) of transcripts are one of the crucial regulators of gene expression (influencing mRNA stability and translation efficiency).\"}, {\"id\": 9, \"text\": \"The untranslated regions of mRNAs can determine gene expression by influencing mRNA stability and translational efficiency.\"}, {\"id\": 4, \"text\": \"Untranslated regions (UTRs) of eukaryotic mRNAs play crucial roles in post-transcriptional regulation of gene expression via the modulation of nucleocytoplasmic mRNA transport, translation efficiency, subcellular localization, and message stability.\"}, {\"id\": 0, \"text\": \"Untranslated gene regions (UTRs) play an important role in controlling gene expression.\"}, {\"id\": 1, \"text\": \" In higher eukaryotes, untranslated regions (UTRs) of transcripts are one of the crucial regulators of gene expression (influencing mRNA stability and translation efficiency).\"}, {\"id\": 14, \"text\": \"Untranslated regions (UTR) play important roles in the posttranscriptional regulation of mRNA processing.\"}]``` return a json array of their ids called 'snippets'"}, {"role": "assistant", "content": "{\"snippets\": [8, 13, 16, 5, 11, 9, 6, 17, 2, 10, 18, 12, 1, 14, 0, 7, 3, 4, 15]}"}]}
{"messages": [{"role": "system", "content": "You are BioASQ-GPT, an AI expert in question answering, research, and information retrieval in the biomedical domain."}, {"role": "user", "content": "Given this question: 'Is alternative splicing associated with heart disease?' select the top 10 snippets that are most helpful for answering this question from this list of snippets, \n        rerank them by helpfulness: ```[{\"id\": 1, \"text\": \"We identified >200 significant alternative splicing (AS) events and distinct AS profiles were observed in the right (RV) and left (LV) ventricles in PLN-R14del compared to WT mouse hearts. \"}, {\"id\": 0, \"text\": \"Our findings suggest that aberrant splicing may affect Ca2+-homeostasis in the heart, contributing to the increased risk of arrythmogenesis in PLN-R14del ACM.\"}]``` return a json array of their ids called 'snippets'"}, {"role": "assistant", "content": "{\"snippets\": [1, 0]}"}]}
{"messages": [{"role": "system", "content": "You are BioASQ-GPT, an AI expert in question answering, research, and information retrieval in the biomedical domain."}, {"role": "user", "content": "Given this question: 'Should Intepirdine be used for Alzheimer's disease?' select the top 10 snippets that are most helpful for answering this question from this list of snippets, \n        rerank them by helpfulness: ```[{\"id\": 2, \"text\": \"There were no statistically significant differences between intepirdine and placebo groups (adjusted mean [95% confidence interval]) on the co-primary endpoints ADAS-Cog (-0.36 [-0.95, 0.22], P\\u00c2\\u00a0=\\u00c2\\u00a00.2249) and ADCS-ADL (-0.09 [-0.90, 0.72], P\\u00c2\\u00a0=\\u00c2\\u00a00.8260). \"}, {\"id\": 0, \"text\": \"EXPERT OPINION: Despite early positive findings, larger phase-III trials have failed to demonstrate any statistically significant impact on cognition for both idalopirdine and intepirdine, as adjunct to cholinesterase inhibitors.\"}, {\"id\": 1, \"text\": \"Discussion: Intepirdine as adjunctive therapy to donepezil did not produce statistical improvement over placebo on cognition or activities of daily living in mild-to-moderate AD dementia patients.\"}]``` return a json array of their ids called 'snippets'"}, {"role": "assistant", "content": "{\"snippets\": [2, 1, 0]}"}]}
{"messages": [{"role": "system", "content": "You are BioASQ-GPT, an AI expert in question answering, research, and information retrieval in the biomedical domain."}, {"role": "user", "content": "Given this question: 'What human cells are usually targeted with a Gal-Nac conjugated siRNA or ASO' select the top 10 snippets that are most helpful for answering this question from this list of snippets, \n        rerank them by helpfulness: ```[{\"id\": 4, \"text\": \"Most siRNA therapeutic efforts to date have focused on the treatment of liver diseases due to major breakthroughs in the development of efficient strategies for delivering siRNA drugs to the liver. Indeed, the development of lipid nanoparticle-formulated and GalNAc-conjugated siRNA therapeutics has resulted in recent FDA approvals of the first siRNA-based drugs, patisiran for the treatment of hereditary transthyretin amyloidosis and givosiran for the treatment of acute hepatic porphyria, respectively.\"}, {\"id\": 7, \"text\": \"the first siRNA drugs received approval for clinical use by the US Food and Drug Administration and the European Medicines Agency between 2018 and 2022. These are mainly based on an siRNA conjugation with a targeting moiety for liver hepatocytes, N-acetylgalactosamine,\"}, {\"id\": 5, \"text\": \"Triantennary N-acetyl galactosamine (GalNAc, GN3: ), a high-affinity ligand for the hepatocyte-specific asialoglycoprotein receptor (ASGPR), enhances the potency of second-generation gapmer antisense oligonucleotides (ASOs) 6-10-fold in mouse liver.\"}, {\"id\": 1, \"text\": \"Beyond that, we show that GalNAc-conjugated siRNAs with bulges at certain positions of the guide strand repress transthyretin in murine primary hepatocytes and in\\u00c2\\u00a0vivo in mice.\"}, {\"id\": 3, \"text\": \"GalNAc-conjugated siRNAs rapidly distribute into the liver via asialoglycoprotein receptor (ASGPR) mediated uptake in the hepatocytes\"}, {\"id\": 8, \"text\": \"TriantennaryN-acetyl galactosamine (GalNAc, GN3) and lipophilic ligands such as cholesterol and\\u00ce\\u00b1-tocopherol conjugations dramatically improve the distribution and efficacy of second-generation antisense oligonucleotides (ASOs) in the whole liver.\"}, {\"id\": 0, \"text\": \"ng and NAFLD/NASH. Here, we studied the metabolic benefit of liver-specific STK25 inhibitors on NAFLD development and progression in a mouse model of diet-induced obesity.METHODS: We developed a hepatocyte-specific triantennary N-acetylgalactosamine (GalNAc)-conjugated antisense oligonucleotide (ASO) targeting Stk25 and evaluated its effect on NAFLD features in mice after chronic exposure to dietary lipids.RESULTS: We found that systemic administration of hepatocyte-targeting GalNAc-Stk25 ASO in obese mice effectively ameliorated steatosis, inflammatory infiltration, hepatic stellate cell activation, nutritional fibrosis, and hepatocellular damage in the liver compared with mice treated with GalNAc-conjugated nontargeting ASO, without any systemic tox\"}, {\"id\": 6, \"text\": \"One example is the targeted delivery of ASOs to hepatocytes, achieved with N-acetylgalactosamine (GalNAc) conjugation to ASO, which results in selective uptake by asialoglycoprotein receptor (ASGR).\"}, {\"id\": 2, \"text\": \"hree such products (givosiran, lumasiran and inclisiran) are liver-targeted, using tris N-acetylgalactosamine (GalNAc)3 as the targeting ligand. Upon subcutaneous administration,\"}]``` return a json array of their ids called 'snippets'"}, {"role": "assistant", "content": "{\"snippets\": [4, 7, 3, 2, 1, 6, 0, 5, 8]}"}]}
{"messages": [{"role": "system", "content": "You are BioASQ-GPT, an AI expert in question answering, research, and information retrieval in the biomedical domain."}, {"role": "user", "content": "Given this question: 'What is rebound COVID-19?' select the top 10 snippets that are most helpful for answering this question from this list of snippets, \n        rerank them by helpfulness: ```[{\"id\": 10, \"text\": \"One of the most recently described clinical associations with SARS-CoV-2 infection is rebound COVID-19, which occurs between five and eight days following the cessation of antiviral treatment. Most case reports of rebound COVID-19 have been associated with cessation of treatment with the combined oral antiviral agent nirmatrelvir/ritonavir (Paxlovid).\"}, {\"id\": 9, \"text\": \"Clinical rebound of COVID-19 after nirmatrelvir/ritonavir treatment has been reported.\"}, {\"id\": 3, \"text\": \"There are reports of viral RNA and symptom rebound in people with COVID-19 treated with nirmatrelvir/ritonavir. Since the natural course of viral and symptom trajectories of COVID-19 has not been well described, we evaluated the incidence of viral and symptom rebound in untreated outpatients with mild-moderate COVID-19.\"}, {\"id\": 5, \"text\": \"One of the most recently described clinical associations with SARS-CoV-2 infection is rebound COVID-19, which occurs between five and eight days following the cessation of antiviral treatment.\"}, {\"id\": 11, \"text\": \"The mechanisms of rebound COVID-19 remain unclear but may involve the development of resistance to the antiviral drug, impaired immunity to the virus, or insufficient drug dosing. A further explanation may be the persistence of a high viral load of SARS-CoV-2 in individuals who are no longer symptomatic.\"}, {\"id\": 6, \"text\": \"Some patients treated with nirmatrelvir-ritonavir have experienced rebound of COVID-19 infections and symptoms; however, data are scarce on whether viral rebound also occurs in patients with COVID-19 receiving or not receiving molnupiravir.\"}, {\"id\": 12, \"text\": \"The 7-day and 30-day COVID-19 rebound rates after Paxlovid treatment were 3.53% and 5.40% for COVID-19 infection, 2.31% and 5.87% for COVID-19 symptoms, and 0.44% and 0.77% for hospitalizations.\"}, {\"id\": 4, \"text\": \"Most case reports of rebound COVID-19 have been associated with cessation of treatment with the combined oral antiviral agent nirmatrelvir/ritonavir (Paxlovid).\"}, {\"id\": 1, \"text\": \"Viral RNA rebound or symptom relapse in the absence of antiviral treatment is common, but the combination of high-level viral and symptom rebound is rare.\"}, {\"id\": 0, \"text\": \"The combination of high-level viral rebound to \\u00e2\\u2030\\u00a55.0 log10 RNA copies/mL and symptom rebound after initial improvement was observed in 1-2% of participants.\"}, {\"id\": 7, \"text\": \"The mechanisms of rebound COVID-19 remain unclear but may involve the development of resistance to the antiviral drug, impaired immunity to the virus, or insufficient drug dosing.\"}, {\"id\": 2, \"text\": \"Nirmatrelvir/ritonavir, the first severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) protease inhibitor, reduces the risk of hospitalization and death by coronavirus disease 2019 (COVID-19) but has been associated with symptomatic rebound after therapy completion.\"}, {\"id\": 8, \"text\": \"Recent case reports document that some patients who were treated with Paxlovid experienced rebound COVID-19 infections and symptoms 2 to 8 days after completing a 5-day course of Paxlovid.\"}]``` return a json array of their ids called 'snippets'"}, {"role": "assistant", "content": "{\"snippets\": [10, 11, 2, 8, 1, 3, 12, 0, 5, 7, 4, 9, 6]}"}]}
{"messages": [{"role": "system", "content": "You are BioASQ-GPT, an AI expert in question answering, research, and information retrieval in the biomedical domain."}, {"role": "user", "content": "Given this question: 'What clinical applications is Zanubrutinib approved for in the United States?' select the top 10 snippets that are most helpful for answering this question from this list of snippets, \n        rerank them by helpfulness: ```[{\"id\": 1, \"text\": \"In the United States, zanubrutinib, a next-generation BTK inhibitor, has been approved for treating adults with mantle cell lymphoma who have received at least one prior therapy, for adults with Waldenstr\\u00c3\\u00b6m macroglobulinemia, and for adults with relapsed or refractory marginal zone lymphoma who have received at least one anti-CD20-based therapy. \"}, {\"id\": 0, \"text\": \"Zanubrutinib is currently approved for use for treatment of adult patients with MCL who have received at least one prior therapy, for adults with WM, and for adults with MZL who have received at least one anti-CD20-based therapy.\"}]``` return a json array of their ids called 'snippets'"}, {"role": "assistant", "content": "{\"snippets\": [1, 0]}"}]}
{"messages": [{"role": "system", "content": "You are BioASQ-GPT, an AI expert in question answering, research, and information retrieval in the biomedical domain."}, {"role": "user", "content": "Given this question: 'Is rilonacept effective for pericarditis?' select the top 10 snippets that are most helpful for answering this question from this list of snippets, \n        rerank them by helpfulness: ```[{\"id\": 4, \"text\": \"Overproduction of both IL-1\\u00ce\\u00b1 (released by inflamed/damaged pericardial cells) and IL-1\\u00ce\\u00b2 (released by inflammatory cells) is now a well-recognized therapeutic target in patients with recurrent idiopathic pericarditis. Currently, there are three available anti-IL-1 agents: anakinra (recombinant human IL-1Ra), rilonacept (a soluble decoy receptor 'trap', binding both IL-1\\u00ce\\u00b1 and IL-1\\u00ce\\u00b2), and canakinumab (human monoclonal anti-IL-1\\u00ce\\u00b2 antibody). \"}, {\"id\": 3, \"text\": \"Rilonacept: A Newly Approved Treatment for Recurrent Pericarditis.\"}, {\"id\": 1, \"text\": \"CONCLUSION: Rilonacept is a safe, once weekly, subcutaneously administered IL-1 \\\"trap,\\\" indicated for the treatment of RP, and reduction in risk of recurrent pericarditis in adults and children \\u00e2\\u2030\\u00a512 years of age.\"}, {\"id\": 6, \"text\": \"Currently, anakinra and rilonacept, have demonstrated beneficial impact in clinical outcomes with a reasonable safety profile in randomized clinical trials. There is still paucity of data regarding the use of canakinumab in the treatment of patients with RP. \"}, {\"id\": 5, \"text\": \"OBJECTIVE: To review the pharmacology, efficacy, and safety of rilonacept for the prevention and treatment of recurrent pericarditis (RP).\"}, {\"id\": 2, \"text\": \" Concerning acute recurrent pericarditis (RP), an innovative interaction between cardiologists, internists and pediatric rheumatologists led to the intuition of a pivotal role of IL-1 in recurrent pericarditis characterized by an evident inflammatory recurrent phenotype, and recent data have shown the striking efficacy of anakinra and rilonacept in these patients. \"}, {\"id\": 0, \"text\": \"Pericarditis is regarded as a stereotypical response to an acute damage of the mesothelial cells of the pericardial layers. NLRP3 inflammasome, a macromolecular structure sensing damage and releasing pro-inflammatory cytokines, is centrally involved as it releases interleukin (IL)-1\\u00ce\\u00b2, whose auto-induction feeds an autoinflammatory disease, mostly responsible for recurrences. Colchicine, an inhibitor of NLRP3 inflammasome formation, and IL-1-targeted therapies, such as anakinra and rilonacept, were found to effectively blunt the acute inflammation and reduce the risk for recurrences.\"}]``` return a json array of their ids called 'snippets'"}, {"role": "assistant", "content": "{\"snippets\": [2, 0, 6, 3, 5, 1, 4]}"}]}
{"messages": [{"role": "system", "content": "You are BioASQ-GPT, an AI expert in question answering, research, and information retrieval in the biomedical domain."}, {"role": "user", "content": "Given this question: 'The 1p19q co-deletion is associated with what types of tumors?' select the top 10 snippets that are most helpful for answering this question from this list of snippets, \n        rerank them by helpfulness: ```[{\"id\": 23, \"text\": \"1p/19q co-deleted fibrillary astrocytomas: Not everything that is co-deleted is an oligodendroglioma.\"}, {\"id\": 33, \"text\": \"Background: Co-deletion of 1p and 19q marks a diffuse glioma subtype associated with relatively favorable overall survival; however, heterogeneous clinical outcomes are observed within this category.Methods: We assembled gene expression profiles and sample annotation of 374 glioma patients carrying th\"}, {\"id\": 25, \"text\": \"diffuse gliomas into three distinct molecular categories: chromosome 1p/19q co-deleted/IDH mutant, intact 1p/19q/IDH mutant and IDH wild type.\"}, {\"id\": 15, \"text\": \"Systematically characterize the clinical and biological significances of 1p19q genes in 1p/19q non-codeletion glioma.\"}, {\"id\": 20, \"text\": \"eptomeningeal dissemination of an oligodendroglioma is rarely reported in the neurosurgical literature, especially in cases with a classical 1p19q deletion\"}, {\"id\": 51, \"text\": \"1p/19q codeletion, which leads to the abnormal expression of 1p19q genes in oligodendroglioma, is associated with chemosensitivity and favorable prognosis. Here, we aimed to explore the clinical implications of 1p19q gene expression in 1p/19q non-codel gliomas. We analyzed expression of 1p19q genes in 668 1p/19q non-codel gliomas obtained from The Cancer Genome Atlas (n = 447) and the Chinese Glioma Genome Atlas (n = 221) for training and validation, respectively. The express\"}, {\"id\": 54, \"text\": \"The 1p deletions and 1p19q codeletion mean rates were respectively 65.4 and 63.3% in oligodendrogliomas, 28.7 and 21.6% in oligoastrocytomas, 13.2 and 7.5% in astrocytomas, 11.6 and 2.9% in glioblastoma\"}, {\"id\": 28, \"text\": \" The presence of 1p deletion and 1p19q codeletion were strongly correlated with the histological diagnosis corresponding to oligodendroglioma.\"}, {\"id\": 22, \"text\": \"The presence of chromosome 1p/19q co-deletion is one of the hallmark required criteria for the diagnosis of oligodendroglioma, using the 2016 World Health Organization (WHO) Classification of Tumours of the Central Nervous System.\"}, {\"id\": 49, \"text\": \"The IDH-mutant and 1p/19q co-deletion (1p19q codel) provides significant diagnostic and prognostic value in lower-grade gliomas.\"}, {\"id\": 16, \"text\": \"Oligodendroglioma, IDH-mutant and 1p/19q codeleted: 37;\"}, {\"id\": 53, \"text\": \"the 26 tumours, 6 oligodendrogliomas had 1p19q co-deletion and the remaining 3 oligodendrogliomas showed no co-deletion. Th\"}, {\"id\": 52, \"text\": \"Oligodendroglioma (OD) is a subtype of glioma occurring in the central nervous system. The 1p/19q codeletion is a prognostic marker of OD with an isocitrate dehydrogenase (IDH) mutation and is associated with a clinically favorable\"}, {\"id\": 2, \"text\": \" two biomarkers, IDH1/2 mutations and 1p/19q codeletion, to stratify anaplastic oligodendroglioma in three groups: a single-center experience\"}, {\"id\": 14, \"text\": \"In the WHO glioma classification guidelines grade (glioblastoma versus lower-grade glioma), IDH mutation and 1p/19q co-deletion status play a central role as they are important markers for prognosis and optimal therapy planning.\"}, {\"id\": 43, \"text\": \"The lack of CIC expression was detected in 13 cases (68\\u00c2\\u00a0%) of oligodendroglial tumors with the 1p/19q co-deletion, and in only 1 case of oligodendroglial tumors without the 1p/19q co-deletion (5\\u00c2\\u00a0%, P\\u00c2\\u00a0<\\u00c2\\u00a00.0001).\"}, {\"id\": 11, \"text\": \" three subgroups within 1p/19q co-deleted tumours, associated with specific expression patterns of nervous system cell types: oligodendrocyte, oligodendrocyte precursor cell (OPC) and neuronal lineage.\"}, {\"id\": 1, \"text\": \"Lower grade gliomas (LGGs) with codeletion of chromosomal arms 1p and 19q (1p/19 codeletion) have a favorable outcome. \"}, {\"id\": 35, \"text\": \"Whole arm 1p19q co-deletion was present in three cases from adolescent patients and 9p loss in 3, including one low-grade oligodendroglioma with CDKN2A homozygous deletion.\"}, {\"id\": 46, \"text\": \" We investigated a series of 1305 gliomas and showed that IDH mutation is almost constant in 1p19q codeleted tumors.\"}, {\"id\": 42, \"text\": \"The authors describe a case wherein a 1p19q deletion in a disseminated tumor with mixed immunohistochemical features of oligodendroglioma and neurocytoma was encountered and treated.\"}, {\"id\": 4, \"text\": \"We aimed to explore the expression of Olig2 in different glial neoplasms and to investigate if diffuse Olig2 expression can replace 1p19q co-deletion for the diagnosis of oligodendroglioma.\"}, {\"id\": 40, \"text\": \"ultigene signature for predicting prognosis of patients with 1p19q co-deletion diffuse glioma.\"}, {\"id\": 12, \"text\": \" In conclusion, the expression profile of 1p19q genes is highly associated with the malignancy and prognosis of 1p/19q non-codel gliomas.\"}, {\"id\": 45, \"text\": \"PURPOSE: Anaplastic gliomas represent a heterogeneous group of primary high-grade brain tumors, and the optimal postoperative treatment remains controversial. In this report, we present our institutional data on the clinical outcomes of radiation therapy (RT) plus temozolomide (RT + TMZ) for anaplastic gliomas, stratified by histology and 1p/19q codeletion.METHODS AND MATERIALS: A singl\"}, {\"id\": 29, \"text\": \"INTRODUCTION: Anaplastic oligodendrogliomas are high-grade gliomas defined molecularly by 1p19q co-deletion\"}, {\"id\": 34, \"text\": \" On the other hand, sequence studies have recently linked the CIC mutation and subsequent altered CIC expression to the 1p/19q co-deletion in oligodendroglial tumors.\"}, {\"id\": 18, \"text\": \"1p/19q Codeletion in Oligodendroglioma\"}, {\"id\": 59, \"text\": \"A total of 124 cases of diffuse gliomas were collected, and tissue microarray blocks were made. IDH1 mutation was tested using immunohistochemistry, and 1p/19q co-deletion status was examined using fluorescence in situ hybridization analysis.\"}, {\"id\": 27, \"text\": \"Background: Co-deletion of 1p and 19q marks a diffuse glioma subtype associated with relatively favorable overall survival; however, heterogeneous clinical outcomes are observed within th\"}, {\"id\": 38, \"text\": \"Losses of chromosomes 1p and 19q are deemed correlated with diagnosis of oligodendroglioma, higher chemosensitivity and better prognosis. \"}, {\"id\": 7, \"text\": \"oligodendrocyte transcriptional factor-2 (Olig2) be used as an alternative for 1p/19q co-deletions to distinguish oligodendrogliomas from other glial neoplasms\"}, {\"id\": 37, \"text\": \"Oligodendroglial tumours (OT) are a heterogeneous group of gliomas. Three molecular subgroups are currently distinguished on the basis of the IDH mutation and 1p/19q co-deletion.\"}, {\"id\": 48, \"text\": \"IDH1/2 mutations and 1p/19q codeletion occur frequently in anaplastic gliomas and are prognostic factors.\"}, {\"id\": 55, \"text\": \"Oligodendroglial tumors (OTs) are primary brain tumors that show variable clinical and biological behavior. The 1p/19q codeletion is frequent in these tumors, indicating a better prognosis and/or treatment response. Recently, the prognostically favorable CpG island methylator phenotype (CIMP) in gliomas (G-CIMP+) was associated with mutations in the isocitrate dehydrogenase 1 and isocitrate dehydrogenase 2 (IDH) genes, as opposed to G-CIMP- tumors, highlighting the relevance of epi\"}, {\"id\": 60, \"text\": \"1p19q co-deletion is a chromosomal alteration associated with primary brain tumours of oligodendroglial histology.\"}, {\"id\": 62, \"text\": \"Together with isocitrate dehydrogenase (IDH) mutation, co-deletion of 1p19q (1p19q codel) is a prerequisite for diagnosis of oligodendroglioma, making it imperative that histopathology laboratories introduce testing for 1p19q codel.\"}, {\"id\": 32, \"text\": \" results for 1p19q co-deletions (n\\u00e2\\u20ac\\u2030=\\u00e2\\u20ac\\u20309) or EGFR amplification (n\\u00e2\\u20ac\\u2030=\\u00e2\\u20ac\\u20308). Gliomas positive for 1p19q co-deletions did not have other frequently recurrent\"}, {\"id\": 47, \"text\": \"To evaluate the prevalence of 1p19q co-deletion and t(1;19) in extraventricular neurocytomas (EVN), we studied tumors from 23 patients, including 13 females and 10 males (median age at diagnosis 34 years, range 2-76 years).\"}, {\"id\": 0, \"text\": \"reatment strategy. However, there are still unanswered questions regarding whether upfront chemotherapy, omitting/deferring radiotherapy, in the desire to avoid late neurocognitive toxicity of radiotherapy should be the initial therapy for AO tumors with codeleted 1p19q, or whether temozolomide, an oral agent with a better toxicity profile, can be substituted for procarbazine, lomustine, and\"}, {\"id\": 50, \"text\": \"Glioblastoma remains a deadly brain cancer with dismal prognosis. Genetic alterations, including IDH mutations, 1p19q co-deletion status and MGMT promoter methylation have been proven to be prognostic and predictive to response to treatment in gliomas. I\"}, {\"id\": 36, \"text\": \" IDH mutant 1p/19q co-deleted gliomas have low tumor acidity as evidenced by molecular MRI and PET: a retrospective stud\"}, {\"id\": 39, \"text\": \"etrospective review of prognostic factors, including 1p19q deletion, in low-grade oligodendrogliomas and a review of recent published works\"}, {\"id\": 8, \"text\": \"1p/19q codeletion and histology on outcomes of anaplastic gliomas treated with radiation therapy and temozolomide\"}, {\"id\": 44, \"text\": \"Co-deletion of 1p/19q is a hallmark of oligodendroglioma and predicts better survival.\"}, {\"id\": 57, \"text\": \"diffuse glioma cases (grade 2, 56; grade 3, 62; grade 4, 182) based on this classification. Mutations in the isocitrate dehydrogenase (IDH) genes were common in lower grade glioma (LGG: grade2-3), and when combined with 1p/19q status,\"}, {\"id\": 31, \"text\": \"It has been reported recently that oligodendroglial tumors arising in the insula rarely harbor co-deletions of chromosomes 1p and 19q, a molecular signature which is associated with a good prognosis and increased responsiveness to radiation and chemotherapy compared with tumors in which 1p and/or 19q is intact.\"}, {\"id\": 17, \"text\": \"The majority of oligodendrogliomas (ODGs) exhibit combined losses of chromosomes 1p and 19q and mutations of isocitrate dehydrogenase (IDH1-R132H or IDH2-R172K).\"}, {\"id\": 30, \"text\": \" The study demonstrated that 1p/19q co-polysomy is a poor prognostic marker for glial tumor.\"}, {\"id\": 13, \"text\": \"We confirmed the high incidence (82%) of combined 1p19q deletion in LGOs and the feasibility of successful FISH testing in paraffin embedded specimens up to 10-years-old.\"}, {\"id\": 21, \"text\": \"Descriptions in the literature of astrocytomas, primarily glioblastomas, demonstrating partial losses on one or the other chromosome have been described.\"}, {\"id\": 6, \"text\": \"Co-deletion of chromosome arms 1p and 19q, characteristic of oligodendroglial tumors, was recently found to be mediated by t(1;19)(q10;p10).\"}, {\"id\": 61, \"text\": \"These results suggest that 1p19q loss and t(1;19) occur in a subset of EVN, and may be associated with aggressive histology in these tumors.\"}, {\"id\": 5, \"text\": \"Glial tumors are malignant brain tumors that arise from glial cells of brain or spine and have genetic aberrations in their genome. 1p/19q co-deletion is associated with increased\"}, {\"id\": 10, \"text\": \"eptomeningeal dissemination of a pediatric neoplasm with 1p19q deletion showing mixed immunohistochemical features of an oligodendroglioma and neurocytoma\"}, {\"id\": 26, \"text\": \" In the brain tumor, identification of molecular alterations, including 1p/19q co-deletion, is essential for accurate glial tumor classification.\"}, {\"id\": 58, \"text\": \"Oligodendrogliomas (ODs) are the second most common malignant brain tumor and exhibit characteristic co-deletion of chromosomal arms 1p and 19q (co-deletion 1p/19q), which is associated with down-regulation of tumor suppressors.\"}, {\"id\": 9, \"text\": \"uation. Data concerning low-grade gliomas were more controversial. Oligodendroglial tumors with 1p deletion or 1p19q codeletion seemed to have a bette\"}, {\"id\": 24, \"text\": \"The second is that examinations for IDH mutations and 1p/19q co-deletion are not sufficient on their own to accurately predict the prognosis of diffuse glioma patients.\"}, {\"id\": 3, \"text\": \"or purity was found to be significantly decreased in high-risk IDH-mutant with 1p/19q co-deletion gliomas and IDH-wild-type glioblastomas but not in IDH-wild-type lower grade or IDH-mutant, non-co-deleted gliomas.Con\"}, {\"id\": 41, \"text\": \"Diagnostic and prognostic values of 1p and 19q deletions in adult gliomas: critical review of the literature and implications in daily clinical practice\"}, {\"id\": 56, \"text\": \"Oligodendrogliomas are primary human brain tumors with a characteristic 1p/19q co-deletion of important prognostic relevance, but little is known about the pathology of this chromosomal mutation.\"}, {\"id\": 19, \"text\": \"Combined immunohistochemical analysis assessed by INA expression and/or the lack of CIC expression was strongly associated with the 1p/19q co-deletion in oligodendroglial tumors, indicating a potential surrogate marker of the 1p/19q state.\"}]``` return a json array of their ids called 'snippets'"}, {"role": "assistant", "content": "{\"snippets\": [1, 57, 50, 16, 23, 22, 21, 37, 11, 25, 44, 24, 6, 61, 33, 60, 62, 47, 49, 17, 35, 58, 56, 31, 15, 46, 30, 26, 12, 34, 29, 19, 3, 0, 32, 9, 14, 13, 53, 42, 43, 51, 55, 45, 52, 27, 48, 59, 36, 40, 5, 4, 7, 41, 54, 28, 38, 10, 20, 39, 8, 18, 2]}"}]}
{"messages": [{"role": "system", "content": "You are BioASQ-GPT, an AI expert in question answering, research, and information retrieval in the biomedical domain."}, {"role": "user", "content": "Given this question: 'The X-inactive specific transcript (Xist) gene is responsible for mediating the X-chromosome inactivation in females, where one X-chromosome is silenced and transcriptionally inactivated. What does Xist encode?' select the top 10 snippets that are most helpful for answering this question from this list of snippets, \n        rerank them by helpfulness: ```[{\"id\": 15, \"text\": \" The X-linked Xist long non-coding RNA functions as an X inactivation master regulator; Xist is selectively upregulated from the prospective inactive X chromosome and is required in cis for X inactivation.\"}, {\"id\": 3, \"text\": \"Xist (X-inactive specific transcript) plays a crucial role in X-inactivation. This non-coding RNA becomes upregulated on the X chromosome that is to be inactivated upon differentiation.\"}, {\"id\": 20, \"text\": \"X chromosome inactivation (X-inactivation) is triggered by X-linked noncoding Xist RNA, which is expressed asymmetrically from one of the two X chromosomes in females and coats it in cis to induce chromosome-wide silencing.\"}, {\"id\": 16, \"text\": \"While most genes are silenced on the inactive X chromosome, the gene for the long non-coding RNA XIST is silenced on the active X chromosome and expressed from the inactive X chromosome with which the XIST RNA associates, triggering silencing of the chromosome.\"}, {\"id\": 2, \"text\": \"Central to XCI is the long non-coding RNA Xist, which is highly and specifically expressed from the inactive X chromosome.\"}, {\"id\": 4, \"text\": \"Dosage compensation in mammals is achieved by the transcriptional inactivation of one X chromosome in female cells.\"}, {\"id\": 14, \"text\": \"X-inactive-specific transcript (Xist) is a long noncoding RNA (lncRNA) essential for inactivating one of the two X chromosomes in mammalian females.\"}, {\"id\": 11, \"text\": \"Xist encodes a noncoding RNA that influences the probability that the cis-linked X chromosome will be silenced.\"}, {\"id\": 18, \"text\": \"In eutherian mammals X inactivation is regulated by the X-inactive specific transcript (Xist), a cis-acting non-coding RNA that triggers silencing of the chromosome from which it is transcribed.\"}, {\"id\": 5, \"text\": \"The Xist gene produces a non-coding RNA that functions as the primary switch for X-inactivation, coating the X chromosome from which it is transcribed in cis.\"}, {\"id\": 9, \"text\": \"X-inactive specific transcript (Xist) long noncoding RNA (lncRNA) is thought to catalyze silencing of X-linked genes in cis during X-chromosome inactivation, which equalizes X-linked gene dosage between male and female mammals.\"}, {\"id\": 8, \"text\": \"Xist encodes a long noncoding RNA which is a central player to induce X-chromosome inactivation in female mammals and has two major splicing variants: long and short isoforms of Xist RNA.\"}, {\"id\": 0, \"text\": \"The long noncoding X-inactivation-specific transcript (Xist gene) is responsible for mammalian X-chromosome dosage compensation between the sexes, the process by which one of the two X chromosomes is inactivated in the female soma.\"}, {\"id\": 10, \"text\": \"XIST encodes a functional RNA that is expressed exclusively from the inactive X in female mammals and is required for the silencing of most of the genes on the chromosome. XIST transcripts remain in the nucleus, and their specific localization to the inactive X is important for silencing; however, it is not known how these transcripts localize to the inactive X chromosome.\"}, {\"id\": 6, \"text\": \"This process, known as X-chromosome inactivation, relies on monoallelic activation of the Xist gene. Xist produces a non-coding RNA that can coat the chromosome from which it is transcribed in cis and trigger its silencing.\"}, {\"id\": 13, \"text\": \"The X inactive-specific transcript (Xist) gene is the master regulator of X chromosome inactivation in mammals. Xist produces a long noncoding (lnc)RNA that accumulates over the entire length of the chromosome from which it is transcribed, recruiting factors to modify underlying chromatin and silence X-linked genes in cis\"}, {\"id\": 1, \"text\": \"The process of inactivation is initiated by the long non-coding RNA X-inactive specific transcript (XIST) and achieved through interaction with multiple synergistic silencing pathways.\"}, {\"id\": 12, \"text\": \"Silencing on the inactive X chromosome coincides with the acquisition of a multitude of chromatin modifications, resulting in the formation of extraordinarily stable facultative heterochromatin that is faithfully propagated through subsequent cell divisions. The integration of all these processes requires a region of the X chromosome known as the X-inactivation center, which contains the Xist gene and its cis-regulatory elements. Xist encodes an RNA molecule that plays critical roles in the choice of which X chromosome remains active, and in the initial spread and establishment of silencing on the inactive X chromosome.\"}, {\"id\": 21, \"text\": \"In mammals, the process of X-chromosome inactivation ensures equivalent levels of X-linked gene expression between males and females through the silencing of one of the two X chromosomes in female cells. The process is established early in development and is initiated by a unique locus, which produces a long noncoding RNA, Xist.\"}, {\"id\": 19, \"text\": \"X-inactive specific transcript (Xist) is a long noncoding RNA that is essential for initiating and maintaining epigenetic silencing of one copy of the X chromosome in mammalian females.\"}, {\"id\": 17, \"text\": \" X-inactive specific transcript (Xist) lncRNA accumulation (called an Xist cloud) on one of the two X-chromosomes in mammalian females is a critical step to initiate X-chromosome inactivation.\"}, {\"id\": 7, \"text\": \"XIST encodes a spliced noncoding polyadenylated transcript that is unique in being expressed exclusively from the inactive X chromosome and is involved in the X-inactivation process.\"}]``` return a json array of their ids called 'snippets'"}, {"role": "assistant", "content": "{\"snippets\": [8, 7, 10, 4, 12, 14, 9, 18, 15, 0, 20, 17, 19, 11, 2, 16, 21, 13, 6, 1, 5, 3]}"}]}
{"messages": [{"role": "system", "content": "You are BioASQ-GPT, an AI expert in question answering, research, and information retrieval in the biomedical domain."}, {"role": "user", "content": "Given this question: 'What are microexons?' select the top 10 snippets that are most helpful for answering this question from this list of snippets, \n        rerank them by helpfulness: ```[{\"id\": 0, \"text\": \"However, the analysis of RNAs-seq data for detection and quantification of microexons, extremely short exons of length up to 30\\u00c2\\u00a0nt, require specialized computational workflows. \"}]``` return a json array of their ids called 'snippets'"}, {"role": "assistant", "content": "{\"snippets\": [0]}"}]}
{"messages": [{"role": "system", "content": "You are BioASQ-GPT, an AI expert in question answering, research, and information retrieval in the biomedical domain."}, {"role": "user", "content": "Given this question: 'Is tebentafusp effective for uveal melanoma?' select the top 10 snippets that are most helpful for answering this question from this list of snippets, \n        rerank them by helpfulness: ```[{\"id\": 1, \"text\": \"This article summarizes the milestones in the development of tebentafusp leading to this first approval for unresectable or metastatic uveal melanoma.\"}, {\"id\": 3, \"text\": \"In a large meta-analysis, surgical treatment was associated with 6 months longer median overall survival as compared to conventional chemotherapy and, recently, tebentafusp as first-line treatment at the first interim analysis of a randomized phase III trial likewise provided a 6 months longer median overall survival compared to investigator's choice, mostly pembrolizumab; these treatments currently apply to selected patients. \"}, {\"id\": 2, \"text\": \"Tebentafusp was granted full approval on January 25th 2022 in the setting of HLA-A*02:01-positive adult patients with unresectable or metastatic uveal melanoma.\"}, {\"id\": 0, \"text\": \"Tebentafusp (tebentafusp-tebn; Kimmtrak\\u00c2\\u00ae) is a first-in-class, bispecific gp100 peptide-HLA-A*02:01 directed T cell receptor (TCR) CD3 T cell engager being developed by Immunocore for the treatment of uveal melanoma and malignant melanoma. \"}]``` return a json array of their ids called 'snippets'"}, {"role": "assistant", "content": "{\"snippets\": [0, 1, 2, 3]}"}]}
{"messages": [{"role": "system", "content": "You are BioASQ-GPT, an AI expert in question answering, research, and information retrieval in the biomedical domain."}, {"role": "user", "content": "Given this question: 'What is the Fenton reaction' select the top 10 snippets that are most helpful for answering this question from this list of snippets, \n        rerank them by helpfulness: ```[{\"id\": 10, \"text\": \"Hydrogen peroxide and ferrous iron (components of the Fenton reaction which generate free radicals) \"}, {\"id\": 12, \"text\": \" In this study, the antioxidant capacity of B. vulgaris was investigated using DPPH and its protective effect was evaluated on pBR322 plasmid and lymphocyte genomic DNA cleavage induced by Fenton reaction,\"}, {\"id\": 7, \"text\": \"In this review, the power of a classical chemical reaction, the Fenton reaction for initiating radical polymerizations, is demonstrated. The reaction between the Fenton reagents (i.e., Fe2+ and H2 O2 ) generates highly reactive hydroxyl radicals, which can act as radical initiators for the polymerization of vinyl monomers. Since the Fenton reaction is fast, easy to set up, cheap, and biocompatible, this unique chemistry is\"}, {\"id\": 1, \"text\": \"Oxidative stress plays a central role in age-related macular degeneration (AMD). Iron, a potent generator of hydroxyl radicals through the Fenton reaction, has been implicated in AMD. \"}, {\"id\": 6, \"text\": \"The reaction of iron(ii) and hydrogen peroxide, namely the Fenton reaction, is well-known for its strong oxidizing capability.\"}, {\"id\": 0, \"text\": \"Furthermore the in\\nvitro experiment showed that Fenton reaction (hydrogen peroxide in the presence of iron) products alone had\\nno effect on semicarbazide-sensitive amine oxidase activity in rat liver cell fraction whereas supplementation\\nwith methylglyoxal resulted in its significant 2.5-fold enhancement.\"}, {\"id\": 11, \"text\": \"The use of iron ions as catalyst of oxidation with hydrogen peroxide, known as the Fenton reaction, is important for industry and biological systems.\"}, {\"id\": 5, \"text\": \"The Fenton reaction is the reaction between iron and hydrogen peroxide, generating hydroxyl radical, which is highly reactive and highly toxic to living cells.\"}, {\"id\": 8, \"text\": \"The Fenton process, one of several advanced oxidation processes, describes the reaction of Fe(II) with hydrogen peroxide.\"}, {\"id\": 3, \"text\": \"The main forms of modified LDL detected in both coronary artery and aortic plaques are peroxidation products from the Fenton reaction and myeloperoxidase-hypochlorite pathway. \"}, {\"id\": 2, \"text\": \"During the Fenton reaction, H2 O2 and HO\\u00e2\\u20ac\\u00a2 with high oxidative activity broke the hydrogen bonds in the chitosan structure, resulting in the release of free amine groups for Fe3+ to form metal-binding biopolymers.\"}, {\"id\": 9, \"text\": \"Iron is the most abundant mineral in the human body and plays essential roles in sustaining life, such as the transport of oxygen to systemic organs. The Fenton reaction is the reaction between iron and hydrogen peroxide, generating hydroxyl radical, which is highly reactive and highly toxic to living cells.\"}, {\"id\": 4, \"text\": \"Hydroxyl radical is generated by Fenton reaction of Fe (II) with the ROS, H2O2, which, in turn, is formed by the dismutation of the ROS, superoxide. \"}]``` return a json array of their ids called 'snippets'"}, {"role": "assistant", "content": "{\"snippets\": [10, 1, 12, 3, 0, 4, 5, 6, 8, 2, 11, 7, 9]}"}]}
